The Lubrizol Corporation 10-K/A
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K/A
(Amendment
No. 1)
|
|
|
þ |
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934 |
For the fiscal year ended December 31, 2006
|
|
|
o |
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from
to
Commission file number 1-5263
THE LUBRIZOL CORPORATION
(Exact name of registrant as specified in its charter)
|
|
|
OHIO
|
|
34-0367600 |
(State of incorporation)
|
|
(I.R.S. Employer Identification No.) |
29400 Lakeland Boulevard
Wickliffe, Ohio 44092-2298
(Address of principal executive officers, including zip code)
Registrants telephone number, including area code: (440) 943-4200
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
Title of each class
|
|
Name of each exchange on which registered |
Common Shares without par value
|
|
New York Stock Exchange |
Common Share purchase rights
|
|
New York Stock Exchange |
Securities registered pursuant to Section 12(g) of the Exchange Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined by Rule 405 of
the Securities Act of 1933. Yes þ No o
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or
15(d) of the Exchange Act. Yes o No þ
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days. Yes þ No o
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is
not contained herein, and will not be contained, to the best of registrants knowledge, in
definitive proxy or information statements incorporated by reference
in Part III of this Form 10-K/A
or any amendment to this Form 10-K/A. o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer,
or a non-accelerated filer. See definition of accelerated filer and large accelerated filer in
Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer: þ Accelerated filer: o Non-accelerated filer o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the
Exchange Act). Yes o No þ
Aggregate market value (on basis of closing sale price) of voting stock held by nonaffiliates as of
June 30, 2006: $2,722,535,900.
Number of the registrants Common Shares, without par value, outstanding as of February 15, 2007:
69,160,429.
Documents Incorporated by Reference
Portions of the proxy statement for the 2007 Annual Meeting of Shareholders (Incorporated into Part
III of this Form 10-K/A)
TABLE OF CONTENTS
References to Lubrizol, the company, we, us or our refer to The Lubrizol Corporation
and its subsidiaries, except where the context makes clear that the reference is only to The
Lubrizol Corporation itself and not its subsidiaries.
EXPLANATORY NOTE
On October 22, 2007, we concluded to restate our previously issued financial statements
because of reporting errors relating to five postemployment employee benefit plans in three foreign
countries. Accordingly, we have restated our consolidated balance sheets as of December 31, 2006
and 2005 and our consolidated statements of income, consolidated statements of cash flows and
consolidated statements of shareholders equity for fiscal years 2006, 2005 and 2004 as well as the
related financial statement disclosures included in Item 15 to this annual report on Form 10-K/A.
This annual report on Form 10-K/A also includes the effects of the restatement in Item 7 - Managements Discussion
and Analysis of Financial Condition and Results of Operations and Item 6 - Selected Financial
Data for the 2002 through 2006 fiscal years.
The impact of the restatement decreased income from continuing operations and net income for
2006 by $2.0 million or 1.1% and 1.9%, respectively, for 2005 by $2.1 million or 1.3% and 1.1%,
respectively, and for 2004 by $1.7 million, or 1.9% and 1.8%, respectively, from amounts previously
reported. The restatement had no effect on our previously reported revenues or net cash flows.
The cumulative effect of the errors decreased shareholders equity as of December 31, 2006 by
$24.3 million or 0.6% of total liabilities and shareholders equity and 1.4% of total shareholders
equity. The cumulative effect of the errors decreased shareholders equity as of December 31, 2005
by $15.3 million or less than one-half percent of total liabilities and shareholders equity and
1.0% of total shareholders equity.
The errors primarily arose in three different postemployment employee benefit plans at a
wholly owned subsidiary and in postemployment employee benefit plans at two of our consolidated
joint ventures. Four of these postemployment employee benefit plans had been accounted for
inappropriately on a cash basis rather than an accrual basis as required by U.S. generally accepted
accounting principles (U.S. GAAP), while the accrual recorded in the financial statements for the
fifth plan was not calculated in accordance with U.S. GAAP. The cumulative effect of the errors
resulted in an understatement of postemployment employee benefit plan liabilities of $38.9 million
and $27.1 million at December 31, 2006 and 2005, respectively.
See Item 7 - Managements Discussion and Analysis of Financial Condition and Results of
Operations and Note 20 - Restatement of Consolidated Financial Statements contained in the Notes
to Financial Statements for more information regarding the restatement and changes to previously
issued financial statements.
We also concluded that a material weakness in internal control over financial reporting
existed for deficiencies at some international locations due to insufficient requisite technical
knowledge of accounting for postemployment employee benefit plans in accordance with U.S. GAAP for
the 2004 through 2006 fiscal years and through June 30, 2007, and that our disclosure controls were
not effective solely because of this material weakness. As such, we have modified our discussion of
disclosure controls and procedures included in Item 9A and our report on internal control over
financial reporting contained in this annual report on Form 10-K/A to disclose how the restatement
affected our chief executive officers and chief financial officers assessment of internal
controls over financial reporting.
Except as noted herein, we have not modified or updated disclosures presented in the original
annual report on Form 10-K for the year ended December 31, 2006 except as required to reflect the
effects of the restatement on this Form 10-K/A. Accordingly, this annual report on Form 10-K/A does not reflect
events occurring after the filing of our original annual report on Form 10-K on February 28, 2007. This annual report on
Form 10-K/A should be read in conjunction with our filings made with the Securities and Exchange Commission subsequent
to the filing of the original annual report on Form 10-K, including any amendments to those filings. The following
items have been amended as a result of the restatement:
|
|
|
Part I - Item 1. Business (page 5) |
|
|
|
|
Part II - Item 6. Selected Financial Data |
2
|
|
|
Part II - Item 7. Managements Discussion and Analysis of Financial Condition
and Results of Operations |
|
|
|
|
Part II - Item 9A. Controls and Procedures |
|
|
|
|
Part IV - Item 15. Exhibits and Financial Statement Schedules |
PART I
ITEM 1. BUSINESS
Overview
We are an innovative specialty chemical company that produces and supplies technologies that
improve the quality and performance of our customers products in the global transportation,
industrial and consumer markets. Our business is founded on technological leadership. Innovation
provides opportunities for us in growth markets as well as advantages over our competitors. From a
base of approximately 1,700 patents, we use our product development and formulation expertise to
sustain our leading market positions and fuel our future growth. We create additives, ingredients,
resins and compounds that enhance the performance, quality and value of our customers products,
while minimizing their environmental impact. Our products are used in a broad range of
applications, and are sold into stable markets such as those for engine oils, specialty driveline
lubricants and metalworking fluids, as well as higher-growth markets such as personal care and
over-the-counter pharmaceutical products and performance coatings and inks. Our specialty materials
products also are used in a variety of industries, including the construction, sporting goods,
medical products and automotive industries.
We are an industry leader in many of the markets in which our product lines compete. We also
produce products with well-recognized brand names, such as Anglamol® (gear oil
additives), Carbopol® (acrylic thickeners for personal care products),
Estane® (thermoplastic polyurethane) and TempRite® (engineered polymers
resins and compounds used in plumbing, industrial and fire sprinkler systems).
We are geographically diverse, with an extensive global manufacturing, supply chain, technical
and commercial infrastructure. We operate facilities in 29 countries, including production
facilities in 20 countries and laboratories in 13 countries, in key regions around the world
through the efforts of more than 6,700 employees. We derived approximately 45% of our consolidated
total revenues from North America, 29% from Europe, 20% from the Asia/Pacific and the Middle East
region and 6% from Latin America. We sell our products in more than 100 countries and believe that
our customers recognize and value our ability to provide customized, high quality, cost-effective
performance formulations and solutions worldwide. We also believe our customers value highly our
global supply chain capabilities.
Our consolidated results for the year ended December 31, 2006 included total revenues of
$4,040.8 million. We have generated consistently strong cash flows from our diverse product lines,
leading market positions, disciplined capital expenditure programs and working capital management.
We believe our strong cash flow will enable us to maintain our leading market positions and to
invest in targeted growth strategies while continuing to reduce indebtedness.
We are organized into two operating and reporting segments. We made the final determination
in January 2007 to change the names of our two reporting segments. The new segment names are
Lubrizol Additives, previously known as Lubricant Additives, and Lubrizol Advanced Materials,
previously known as Specialty Chemicals. The change was in name only as the management structure
of the segments and product lines included in each segment remain unchanged.
Our
principal executive offices are located at 29400 Lakeland Boulevard, Wickliffe, Ohio
44092-2298 and our telephone number is 440-943-4200. Our website is located at www.lubrizol.com.
Information contained on our website does not constitute part of this annual report on Form 10-K/A. We make
available free of charge on our website the annual reports on Form 10-K, the quarterly reports on
Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant
to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as soon as reasonably practicable
after we electronically file or furnish the material to the Securities and Exchange Commission.
3
Acquisitions and Divestitures
On February 7, 2007, we acquired a broad line of additive products in the metalworking markets
worldwide from Lockhart Chemical Company (Lockhart), a private company with headquarters in
Gibsonia, Pennsylvania. We purchased Lockharts entire metalworking product line, which includes:
natural, synthetic and gelled sulfonates; emulsifier packages; corrosion inhibitors and lubricity
agents; grease additives; oxidates; esters; soap; semi-finished coatings; and rust preventatives.
In 2006, these product lines had annualized revenues of approximately $20.0 million.
In May 2006, we sold the food ingredients and industrial specialties business (FIIS) and the
active pharmaceutical ingredients and intermediate compounds business (A&I), both of which were
included in the Lubrizol Advanced Materials segment. A&I and most of the FIIS divestiture reported
in to the Noveon consumer specialties product line, while a small portion of the FIIS divestiture
reported into the performance coatings product line. We recorded a $15.9 million after-tax loss on
the sale of these divested businesses.
In February 2006, we sold certain assets and liabilities of Noveon International, Inc.s
Telene® resins business (Telene), which was included in the Lubrizol Advanced Materials segment.
In December 2005, we sold certain assets, liabilities and stock of our Engine Control Systems
(ECS) business, with facilities located in Canada, the United States and Sweden. In September
2005, we sold certain assets and liabilities of our U.S. and U.K. Lubrizol Performance Systems
(LPS) operations. Both of these businesses had been included in the Lubrizol Additives segment.
On June 3, 2004, we acquired Noveon International, Inc. (Noveon International) a leading
global producer and marketer of technologically advanced specialty materials and chemicals used in
the industrial and consumer markets.
In January 2004, we acquired the coatings hyperdispersants business from Avecia for cash
totaling $129.7 million, including transaction costs of $2.2 million. This business is included in
the Lubrizol Advanced Materials segment and develops, manufactures and markets high-value additives
that are used in coatings and inks.
Business Segments
The Lubrizol Additives segment represents 64% of our 2006 consolidated revenues and is
comprised of our businesses in engine additives and driveline and industrial additives. The
Lubrizol Advanced Materials segment represents 36% of our 2006 consolidated revenues and is
comprised of the businesses of the acquired Noveon International and our former performance
chemicals product group.
4
The following chart summarizes the product groupings within each of our key product lines.
The Lubrizol Corporation
Lubrizol Additives Segment
The Lubrizol Additives segment is the leading global supplier of additives for transportation
and industrial lubricants. We pioneered the development of lubricant additives over 75 years ago
and continue to maintain leadership in what we estimate to be an $8.0 billion industry. Our
customers rely on our products to improve the performance and lifespan of critical components, such
as engines, transmissions and gear drives for cars, trucks, buses, off-highway equipment, marine
engines and industrial applications.
For the year ended December 31, 2006, the Lubrizol Additives segment generated revenues of
$2,600.5 million and segment operating income of $303.0 million.
Our products serve to increase cost-effectiveness by reducing friction and heat, resisting
oxidation, minimizing deposit formation, and preventing corrosion and wear. Through our in-house
research, development and testing programs, we have the capability to invent and develop a broad
range of proprietary chemical components, including antioxidants, anti-wear agents, corrosion
inhibitors, detergents, dispersants, friction modifiers and viscosity modifiers. We formulate
proprietary additive packages by combining these different components to create unique products
targeting specific customer problems. We are recognized by our customers for innovative technology,
the broadest product line and high-quality products. Our key components of our additive packages
include:
|
|
|
antioxidants that retard oil thickening; |
|
|
|
|
anti-wear agents that prevent surfaces metal-to-metal contact; |
5
|
|
|
corrosion inhibitors that prevent rust; |
|
|
|
|
detergents that prevent deposit build-up; |
|
|
|
|
dispersants that protect equipment by suspending contaminant particles; |
|
|
|
|
friction modifiers that control friction at surfaces; |
|
|
|
|
polymer-based viscosity modifiers that allow lubricants to operate over broad
temperature ranges; and |
|
|
|
|
pour point depressants that control low temperature fluid thickening. |
Our products are essential to the performance of the finished lubricant, yet represent a
relatively small portion of its volume. Our products are often designed to meet specific customer
requirements. For example, we work with customers to develop additive packages that perform in
combination with their proprietary base oil or that meet their marketing objectives to
differentiate their lubricant. Extensive testing is conducted in our world-class laboratories,
global mechanical testing facilities and in the field to determine additive performance under
actual operating conditions. With this testing, we provide proof of performance, which enables our
customers to label and certify the lubricant as meeting the exact performance specifications
required for these products by the industry. The majority of our products are designed to meet an
industry standard or specification.
During 2006, we had two primary product lines within our Lubrizol Additives segment: engine
additives and driveline and industrial additives.
Engine Additives. Our engine additives products hold a leading global position for a wide
range of additives for lubricating engine oils, such as for gasoline, diesel, marine and stationary
gas engines. We also produce additives for fuel and refinery and oilfield chemicals. In addition,
this product line sells additive components and viscosity improvers within its lubricant and fuel
additives product areas. Our customers, who include major global and regional oil companies,
refineries and specialized lubricant producers and marketers, blend our additive products with
their base oil and distribute the finished lubricant to end users via retail, commercial or vehicle
original equipment manufacturer (OEM) channels. Passenger car motor oils and diesel engine oils
are approximately 80% of our engine additive sales. In 2006, our engine additives products
generated total revenues of $1,665.4 million.
The following is a list of representative uses for and a description of our engine additives
products:
|
|
|
|
|
Category |
|
Product/Brand |
|
Description |
|
Engine Additives
|
|
Passenger car motor
oils, heavy-duty
diesel engine oils,
marine diesel,
small engines,
stationery gas and
viscosity modifiers
|
|
Additives that
extend engine life,
lower emissions and
enhance fuel
economy. |
|
|
|
|
|
|
|
Fuel, refinery and
oilfield products
and other
components
|
|
Additives designed
to eliminate
deposits and
provide fuel system
cleanliness,
prevent rust and
corrosion, enhance
fuel economy,
provide anti-knock,
lower volatility
and improve storage
stability. |
Driveline and Industrial Additives. We are a global supplier of specialty driveline and
industrial oil additive products for use in driveline and industrial applications. This product
line also provides outsourcing services for supply chain and knowledge center management. In 2006,
our driveline and industrial additives generated total revenues of $935.1 million.
Driveline Additives
Our driveline additives products include additives for driveline oils, such as automatic
transmission fluids, gear oils and tractor lubricants. Relative to engine oils, specialty
driveline additives are more complex formulations that carry higher average pricing and value and
have longer product life cycles. We sell our products to major global and regional oil companies,
specialized lubricant producers and marketers. Our customers use our products
6
to blend with their lubricant fluids and distribute the finished lubricant to end users via
retail, commercial or vehicle OEM channels. The specialty driveline additives industry is
characterized by well-established product lines that meet OEM specifications and carry OEM
approvals.
Industrial Additives
Our industrial oil additives products include additives for hydraulic lubricants, metalworking
fluids, industrial gear oils and grease, as well as compressor lubricants. We sell our products to
major global and regional oil companies, specialized lubricant producers and marketers. Our
customers use our products to blend with their fluid products and distribute the finished lubricant
to end users via retail, commercial or OEM channels. Because our products are sold to industrial
end-markets, our industrial oil additives products are exposed to economic cycles more than other
products within the Lubrizol Additives segment.
The following is a list of representative uses for and a description of our driveline and
industrial oil additives products:
|
|
|
|
|
Category |
|
Product/Brand |
|
Description |
|
Driveline and
Industrial
Additives
|
|
Driveline additives
for automatic
transmission
fluids, gear oils
and farm tractor
fluids
|
|
Additives that
provide multiple
and complex
performance
properties,
including reducing
friction in order
to prevent wear of
transmissions,
gears and farm
tractor components. |
|
|
|
|
|
|
|
Additives for
industrial fluids,
including
hydraulics,
metalworking,
industrial gear,
grease and
compressor fluids
|
|
A wide range of
additives to meet
the lubricant
performance
requirements of
industrial
equipment. |
Lubrizol Advanced Materials Segment
The Lubrizol Advanced Materials segment represents a diverse portfolio of performance
chemicals used in consumer and industrial applications, such as ingredients for personal care and
pharmaceutical products, emulsions and additives for coatings and inks, and specialty plastics and
materials.
For the year ended December 31, 2006, the Lubrizol Advanced Materials segment generated
revenues of $1,440.3 million and segment operating income of $167.6 million.
We have three primary product lines within our Lubrizol Advanced Materials segment: Noveon
consumer specialties, performance coatings and engineered polymers.
Noveon Consumer Specialties. We are a global producer of specialty chemicals targeting the
personal care and pharmaceutical industries. Key products include Carbopol acrylic thickeners,
film formers, fixatives, emollients, silicones, botanicals and process chemicals. In 2006, our
Noveon consumer specialties products generated total revenues of $373.5 million.
We are a global producer of specialty chemicals targeting the personal care and pharmaceutical
industries. Our products impart physical and sensory properties, such as texture, stability and
thickness to products, including lotions, shampoos, hair gels, cosmetics and personal and oral
hygiene products. Key products in this area include selected functional specialties and
formulation additives such as specialty surfactants, methyl glucoside and lanolin derivatives, and
acrylic thickeners, specialty monomers, film formers and fixatives. Our products are an important
component of the functionality and aesthetics of the end product, but typically represent a small
portion of the customers total product costs. Key product families include:
|
|
|
Carbopol acrylic thickener, which is a global leader in synthetic thickeners due to
its efficient stabilizing properties and superior thickening capabilities. Primary
end-uses in the personal care industry include hair care, skin care and personal and
oral hygiene products. Pharmaceutical primary end-uses include topical and
controlled-release applications. |
7
|
|
|
Methyl glucoside and lanolin derivatives that enhance the functional and aesthetic
properties of personal care products by delivering characteristics such as
emulsification, thickening and moisturizing, as well as imparting the elegant feel to
lotions and creams. |
|
|
|
|
AMPS® specialty monomers that are used in the manufacture of polymers for
a variety of applications such as dishwashing detergents to reduce spotting, skin
creams to improve lubricity and feel, medical gels for defibrillator pads to enhance
conductivity, and coatings and adhesives to improve adhesion. |
|
|
|
|
Specialty surfactants and additives that enhance the functional and aesthetic
properties of personal care products and household and industrial cleaners by improving
characteristics such as foaming, cleansing, conditioning and mildness. Surfactants
primarily are used in hair care products, such as shampoos and body washes. |
The following is a list of representative uses for and a description of our personal care and
pharmaceuticals products:
|
|
|
|
|
Category |
|
Product/Brand |
|
Description |
|
Personal Care and
Pharmaceuticals
|
|
Carbopol®
|
|
Acrylic thickener, which imparts stability
and improves aesthetics. Often used as a
controlled release agent. |
|
|
|
|
|
|
|
Pemulen®
|
|
Polymeric emulsifier reducing formulation
irritancy and providing unique sensory
properties. |
|
|
|
|
|
|
|
Avalure®
|
|
Polymers for color cosmetics and skin care. |
|
|
|
|
|
|
|
Specialty silicones
|
|
Polymers affecting slip-and-feel. |
|
|
|
|
|
|
|
Fixate®
|
|
Resin for hair styling. |
|
|
|
|
|
|
|
Emollients
|
|
Improve skin feel and appearance. |
|
|
|
|
|
|
|
Botanical extracts
|
|
Specialty additives for cosmetic and skin
care formulations. |
|
|
|
|
|
|
|
Methyl glucoside
derivatives, including
Glucamate®
|
|
Natural thickeners, emulsifiers and
moisturizers for shampoos, liquid
cleansers, face and body creams and
lotions. |
|
|
|
|
|
|
|
Lanolin derivatives
|
|
Natural emollients, emulsifiers and
conditioners for creams, lotions and color
cosmetics. |
|
|
|
|
|
|
|
AMPS® monomers
|
|
Specialty monomer for high performance
polymers. |
|
|
|
|
|
|
|
Specialty surfactants, including
Sulfochem®
|
|
Enhance cleansing, foaming and
moisturizing of shampoos, body washes and
industrial and household cleaners. |
|
|
|
|
|
|
|
Polycarbophil
|
|
Active agent for bulk laxatives. |
|
|
|
|
|
|
|
Cassia gum
|
|
Gelling agents for human food (Japan) and
pet food. |
Performance Coatings. We are a leading supplier of specialty resins and additives for the
coatings and ink markets worldwide. We offer a wide range of products for formulating paints,
coatings and inks. In 2006, our performance coatings products generated total revenues of
$543.7 million.
Our business strategy for performance coatings is centered on our ability to formulate and
compound polymer emulsions to create customized solutions meeting the specific needs of our
customers. The performance coatings product line includes high-performance polymers and additives
for specialty paper, graphic arts, paint and textile coating applications.
8
Specialty Resins and Polymers
Our water-based polymer emulsions and dispersions, including resins and auxiliaries, are used
in the production of high-end paint and coatings for wood, paper, metal, concrete, plastic,
textiles and other surfaces. Our acrylic emulsions and polyurethane dispersions, which are
environmentally attractive substitutes for solvent-based and hydrocarbon products, are valued for
the superior gloss and durability properties they provide. In addition, our polymers are used as
ink vehicles, overprint varnishes and functional coatings for specialty paper, printing and
packaging applications. We supply acrylic emulsions used to improve the appearance, texture,
durability and flame retardance of high-end specialty textiles sold to the home furnishings and
technical fabrics industries. In addition to water-based polymers, we specialize in unique,
non-aqueous acrylic and other proprietary polymer resins for the paint and coatings, printing ink,
laminating, adhesives and sealants markets. These value-added Doresco® specialty resins
not only function as carriers for pigment, but also provide surface protection and adhesion
properties. We work closely with our customers to develop resins that address their specific
needs.
The following is a list of representative uses for and a description of our resins and polymer
products:
|
|
|
|
|
Category |
|
Product-line |
|
Description |
|
Specialty Resins
and Polymers
|
|
Acrylic Emulsions,
Polyurethane
Dispersions and
Other Water-based
Systems,
Hycar®,
Sancure®,
Algan®,
Performax®
|
|
Provide superior
gloss and
durability
properties to
paints and
coatings. End
markets include
wood, paper, metal,
concrete, plastic
and textiles. |
|
|
|
|
|
|
|
Acrylic and Other
Polymer Resins,
Doresco®
|
|
Function as
carriers for
pigments, and
provide surface
protection and
adhesion
properties.
End-markets include
paint and coatings,
printing ink,
laminating,
adhesives and
sealants. |
Coating Additives
Our additives for coatings and inks are used to enhance the appearance and durability of
coatings in architectural and industrial uses, as well as to improve their processing and
application characteristics. Additives such as pigment dispersants enhance the processing and
performance of printing ink, while also maximizing color strength and stability in coatings and
plastics. We expanded this product line by purchasing the dispersants business of Avecia in
January 2004. We are a leading global supplier of surface modifiers that improve the abrasion
resistance properties, gloss, leveling and film characteristics of printing ink and coatings. Our
products include:
|
|
|
High-performance hyperdispersants for coatings, inks, thermoplastics and thermoset
composites. We are a world leader in polymeric hyperdispersant technology, sold under
the Solsperse® and Solplus® trade names. Hyperdispersants
improve the dispersion of almost any solid particulate (including pigments, fillers,
flame retardants and fibers) into almost any liquid medium (water, solvents and
resins). They are primarily used to achieve even color saturation. They enrich and
strengthen color, while reducing production costs and solvent emissions. We also
produce Ircosperse® pigment dispersants for coatings and COLORBURST pigment
dispersants for printing inks. |
|
|
|
|
Surface modifiers improve the performance of industrial, architectural, can, coil,
wood and powder coatings by enhancing and protecting surfaces. Lanco®,
Lanco® Glidd, Lanco® Matt and Aquaslip surface modifiers impart
a variety of properties to a coating, including enhanced slip, improved abrasion and
scratch resistance, matting, texturing and a silky, soft feel. |
|
|
|
|
Rheology control additives improve the performance of coatings by providing
thickening, sag control, pigment anti-settling and improved surface appearance.
Rheology control additives are sold under the brand names Ircothix®,
Ircogel® and Solthix®. |
|
|
|
|
Specialized additives for inks improve rub resistance properties and film
characteristics. |
9
The following is a list of representative uses for and a description of our coating additives
products:
|
|
|
|
|
Category |
|
Product/Brand |
|
Description |
|
Coating Additives
|
|
Dispersants, Solsperse®
Ircosperse®,
COLORBURST
|
|
Improve the
dispersion of solid
particulates into
liquid mediums.
End-markets include
paints and printing
inks. |
|
|
|
|
|
|
|
Surface Modifiers
Lanco®,
Lanco®
Glidd,
Lanco®
Matt, Aquaslip
|
|
Impart a variety of
properties to a
coating, including
enhanced slip,
improved abrasion
and scratch
resistance, matting
and texturing. End
markets include
industrial,
architectural, can
and coil, wood and
powder coatings. |
|
|
|
|
|
|
|
Rheology Control
Additives,
Ircothix®,
Ircogel®
and
Solthix®
|
|
Provide thickening,
sag control and
improved surface
appearance of
coatings. |
|
|
|
|
|
|
|
Specialized
Additives for Inks,
Duotron®,
Liquitron®,
Fluotron®
|
|
Improve the
processing,
performance and rub
resistance
properties. |
Engineered Polymers. We are a leading global supplier of engineered polymers (EP) resins and
compounds sold under the trademark TempRite. Applications for TempRite resins and compounds
include piping for residential and commercial plumbing and fire sprinkler systems. In addition to
TempRite, we are also a leading producer of thermoplastic polyurethane (TPU) sold under the
trademark Estane. Applications for Estane TPU include plastic film and sheet for various coatings
processes. In 2006, the engineered polymers product line generated total revenues of $523.1
million.
TempRite Engineered Polymers
TempRite EP is a technologically advanced heat, fire and chemical resistant polymer that we
developed to serve technically demanding applications not well served by traditional PVC and other
commodity plastics. Our TempRite EP is sold to customers who produce plastic piping for
residential and commercial plumbing, fire sprinkler systems and industrial piping applications.
TempRite EP piping has inherent advantages over copper and other metals due to its heat and
corrosion resistance, increased insulation properties, mold resistance, ease of installation and
lower installed cost. We market our branded TempRite EP products for specific applications:
FlowGuard® and FlowGuard Gold® for residential and commercial plumbing,
BlazeMaster® for fire sprinkler systems and Corzan® for industrial piping.
We believe we have built strong end-user awareness of our brands by using a sales force that
markets directly to builders, contractors, plumbers, architects, engineers and building owners.
In 2001, Noveon International purchased select assets and technology to manufacture PEX
compounds, further used to produce PEX pipe. TempRite PEX enables us to add a flexible piping
compound to our rigid piping product offering. TempRite PEX is a small but growing product for
applications that demand flexible piping systems.
In January 2007, TempRite EP introduced two new piping products, FlowGuard Gold®
Bendable and FlowGuard Flex. Both products are used in residential and commercial plumbing.
10
The following is a list of representative uses for and a description of our EP and PEX
products:
|
|
|
|
|
Category |
|
Product/Brand |
|
Description |
|
EP
|
|
TempRite®
|
|
Residential plumbing |
|
|
|
|
|
|
|
FlowGuard®
|
|
Residential and commercial plumbing |
|
|
|
|
|
|
|
FlowGuard Gold®
|
|
Residential and commercial plumbing |
|
|
|
|
|
|
|
Corzan®
|
|
Industrial and commercial piping |
|
|
|
|
|
|
|
BlazeMaster®
|
|
Fire sprinkler piping |
|
|
|
|
|
PEX
|
|
TempRite®
|
|
Flexible piping systems |
Estane Engineered Polymers
Estane TPU, an engineered, highly versatile thermoplastic, provides a high performance
alternative to rigid plastics and flexible rubber. Performance attributes of Estane TPU include
abrasion, heat and chemical resistance, minimal fatigue from bending, ease of processing and good
paintability. These performance characteristics make Estane TPU attractive for use in a broad
range of end-uses, including film and sheet for various coating processes, wire and cable
insulation, athletic equipment (such as footwear), medical applications, pneumatic tubing and
automotive molded parts. In addition, Estane TPU has expanded into products that can be melt spun
into elastic spandex fibers and materials that offer enhanced breathability for garments. We
believe that Estane TPU is one of the industrys leading brand names. We also market
Stat-Rite® conductive polymers, which are static dissipative materials used in packaging
for the electronics industry. In addition, we market fiber-reinforced TPU under the
Estaloc® brand. Estaloc reinforced engineering thermoplastics offer the functional
properties of traditional TPU, yet are reinforced for higher stiffness to provide the strength,
dimensional stability and impact resistance required to withstand a variety of tough applications
and harsh environments. Applications include sporting goods, agricultural equipment and other
mechanical components.
The following is a list of representative uses for and a description of our Estane engineered
polymers products:
|
|
|
|
|
Category |
|
Product/Brand |
|
Description |
|
TPU
|
|
Estane®
|
|
Aromatic grades for
film and sheet, wire
and cable
insulation, athletic
equipment, medical
applications,
pneumatic tubing,
automotive molded
parts and adhesives. |
|
|
|
|
|
|
|
Estaloc®
|
|
Automotive trim,
sporting goods,
agricultural
equipment and other
mechanical
components. |
|
|
|
|
|
|
|
Stat-Rite®
|
|
Packaging of
semiconductors,
sensitive electronic
components, disk
drive heads and cell
phone components. |
|
|
|
|
|
|
|
Tecoflex®
|
|
Aliphatic grades for
optical film,
medical tubing and
general industrial
applications. |
Competition
Our Lubrizol Additives segment is highly competitive in terms of price, technology
development, product performance and customer service. Our principal competitors, both in the
United States and overseas, are: Infineum, a joint venture involving Shell Oil Company and Exxon
Mobil Corporation; Chevron Oronite Company, a subsidiary of Chevron Corporation; and Afton Chemical
Corporation, a subsidiary of NewMarket Corporation (formerly Ethyl Corporation). Petroleum
companies also produce, either directly or indirectly, lubricants and fuel additives for their own
use and also sell additives to others. These petroleum companies also are our customers, and some
of them sell raw materials to us. We believe, based on volume sold, that we are a leading supplier
of performance additives for lubricants to the petroleum industry.
11
Our Lubrizol Advanced Materials segment faces a variety of competitors in each of our product
lines, but we believe no single company competes with us across all of our existing product lines.
The advanced materials industry is highly fragmented. Individual products or service offerings
compete on a global, regional and local level due to the nature of the businesses and products, as
well as the applications and customers served. The following chart sets forth our principal
competitors of the Lubrizol Advanced Materials segment by product line:
|
|
|
|
|
Product Line |
|
Principal Competitors |
|
|
|
Noveon consumer specialties
|
|
Cognis, Croda, Degussa
Goldschmidt, ISP, NK Chemicals,
Rhodia, Rohm and Haas, Stepan,
Sumitomo Seika, 3V Sigma,
Toagosei, Vinati |
|
|
|
|
|
|
|
Performance coatings
|
|
BASF, Bayer, Byk, Ciba,
Clariant, Cytec, Dow Chemical,
DSM, Eastman, OMNOVA, Parachem,
Reichhold, Rohm and Haas, Tego |
|
|
|
|
|
|
|
Engineered polymers
|
|
Atofina, BASF, Bayer, Dow, Georgia Gulf, Huntsman, Kaneka,
Merquinsa, Sekisui Chemical, SK,
Vanguard, Victaulic, Wirsbo |
|
|
Sales and Marketing
We primarily market our lubricant and fuel additives products worldwide through our own direct
sales organization. In addition, we use sales agents and distributors where necessary. Our
additive customers primarily consist of oil refiners and independent oil blenders and are located
in more than 100 countries. Our 10 largest customers, most of which are international oil
companies and a number of which are groups of affiliated entities, accounted for approximately 39%
of our consolidated net sales in 2006. In 2006, there was no single customer that accounted for
more than 10% of consolidated net sales.
In order to maximize our understanding of customer needs as well as emerging trends, our sales
and marketing activities for our advanced materials products are organized by end-use applications.
Each sales team includes representatives from sales, marketing and research and development.
Our sales and marketing staff is technically oriented and works closely with customers to
develop products and formulations that deliver the desired product attributes. Some of our
laboratories are equipped with small-scale equipment that replicates our customers processing
capabilities, which ensure our solutions are easily and efficiently implemented at our customers
facilities.
Finally, many of our sales and marketing resources are dedicated to stimulating end-use demand
for our products. For example, in the case of our TempRite plumbing, fire sprinkler and industrial
piping applications, our resources are focused on marketing to building contractors, plumbers,
distributors and construction code officials to convince them to specify our products in their
projects or building codes.
Backlog
We have no material backlog of orders in either business segment at December 31, 2006 or
December 31, 2005. All unfilled orders that were placed by December 31, 2006 are reasonably
expected to be filled during 2007.
Research, Development and Technology
Technology leadership in design and formulation of additives and specialty chemicals drives
our business. Historically, we have emphasized consistent investment in research. We have
developed internally a large percentage of the products we manufacture and sell. Our internal
technical resources encompass chemical synthesis, world-class physical and analytical science,
statistical and computer modeling expertise and extensive applications technology and testing
laboratories. We balance centralized research facilities with applications technology capabilities
that are closely tied to their counterparts in the commercial organizations. Our technical
facilities are located all over the world. We provide tools and processes for knowledge sharing
and for leveraging our technology globally and across product lines.
Lubrizol Additives. In our Lubrizol Additives segment, the majority of the additives we
manufacture and sell are developed by our in-house research group. Technological advances in
materials and in the design of engines
and other automotive equipment, combined with rising demands for environmental protection and
fuel economy, require increasingly sophisticated research capabilities to meet industry performance
standards.
12
We have technical facilities in Wickliffe, Ohio; Hazelwood, United Kingdom; and Kinuura, Japan
for lubricant additives research. We also conduct a limited program of corporate research designed
to leverage technology across our product lines. We maintain mechanical testing laboratories at
those three locations, equipped with a variety of gasoline and diesel engines, driveline and other
mechanical equipment to evaluate the performance of additives for lubricants and fuels. In
addition, we make extensive use of independent research firms. Global field testing is conducted
through various arrangements with fleet operators and others.
We maintain offices in Southfield, Michigan; Hazelwood, United Kingdom; Paris, France;
Hamburg, Germany; Shanghai, China; Mumbai, India; Tokyo, Japan; and Seoul, South Korea to maintain
close contact with the principal automotive OEMs of the world and to keep us abreast of the
performance requirements for our products. These liaison activities also serve as contacts for
cooperative development and evaluation of products for future applications.
Lubrizol Advanced Materials. Our Lubrizol Advanced Materials segment has had a long history
as an industry innovator, creating proprietary, high-performance materials for our customers,
including ingredients for personal care products, the invention of Carbopol acrylic thickener,
additives for coatings and the commercial development of TempRite engineered polymers.
We have leveraged our core surface activity chemistry into new specialty chemicals and materials
markets through acquisitions and application technology expertise. Our specialty chemical and
materials products are derived from a broad range of technology platforms developed either
internally or externally through licensing, acquisition or joint technological alliances with
global suppliers and customers.
Our primary research facility for our Lubrizol Advanced Materials segment is located in
Brecksville, Ohio, where we develop new technologies and products and conduct applications
development and technical service for our customers. We maintain other smaller technical
facilities in various locations in the United States, Europe and Asia.
Patents. We own approximately 1,700 patents worldwide relating to our products and
manufacturing processes. Although these domestic and foreign patents expire from time to time, we
continue to apply for and obtain patent protection for new products on an ongoing basis. We
believe that, in the aggregate, our patents constitute an important asset. However, we do not
regard our business as being materially dependent upon any single patent or any group of related
patents. We use patents in both of our reporting segments.
Research, Testing and Development Expenditures. Our consolidated research and development
expenditures were $135.3 million in 2006, $128.1 million in 2005 and $103.7 million in 2004. These
amounts were equivalent to 3.3%, 3.5% and 3.6% of the respective consolidated total revenues for
those years. These amounts include expenditures for the performance evaluation of additive
developments in engines and other types of mechanical equipment as well as expenditures for the
development of specialty chemicals for industrial applications. In addition, we spent $70.2
million, $70.8 million and $81.1 million in 2006, 2005 and 2004, respectively, for technical
service (testing) activities, principally for evaluation in mechanical equipment of specific
lubricant formulations designed for the needs of petroleum industry customers throughout the world.
Our research and development staff works with both our sales force and customers to use our
wide spectrum of technology platforms and processing capabilities to enhance our product offerings
in the specialty chemicals industry. We have developed many of our products in cooperation with
our customers, often as a result of their specific needs, resulting in long-standing customer
relationships.
Raw Materials
We use a broad variety of specialty and commodity chemical raw materials in our manufacturing
processes, and use oil in processing and blending additives. These raw materials are obtainable
from several sources. The materials that we choose to purchase from a single source generally have
long-term supply contracts as a basis to guarantee supply reliability. For the most part, our raw
materials are derived from petroleum and petrochemical-based feedstocks.
Lubricant base oil is our single largest purchased raw material, representing approximately
30% of our purchases, by weight, for the Lubrizol Additives segment. Other major categories of raw
materials for the Lubrizol Additives segment include olefins and esters (approximately 20% of
purchases); inorganic acids, bases and oxides (approximately 10%); and alcohols and glycols
(approximately 5%). We believe that raw materials derived from petrochemicals are approximately
80% of our purchases for the Lubrizol Additives segment. For our Lubrizol
13
Advanced Materials
segment, no single raw material represents more than 9% of purchases. The top eight raw materials
total about 40% of our purchases for the Lubrizol Advanced Materials segment. Principal raw
materials for the Lubrizol Advanced Materials segment include three different acrylates for
personal care and coatings, styrene for coatings, and PVC, PTMEG, MDI and BDO for engineered
polymers.
Environmental Matters
We are subject to foreign, federal, state and local laws and regulations designed to protect
the environment and limit manufacturing wastes and emissions. We believe that, as a general
matter, our policies, practices and procedures are properly designed to prevent unreasonable risk
of environmental damage and the consequent financial liability to us. Compliance with
environmental laws and regulations requires continuing management effort and expenditures. We have
incurred, and will continue to incur, costs and capital expenditures to comply with these laws and
regulations and to obtain and maintain all necessary permits. We believe that the cost of
complying with environmental laws and regulations will not have a material affect on our earnings,
liquidity or competitive position, although we cannot provide you assurance in that regard.
We believe that our business, operations and facilities are being operated in compliance, in
all material respects, with applicable environmental laws and regulations, many of which provide
for substantial fines, penalties and criminal sanctions for violations. The operation of
manufacturing plants entails environmental risks, and we may incur material costs or liabilities in
the future that could adversely affect us. For example, we may be required to comply with evolving
environmental laws, regulations or requirements that may be adopted or imposed in the future or to
address newly discovered contamination or other conditions or information that require a response
on our part.
Among other environmental laws, we are subject to the Comprehensive Environmental Response,
Compensation and Liability Act of 1980 (commonly known as Superfund), under which we have been
designated as a potentially responsible party that may be liable for cleanup costs associated
with various waste or operating sites, some of which are on the U.S. Environmental Protection
Agency Superfund priority list. Our experience, consistent with what we believe to be the
experience of others in similar cases, is that Superfund site liability tends to be apportioned
among parties based upon the contribution of materials to the Superfund site. Accordingly, we
measure our liability and carry out our financial reporting responsibilities with respect to
Superfund sites based upon this standard, even though Superfund site liability is technically joint
and several in nature. We accrue for estimated environmental liabilities with charges to cost of
sales. We believe our environmental accrual is adequate to provide for our portion of the costs of
all such known environmental liabilities. Based upon consideration of currently available
information, we believe liabilities for environmental matters will not have a material adverse
affect on our financial position, operating results or liquidity, although we cannot provide you
assurance in that regard.
Noveon International is the beneficiary of agreements with Goodrich Corporation (Goodrich)
that require Goodrich to indemnify Noveon International for, among other things, certain
environmental liabilities and costs relating to facilities of the former Performance Materials
Segment of Goodrich. However, we cannot assure you that Goodrich or other third party indemnitors
will, in the future, honor their indemnification obligations to us.
Employees
At December 31, 2006, we had approximately 6,700 employees of which approximately 53% were in
the United States. We believe that our relationship with our employees is good. Three of our
U.S. sites, and approximately 4% of our domestic employees, are organized by labor unions with
collective bargaining agreements that are subject to periodic renegotiation. There are five
agreements covering two plants expiring in 2007 and one agreement expiring in 2008. We expect to
enter into new agreements with these unions as the current agreements expire.
Manufacturing and Properties
We possess global manufacturing, laboratory and sales and technical service facilities
enabling us to provide customers with worldwide service and a reliable supply of products. Our
corporate headquarters are located in Wickliffe, Ohio. We have manufacturing facilities and
laboratories, which we own or lease, at 22 sites in the United States and approximately 41 sites in
19 other countries. We also have entered into long-term contracts for the exclusive use of major
marine terminal facilities at various ports and leases for storage facilities. We
14
maintain a
capital expenditure program to support our operations and believe our facilities are adequate for
our present operations and for the foreseeable future.
Geographic Area Information
Financial information with respect to our domestic and foreign operations is contained in Note
15 to our consolidated financial statements.
We supply our customers abroad through exports from the United States and from overseas
manufacturing plants. We believe the political and economic risks related to our foreign
operations are mitigated due to the stability of the countries in which our largest foreign
operations are located.
ITEM 1A. RISK FACTORS
If any of the events contemplated by the following discussion of risks should occur, our
business, results of operations and financial condition could suffer significantly. The risks
described below are not the only risks that we face. Additional risks not currently known to us or
that we currently deem immaterial may also impair our business.
Financial Risks
The limits imposed on us by the restrictive covenants contained in our credit facilities could
prevent us from making acquisitions or capital improvements or cause us to lose access to these
facilities.
Our existing credit facilities contain restrictive covenants that limit our ability to, among
other things:
|
|
|
borrow money or guarantee the debts of others; |
|
|
|
|
use assets as security in other transactions; |
|
|
|
|
change our business or enter into new lines of business; and |
|
|
|
|
sell assets or merge with or into other companies. |
In addition, our credit facilities require us to meet financial ratios, including debt to
consolidated earnings before income taxes, depreciation and amortization (EBITDA) (as defined in
the credit facilities) and consolidated EBITDA (as defined in the credit facilities) to interest
expense. These restrictions could limit our ability to plan for or react to market conditions or
meet extraordinary capital needs and could otherwise restrict our financing activities.
Our ability to comply with the covenants and other terms of our credit facilities will depend
on our future operating performance. If we fail to comply with such covenants and terms, we will
be in default and the maturity of the related debt could be accelerated and become immediately due
and payable. We may be required to obtain waivers from our lenders in order to maintain compliance
under our credit facilities, including waivers with respect to our compliance with certain
financial covenants. If we are unable to obtain any necessary waivers and the debt under our
credit facilities is accelerated, our financial condition would be adversely affected.
We may not have access to capital in the future.
We may need new or additional financing in the future to expand our business or refinance
existing indebtedness. If we are unable to access capital on satisfactory terms and conditions, we
may not be able to expand our business or meet our payment requirements under our existing credit
facilities. Our ability to obtain new or
additional financing will depend on a variety of factors, many of which are beyond our
control. We may not be able to obtain new or additional financing because we have substantial debt
or because we may not have sufficient cash flow to service or repay our existing or future debt.
In addition, depending on market conditions and our financial performance, equity financing may not
be available on satisfactory terms or at all.
15
We could be adversely affected if our debt is downgraded.
Our ability to complete offerings of debt securities on satisfactory terms in the future will
depend on the status of our credit rating. The current rating of our senior unsecured long-term
indebtedness is BBB- by Standard & Poors Ratings Group (S&P) and Baa3 by Moodys Investors
Service, Inc. (Moodys). Either S&P or Moodys or both may downgrade our credit rating at any
time, which would make it more difficult to complete offerings of debt securities on satisfactory
terms and generally would result in increased future borrowing costs and adversely affect our
access to debt and capital markets.
Risks Relating to our Business
Volatility in raw material prices could reduce our profitability and reductions in the availability
of raw material supplies could disrupt our operations.
Some of the raw materials that we use are derived from petrochemical-based feedstocks, such as
crude oil and natural gas, which have been subject to historical periods of rapid and significant
movements in price. These fluctuations in price could be aggravated by political instability,
terrorist attacks or other hostilities in oil-producing countries or elsewhere in the world, and
supply and demand factors, including OPEC production quotas and increased global demand for
petroleum-based products. We also use natural gas as fuel at our facilities, and increases in the
price of natural gas may reduce our profitability. Any significant variations in the cost and
availability of our specialty and commodity materials or energy may negatively affect our business,
financial condition or results of operations. We typically do not enter into hedging arrangements
with respect to raw materials or energy, other than for natural gas and electricity. We
selectively pass changes in the prices of raw materials to our customers from time to time.
However, we cannot always do so, and any limitation on our ability to pass through any price
increases could affect our financial performance.
We use significant quantities of a variety of specialty and commodity chemicals in our
manufacturing processes, such as lubricant base oils (a derivative of crude oil); C4 feedstreams;
acrylates; PVC; inorganic acids, bases and oxides; alcohols, glycols and polyols; olefins and
esters; sulfonates; phenates; alkylates; sulfonic acids; and amines. These raw materials generally
are available from numerous independent suppliers. However, some of our raw material needs are met
by a sole supplier or only a few suppliers. If any supplier that we rely on for raw materials
ceases or limits production, we may incur significant additional costs, including capital costs, in
order to find alternate, reliable raw material suppliers. We may also experience significant
production delays while locating new supply sources.
We face competition from other chemical companies, which could adversely affect our revenue and
financial condition.
We actively compete with companies producing the same or similar products and, in some
instances, with companies producing different products designed for the same uses. We encounter
competition in price, delivery, service, performance, product innovation and product recognition
and quality, depending on the product involved. For some of our products, our competitors are
larger and have greater financial resources and less debt than we do. As a result, these
competitors may be better able to withstand a change in conditions within the industries in which
we operate, a change in the prices of raw materials or a change in the economy as a whole.
Our competitors can be expected to continue to develop and introduce new and enhanced
products, which could cause a decline in market acceptance of our products. Current and future
consolidation among our competitors and customers also may cause a loss of market share as well as
put downward pressure on pricing. Additionally, a number of our niche product applications are
customized or sold for highly specialized uses. Our competitors could cause a reduction in the
prices for some of our products as a result of intensified price competition. Competitive
pressures can also result in the loss of major customers. If we cannot compete successfully, our
business, financial condition and consolidated results of operations could be adversely affected.
Failure to make continued improvements in our technology and productivity could hurt our
competitive position.
We believe that we must continue to enhance our existing products and to develop and
manufacture new products with improved capabilities in order to continue to be a market leader. We
also believe that we must continue to make improvements in our productivity in order to maintain
our competitive position. When we invest in new technologies, processes or production facilities,
we face risks related to construction delays, cost over-runs
16
and unanticipated technical
difficulties. Our inability to anticipate, respond to or utilize changing technologies could have
a material adverse effect on our business and our consolidated results of operations.
Our and our suppliers production facilities are subject to operating risks that may adversely
affect our operations.
We are dependent upon the continued safe operation of our and our suppliers production
facilities. These production facilities are subject to hazards associated with the manufacture,
handling, storage and transportation of chemical materials and products, including leaks and
ruptures, explosions, fires, inclement weather and natural disasters, unscheduled downtime and
environmental hazards. Incidents at our or our suppliers production facilities could temporarily
shut down or otherwise disrupt our manufacturing operations, causing production delays and, with
respect to our facilities, resulting in liability for workplace injuries and fatalities. In
addition, some of our and our suppliers production facilities are highly specialized, which limits
our ability to shift production to other facilities in the event of an incident at a particular
facility. If a production facility, or a critical portion of a production facility, were
temporarily shut down, we likely would incur higher costs for alternate sources of supply for our
products. Some of our products involve the manufacture and/or handling of a variety of reactive,
explosive and flammable materials. Use of these products by our customers also could result in
liability if an explosion, fire, spill or other accident were to occur. We cannot assure you that
we will not experience these types of incidents in the future or that these incidents will not
result in production delays or otherwise have a material adverse effect on our business, financial
condition or results of operations.
Some of our businesses are cyclical and demand by our customers for our products weakens during
economic downturns.
A portion of our product sales is attributable to industries and markets, such as the
construction and metalworking industries, that historically have been cyclical and sensitive to
relative changes in supply and demand and general economic conditions. The demand for our products
depends, in part, on the general economic conditions of the industries or national economies of our
customers. Downward economic cycles in our customers industries or countries may reduce sales of
some of our products. It is not possible to predict accurately the factors that will affect demand
for our products in the future. Any significant downturn in the health of the general economy,
either globally or regionally, or the markets in which we sell products could have an adverse
effect on our revenues and financial performance.
Failure to implement our common information system platform successfully could negatively impact
our ability to integrate our core business processes.
In 2006 we launched a company-wide initiative to extend our current information system
platform to the entire organization so that our core business processes are integrated globally.
We successfully implemented a common information system platform in 1998 and now we have begun
rolling out the system to the acquired Lubrizol Advanced Materials segment and to those parts of
Lubrizol Additives that are not yet utilizing it. Currently, this substantial investment is
progressing on schedule; we expect to have more than 75% of our revenue base utilizing the same
information system platform by mid-2008 and anticipate completing the migration to our entire
company by mid-2009.
We consider the risk to be low that our information system implementation may significantly
disrupt our business processes and impact our ability to serve customers. We essentially are
implementing an existing design of the system that has worked for the past six years in our
Lubrizol Additives segment. Moreover, we have put together a seasoned project management team.
However, we face the risks that the common information system platform will not be completed on a
timely basis, it may cost more than projected or we may not realize its anticipated benefits.
We face numerous risks relating to our foreign operations, including foreign currency exchange rate
fluctuations, exchange controls and currency devaluations, that may adversely affect our results of
operations.
In 2006 approximately 33% of our consolidated revenues were generated in currencies other than
the U.S. dollar, which is our reporting currency, and 31% of our consolidated cost of sales and
30% of selling, technical, administrative and research (STAR) expenses were generated in currencies
other than the U.S. dollar. We recognize foreign currency transaction gains and losses arising
from our operations in the period incurred. As a result, currency fluctuations between the
U.S. dollar and the currencies in which we do business have caused and
17
will continue to cause
foreign currency transaction gains and losses, which historically have been material and could
continue to be material. We cannot predict the effects of exchange rate fluctuations upon our
future operating results because of the number of currencies involved, the variability of currency
exposures and the potential volatility of currency exchange rates. We take actions to manage our
foreign currency exposure such as entering into hedging transactions, where available, but we
cannot assure you that our strategies will adequately protect our consolidated operating results
from the effects of exchange rate fluctuations.
We also face risks arising from the imposition of exchange controls and currency devaluations.
Exchange controls may limit our ability to convert foreign currencies into U.S. dollars or to
remit dividends and other payments by our foreign subsidiaries or businesses located in or
conducted within a country imposing controls. Currency devaluations result in a diminished value
of funds denominated in the currency of the country instituting the devaluation and, if they occur
or continue for significant periods, could adversely affect our earnings or cash flow.
International social, political and economic conditions may adversely affect our operating
performance.
Our international operations are also subject to the risk of labor unrest, regional economic
uncertainty, political instability, terrorism, expropriation of property, restrictions on the
transfer of funds into or out of a country, trade restrictions, export duties, taxes and quotas,
domestic and foreign customs and tariffs, and current and changing regulatory environments. Any of
these events could have an adverse effect on our international operations in the future by reducing
the demand for our products, increasing the prices at which we can sell our products or otherwise
having an adverse effect on our operating performance.
Our production facilities are of the type that may attract terrorist attacks, and any attack may
disrupt our operations and cause us to incur significant costs and liabilities.
Uncertainty surrounding the possibility and scope of terrorist attacks may affect our
operations in unpredictable ways, including the possibility that our chemical production facilities
may become direct targets, or indirect casualties, of terrorist attacks. Although our production
facilities are under a heightened level of security, this level of security may be insufficient to
prevent a terrorist attack. The resulting damage may be severe and could include loss of life and
property damage. In addition, some of our production and other facilities are located at sites
near to other chemical plants that may be potential targets of terrorist attacks. The resulting
collateral damage may be significant and substantial. Available insurance coverage may not be
sufficient to cover all of the damage incurred or may be prohibitively expensive.
Certain of our employees are covered by collective bargaining agreements, and the failure to renew
these agreements could result in labor disruptions and increased labor costs.
Employees at three of our U.S. sites, who constitute approximately 4% of our domestic
employees, are organized by labor unions that have collective bargaining agreements with us that
are subject to renegotiation. Five agreements covering two plants expire in 2007 and one agreement
expires in 2008. Although we believe that our present labor relations are satisfactory, our
failure to renew these agreements on reasonable terms as the current agreements expire could result
in labor disruptions and increased labor costs, which could adversely affect our financial
performance.
The applicability of numerous environmental laws to our manufacturing facilities could cause us to
incur significant costs and liabilities.
We are subject to extensive federal, state, local and foreign environmental, safety and health
laws and regulations concerning, among other things, emissions to the air, discharges to land and
water and the generation, handling, treatment and disposal of hazardous waste and other materials.
Under certain environmental laws, we can be held strictly liable for hazardous substance
contamination of any real property we have ever owned, operated or used as a disposal site or for
natural resource damages associated with such contamination. We are also required to maintain
various environmental permits and licenses, many of which require periodic modification and
renewal. Our operations entail the risk of violations of those laws and regulations, many of which
provide for substantial fines and criminal sanctions for violations. We cannot assure you that we
have been or will be at all times in compliance with all of these requirements.
18
In addition, these requirements and their enforcement may become more stringent in the future.
Although we cannot predict the ultimate cost of compliance with any such requirements, the costs
could be significant. Non-compliance could subject us to significant liabilities, such as
government fines, third-party lawsuits or the suspension of non-compliant operations. We also may
be required to make significant site or operational modifications at substantial cost. Future
developments also could restrict or eliminate the use of or require us to make modifications to our
products, which could have a significant negative impact on our results of operations and cash
flows.
At any given time, we are involved in claims, litigation, administrative proceedings and
investigations of various types in a number of jurisdictions involving potential environmental
liabilities, including clean-up costs associated with hazardous waste disposal sites, natural
resource damages, property damage and personal injury. We cannot assure you that the resolution of
these environmental matters will not have a material adverse effect on our results of operations or
cash flows.
The ultimate costs and timing of environmental liabilities are difficult to predict.
Liability under environmental laws relating to contaminated sites can be imposed retroactively and
on a joint and several basis. One liable party could be held responsible for all costs at a site,
regardless of fault, percentage of contribution to the site or the legality of the original
disposal. We may also face liability with respect to acquired businesses for violations under
environmental laws occurring prior to the date of our acquisition, and some or all of these
liabilities may not be covered by indemnification from the sellers from which we acquired these
businesses. We could incur significant costs, including cleanup costs, natural resources damages,
civil or criminal fines and sanctions and third-party claims, as a result of past or future
violations of, or liabilities under, environmental laws.
If we are unable to protect our intellectual property rights, our product sales and financial
performance could be adversely affected.
We rely on a combination of patent, trade secret, copyright and trademark law, nondisclosure
agreements and technical security measures to protect our intellectual property rights in our
various lines of business. Our performance may depend in part on our ability to establish, protect
and enforce intellectual property rights with respect to our patented technologies and proprietary
rights and to defend against any claims of infringement, which involves complex legal, scientific
and factual questions and uncertainties.
In the future, we may have to rely on litigation to enforce our intellectual property rights
and contractual rights. In addition, we may face claims of infringement that could interfere with
our ability to use technology or other intellectual property rights that are material to our
business operations. If litigation that we initiate is unsuccessful, we may not be able to protect
the value of some of our intellectual property. In the event a claim of infringement against us is
successful, we may be required to pay royalties or license fees to continue to use technology or
other intellectual property rights that we have been using or we may be unable to obtain necessary
licenses from third parties at a reasonable cost or within a reasonable time. If we are unable to
obtain licenses on reasonable terms, we may be forced to cease selling or using any of our products
that incorporate the challenged intellectual property, or to redesign or, in the case of trademark
claims, rename our products to avoid infringing the intellectual property rights of third parties,
which may not be possible and may be time-consuming if possible. Any litigation of this type,
whether successful or unsuccessful, could result in substantial costs to us and diversions of some
of our resources. Our intellectual property rights may not have the value we believe them to have,
which could result in a competitive disadvantage or adversely affect our business and financial
performance.
ITEM 1B. UNRESOLVED STAFF COMMENTS
We have no unresolved Securities and Exchange Commission staff comments at this time.
19
ITEM 2. PROPERTIES
Our corporate headquarters are located in Wickliffe, Ohio. Our commercial centers for
Lubrizol Additives and Lubrizol Advanced Materials are located in Wickliffe, Ohio and Brecksville,
Ohio, respectively. Our significant Lubrizol Additives segment manufacturing facilities are
located in Bayport, Texas; Deer Park, Texas; Le Havre, France; Painesville, Ohio; and Rouen,
France. Our significant Lubrizol Advanced Materials manufacturing facilities are located in
Antwerp, Belgium; Avon Lake, Ohio; Calvert City, Kentucky; Louisville, Kentucky; and Oevel,
Belgium. We have other offices and facilities around the world. The locations of our
manufacturing and laboratory facilities are indicated below in the following chart.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reporting Segments |
|
|
|
|
|
|
|
|
Lubrizol |
|
|
Owned/ |
|
Laboratory (R&D/Testing) |
|
Lubrizol |
|
Advanced |
Location |
|
Leased |
|
or Manufacturing |
|
Additives |
|
Materials |
Sydney, Australia
|
|
Owned
|
|
Manufacturing
|
|
x
|
|
x |
Antwerp, Belgium
|
|
Owned
|
|
Laboratory, Manufacturing
|
|
|
|
x |
Louvaine Leneuve, Belgium
|
|
Leased
|
|
Laboratory
|
|
|
|
x |
Oevel, Belgium
|
|
Owned
|
|
Manufacturing
|
|
|
|
x |
Vilvoorde, Belgium
|
|
Owned
|
|
Manufacturing
|
|
|
|
x |
Rio de Janeiro, Brazil
|
|
Owned
|
|
Manufacturing
|
|
x
|
|
x |
Sao Paulo, Brazil
|
|
Leased
|
|
Laboratory
|
|
|
|
x |
Niagara Falls, Ontario, Canada
|
|
Owned
|
|
Manufacturing
|
|
x |
|
|
Hong Kong, China
|
|
Leased
|
|
Laboratory
|
|
|
|
x |
Lanzhou, China(1)
|
|
Plant is owned;
land is leased
|
|
Manufacturing
|
|
x |
|
|
Qingpu, China
|
|
Leased
|
|
Laboratory, Manufacturing
|
|
|
|
x |
Shanghai, China
|
|
Leased
|
|
Laboratory
|
|
|
|
x |
Shanghai, China
|
|
Leased
|
|
Laboratory
|
|
x |
|
|
Songjiang, China
|
|
Leased
|
|
Manufacturing
|
|
|
|
x |
Tianjin, China (1)
|
|
Plant is owned;
land is leased
|
|
Manufacturing
|
|
x |
|
|
Zhejiang, China(1)
|
|
Plant is owned;
land is leased
|
|
Manufacturing
|
|
|
|
x |
Le Havre, France
|
|
Owned
|
|
Manufacturing
|
|
x |
|
|
Mourenx, France
|
|
Owned
|
|
Manufacturing
|
|
x |
|
|
Rouen, France
|
|
Owned
|
|
Manufacturing
|
|
x |
|
|
Hamburg, Germany
|
|
Leased
|
|
Laboratory, Manufacturing
|
|
x |
|
|
Ritterhude, Germany
|
|
Owned
|
|
Laboratory, Manufacturing
|
|
|
|
x |
Mumbai, India(1)
|
|
Plant is owned;
land is leased
|
|
Manufacturing
|
|
x |
|
|
Mumbai, India
|
|
Leased
|
|
Laboratory
|
|
|
|
x |
Vadadora, India
|
|
Owned
|
|
Laboratory, Manufacturing
|
|
|
|
x |
Kinuura, Japan
|
|
Owned
|
|
Laboratory, Manufacturing
|
|
x
|
|
x |
Sembilan, Malaysia
|
|
Owned
|
|
Manufacturing
|
|
|
|
x |
Apodaca, Mexico(1)
|
|
Owned
|
|
Laboratory, Manufacturing
|
|
x |
|
|
Mexico City, Mexico
|
|
Leased
|
|
Laboratory
|
|
|
|
x |
Delfzijl, The Netherlands
|
|
Leased
|
|
Manufacturing
|
|
|
|
x |
Yanbu, Saudi Arabia(1)
|
|
Owned
|
|
Laboratory, Manufacturing
|
|
x |
|
|
Singapore
|
|
Plant is owned;
land is leased
|
|
Manufacturing
|
|
x |
|
|
Singapore
|
|
Leased
|
|
Laboratory
|
|
|
|
x |
Durban, South Africa
|
|
Owned
|
|
Manufacturing
|
|
x
|
|
x |
Pohang, South Korea
|
|
Plant is owned;
land is leased
|
|
Manufacturing
|
|
|
|
x |
Barcelona, Spain
|
|
Owned
|
|
Laboratory, Manufacturing
|
|
|
|
x |
20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reporting Segments |
|
|
|
|
|
|
|
|
Lubrizol |
|
|
Owned/ |
|
Laboratory (R&D/Testing) |
|
Lubrizol |
|
Advanced |
Location |
|
Leased |
|
or Manufacturing |
|
Additives |
|
Materials |
Muang, Thailand
|
|
Jointly Owned
|
|
Laboratory, Manufacturing
|
|
|
|
x |
Barnsley, United Kingdom
|
|
Owned
|
|
Laboratory, Manufacturing
|
|
|
|
x |
Blackley, United Kingdom
|
|
Leased
|
|
Laboratory
|
|
|
|
x |
Hazelwood, United Kingdom
|
|
Owned
|
|
Laboratory
|
|
x |
|
|
Huddersfield, United Kingdom
|
|
Plant is owned;
land is leased
|
|
Laboratory, Manufacturing
|
|
|
|
x |
Grangemouth, United Kingdom
|
|
Leased
|
|
Laboratory
|
|
|
|
x |
Paso Robles, CA
|
|
Plant is owned;
land is leased
|
|
Laboratory, Manufacturing
|
|
|
|
x |
Peachtree City, GA
|
|
Owned
|
|
Manufacturing
|
|
|
|
x |
Countryside, IL
|
|
Owned
|
|
Laboratory, Manufacturing
|
|
|
|
x |
McCook, IL
|
|
Leased
|
|
Laboratory, Manufacturing
|
|
|
|
x |
Calvert City, KY
|
|
Owned
|
|
Manufacturing
|
|
|
|
x |
Louisville, KY
|
|
Owned
|
|
Manufacturing
|
|
|
|
x |
Lawrence, MA
|
|
Owned
|
|
Laboratory, Manufacturing
|
|
|
|
x |
Wilmington, MA
|
|
Leased
|
|
Manufacturing
|
|
|
|
x |
Midland, MI
|
|
Owned
|
|
Laboratory, Manufacturing
|
|
x |
|
|
Pedricktown, NJ
|
|
Owned
|
|
Manufacturing
|
|
|
|
x |
Gastonia, NC
|
|
Owned
|
|
Laboratory, Manufacturing
|
|
|
|
x |
Avon Lake, OH
|
|
Owned
|
|
Laboratory, Manufacturing
|
|
|
|
x |
Bowling Green, OH
|
|
Owned
|
|
Laboratory, Manufacturing
|
|
|
|
x |
Brecksville, OH
|
|
Owned
|
|
Laboratory
|
|
|
|
x |
Chagrin Falls, OH
|
|
Owned
|
|
Laboratory, Manufacturing
|
|
|
|
x |
Painesville, OH
|
|
Owned
|
|
Manufacturing
|
|
x
|
|
x |
Wickliffe, OH
|
|
Owned
|
|
Laboratory
|
|
x |
|
|
Spartanburg, SC
|
|
Leased
|
|
Laboratory
|
|
x |
|
|
Spartanburg, SC
|
|
Owned
|
|
Laboratory, Manufacturing
|
|
x
|
|
x |
Bayport, TX
|
|
Owned
|
|
Manufacturing
|
|
x
|
|
x |
Deer Park, TX
|
|
Owned
|
|
Manufacturing
|
|
x |
|
|
Houston, TX
|
|
Owned
|
|
Manufacturing
|
|
|
|
x |
(1) |
|
These manufacturing plants are owned and operated by joint venture companies licensed by
Lubrizol. |
In some cases, the ownership or leasing of these facilities is through a subsidiary or
affiliate. We have entered into long-term contracts for our exclusive use of major marine terminal
facilities at the Port of Houston, Texas.
In September 2006, we entered into an agreement to sell our Lubrizol Additives manufacturing
plant in Bromborough, United Kingdom. The sale closed in January 2007 for a purchase price of
approximately $5.9 million. Production from this U.K. facility was transferred to higher-capacity
Lubrizol facilities in France and the United States. The sale of the facility will save
approximately $3.0 million to $5.0 million in restructuring costs that would have been associated
with the demolition of the plant facilities on the site. Cumulative pretax charges of
approximately $12.8 million were incurred through 2006, of which $6.7 million were incurred in
2006, to satisfy severance and retention obligations, plant dismantling, site restoration and other
site environmental evaluation costs.
We have invested approximately $15.3 million in capital related to the Bromborough plant
closure through December 31, 2006 for capacity upgrades in France and the United States. We expect
additional capacity upgrades through the first quarter of 2007 to total approximately $4.0 million.
21
We maintain a capital expenditure program to support our operations and believe our facilities
are adequate for our present operations and for the foreseeable future.
ITEM 3. LEGAL PROCEEDINGS
In the fourth quarter of 2006, we received a notice of violation from the Louisville (KY)
Metro Air Pollution Control District relating to alleged violations of the air permit held by our
Louisville, Kentucky facility. Initial discussions with the regulators indicate that the final
resolution of this matter may include a penalty greater than the applicable reporting threshold.
At this time, however, we do not have sufficient information to make a reasonable assessment of the
penalty.
In the third quarter of 2005, we voluntarily notified the U.S. Departments of Treasury and
Commerce that an internal review of certain export transactions within the personal care and
pharmaceuticals business of the Lubrizol Advanced Materials segment indicated that some exports
were made that were not in compliance with current U.S. trade sanctions. We voluntarily completed
a thorough review of all possibly non-complying transactions and detailed our findings in a
subsequent report that was made to the government in the third quarter of 2005. While the sales
involved were not substantial in relation to the company or the Lubrizol Advanced Materials
segment, we consider legal compliance to be very important. In 2006, the U.S. Department of
Treasury, Office of Foreign Assets Control, alleged that we violated the Iran Trading Regulations
applicable to U.S. companies and persons and they fined us $5,500 for the behaviors disclosed.
Separately, the U.S. Department of Commerce investigated us and issued a finding that, while the
acts committed and disclosed could have been referred to the U.S. Department of Justice for
criminal prosecution and/or been the basis of a monetary penalty against the company, it had closed
the matter with a written warning and an order to cease and prevent offending acts in the future.
We believe our self-reporting and corrective measures, including disciplinary actions taken,
mitigated the penalties assessed against us.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
No matters were submitted to the vote of the security holders during the three months ended
December 31, 2006.
22
EXECUTIVE OFFICERS OF THE REGISTRANT
The following sets forth the name, age, recent business experience and certain other
information relative to each person who was an executive officer as of February 28, 2007.
|
|
|
|
|
|
|
Name |
|
|
Age |
|
|
Position |
James L. Hambrick
|
|
|
52 |
|
|
Chairman of the Board, President and Chief Executive Officer |
Joseph W. Bauer
|
|
|
53 |
|
|
Vice President and General Counsel |
Donald W. Bogus
|
|
|
59 |
|
|
Senior Vice President and President - Lubrizol Advanced Materials |
Charles P. Cooley
|
|
|
51 |
|
|
Senior Vice President, Treasurer and Chief Financial Officer |
W. Scott Emerick
|
|
|
42 |
|
|
Corporate Controller |
Stephen F. Kirk
|
|
|
57 |
|
|
Senior Vice President and President - Lubrizol Additives |
Mark W. Meister
|
|
|
52 |
|
|
Vice President and Chief Ethics Officer |
Leslie M. Reynolds
|
|
|
46 |
|
|
Corporate Secretary |
Patrick Saunier
|
|
|
51 |
|
|
Vice President, Information Systems |
Gregory D. Taylor
|
|
|
48 |
|
|
Vice President, Corporate Planning, Development and
Communications |
Jeffrey A. Vavruska
|
|
|
46 |
|
|
Chief Tax Officer |
Joanne Wanstreet
|
|
|
55 |
|
|
Vice President, Investor Relations |
James L. Hambrick is chairman of the board of directors, president and chief executive officer of
The Lubrizol Corporation. He was elected president in January 2003, chief executive officer in
April 2004 and chairman of the board effective January 3, 2005. From May 2000 to January 2003, he
was vice president responsible for managing corporate strategies in the Asia Pacific region.
Joseph W. Bauer has been the vice president and general counsel of The Lubrizol Corporation since
April 1992.
Donald W. Bogus became a senior vice president of The Lubrizol Corporation in July 2004 and
president of the Lubrizol Advanced Materials segment in April 2004. He joined Lubrizol in 2000 as
vice president responsible for the Fluid Technologies for Industry segment. He also led Lubrizols
mergers and acquisitions committee.
Charles P. Cooley is a senior vice president and the chief financial officer of The Lubrizol
Corporation. He joined Lubrizol in 1998 as its chief financial officer and vice president. He was
also treasurer from April 1998 to September 2001 and since September 2006. Mr. Cooley became a
senior vice president in July 2004.
W. Scott Emerick joined The Lubrizol Corporation as corporate controller in June 2004. Prior to
that, Mr. Emerick was at Noveon International, where he held the positions of director of finance -
TempRite products from September 2003 to June 2004 and director of accounting and external
financial reporting from April 2001 to September 2003.
Stephen F. Kirk became a senior vice president of The Lubrizol Corporation in July 2004 and the
president of the Lubrizol Additives segment in June 2004. Previously, he was vice president of
sales and marketing for Lubrizol since January 1999.
Mark W. Meister has been the vice president of human resources for The Lubrizol Corporation since
1993 and chief ethics officer since 1994.
Leslie M. Reynolds is corporate secretary and counsel for The Lubrizol Corporation. She has been
counsel since February 1991. She served as assistant secretary from 1997 until her appointment as
corporate secretary in April 2001.
Patrick H. Saunier became the vice president for information systems and business processes for The
Lubrizol Corporation in July 2004. From 1999 to 2004, Mr. Saunier led the European shared services
organization.
Gregory D. Taylor became the vice president for corporate planning, development and communications
for The Lubrizol Corporation in February 2007. From 2003 to 2007, Mr. Taylor was the managing
director of corporate planning for Lubrizol. From 2000-2003, he was a global business manager for
Lubrizol.
23
Jeffrey A. Vavruska joined The Lubrizol Corporation as chief tax officer in April 2004.
Previously, he worked at American Greetings Corporation, where he was executive director of tax
from September 2001 to April 2004.
Joanne Wanstreet was elected vice president with responsibility for global communications and
investor relations for The Lubrizol Corporation in April 2002. From January 2001 to April 2002,
Ms. Wanstreet was manager, investor relations.
All executive officers serve at the pleasure of the Board.
24
PART II
ITEM 5. MARKET FOR REGISTRANTS COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
Our common shares are listed on the New York Stock Exchange under the symbol LZ. The number
of shareholders of record of common shares was 3,229 as of February 15, 2007.
Information relating to the recent price and dividend history of our common shares follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Share Price History |
|
|
Dividends |
|
|
2006 |
|
|
2005 |
|
|
Per Common Share |
|
|
|
High |
|
|
Low |
|
|
High |
|
|
Low |
|
|
2006 |
|
|
2005 |
|
1st quarter |
|
$ |
46.44 |
|
|
$ |
41.70 |
|
|
$ |
43.57 |
|
|
$ |
35.25 |
|
|
|
$ .26 |
|
|
|
$ .26 |
|
2nd quarter |
|
|
45.20 |
|
|
|
38.52 |
|
|
|
44.51 |
|
|
|
36.74 |
|
|
|
.26 |
|
|
|
.26 |
|
3rd quarter |
|
|
46.25 |
|
|
|
38.03 |
|
|
|
44.50 |
|
|
|
39.12 |
|
|
|
.26 |
|
|
|
.26 |
|
4th quarter |
|
|
50.75 |
|
|
|
44.16 |
|
|
|
44.16 |
|
|
|
39.83 |
|
|
|
.26 |
|
|
|
.26 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1.04 |
|
|
|
$ 1.04 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
We have no restrictions on the payment of dividends on Lubrizol common shares.
On October 2, 2006, 235 common shares were issued in a private placement transaction exempt
from registration under the Securities Act of 1933 pursuant to Section 4(2) of that Act. We issued
the common shares to a former officer under a deferred compensation plan for officers.
On December 1, 2006, 193 common shares were issued in a private placement transaction exempt
from registration under the Securities Act of 1933 pursuant to Section 4(2) of that Act. We issued
the common shares to a former officer under a deferred compensation plan for officers.
The following table provides information regarding our purchases of Lubrizol common shares
during the quarter.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Maximum Number |
|
|
|
|
|
|
|
|
|
|
|
Total Number |
|
|
(or Approximate Dollar |
|
|
|
|
|
|
|
|
|
|
|
of Shares (or Units) |
|
|
Value) of Shares (or |
|
|
|
Total Number of |
|
|
Average Price |
|
|
Purchased as Part of |
|
|
Units) that May Yet be |
|
|
|
Shares (or Units) |
|
|
Paid per Share |
|
|
Publicly Announced |
|
|
Purchased Under the |
|
Period |
|
Purchased1 |
|
|
(or Unit) |
|
|
Plans or Programs |
|
|
Plans or Programs |
|
Month #1
(Oct. 1, 2006 through
Oct. 31, 2006) |
|
0 Shares |
|
|
N/A |
|
|
|
N/A |
|
|
|
N/A |
|
Month #2
(Nov. 1, 2006 through
Nov. 30, 2006) |
|
12,267 Shares |
|
|
$ 47.84 |
|
|
|
N/A |
|
|
|
N/A |
|
Month #3
(Dec. 1, 2006 through
Dec. 31, 2006) |
|
0 Shares |
|
|
N/A |
|
|
|
N/A |
|
|
|
N/A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
12,267 Shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
1 |
|
This column represents common shares that we purchased pursuant to: |
(a) our option plan, whereby participants exchange already owned shares to us to pay for the
exercise price of an option or whereby we withhold shares upon the exercise of an option to
pay the withholding taxes on behalf of the employee.
25
(b) our deferred compensation plans, whereby we withhold shares upon a distribution to pay
the withholding taxes on behalf of the employee.
Performance Comparisons
The following chart compares our combined total shareholder returns for the five years ended
December 31, 2006 to the combined total shareholder returns of the Standard & Poors 500 Index and
the Standard & Poors Chemicals Industry.
We have selected the Standard & Poors 500 Index, because we believe it provides a broad
equity market comparison and is widely used for comparison by our peer group. We believe we have a
peer group relationship with companies in the Standard & Poors Chemicals Industry.
No single peer index or peer company is comparable totally to our business. Included in the
Standard & Poors Chemicals Industry are companies that supply specialty chemicals and other
related products to a wide variety of markets. Some of our direct competitors are chemical
divisions that represent small portions of large oil companies. These chemical divisions are not
included in the peer comparison because information is not available to us that shows those
divisions separately from the parent company.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12/01 |
|
|
|
12/02 |
|
|
|
12/03 |
|
|
|
12/04 |
|
|
|
12/05 |
|
|
|
12/06 |
|
The Lubrizol Corporation |
|
|
100.00 |
|
|
|
89.77 |
|
|
|
98.98 |
|
|
|
115.83 |
|
|
|
139.99 |
|
|
|
165.43 |
|
S&P Chemicals Industry |
|
|
100.00 |
|
|
|
96.97 |
|
|
|
123.06 |
|
|
|
148.05 |
|
|
|
147.91 |
|
|
|
171.48 |
|
S&P 500 |
|
|
100.00 |
|
|
|
77.90 |
|
|
|
100.24 |
|
|
|
111.15 |
|
|
|
116.61 |
|
|
|
135.03 |
|
The above chart assumes the investment of $100 on December 31, 2001 and the immediate investment of
all dividends.
26
ITEM 6. SELECTED FINANCIAL DATA
Historical Summary (as restated)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In Millions, Except Shareholders, Employees and Per-Share Data) |
|
2006 |
|
2005 |
|
2004* |
|
2003** |
|
2002** |
|
OPERATING RESULTS: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues |
|
$ |
4,040.8 |
|
|
$ |
3,622.2 |
|
|
$ |
2,864.4 |
|
|
$ |
1,984.2 |
|
|
$ |
1,934.0 |
|
Total cost and expenses*** |
|
|
3,708.0 |
|
|
|
3,286.8 |
|
|
|
2,663.2 |
|
|
|
1,842.6 |
|
|
|
1,737.9 |
|
Net interest expense and other income |
|
|
(70.8 |
) |
|
|
(95.2 |
) |
|
|
(66.7 |
) |
|
|
(17.8 |
) |
|
|
(17.8 |
) |
Income from continuing operations before cumulative effect of
change in accounting principle |
|
|
179.8 |
|
|
|
159.4 |
|
|
|
85.5 |
|
|
|
87.6 |
|
|
|
125.6 |
|
(Loss) income from discontinued operations,
net of income taxes |
|
|
(76.2 |
) |
|
|
27.8 |
|
|
|
6.3 |
|
|
|
1.9 |
|
|
|
(0.1 |
) |
Income before cumulative effect
of change in accounting principle |
|
|
103.6 |
|
|
|
187.2 |
|
|
|
91.8 |
|
|
|
89.5 |
|
|
|
125.5 |
|
Cumulative effect of change in accounting principle |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7.8 |
) |
Net income |
|
|
103.6 |
|
|
|
187.2 |
|
|
|
91.8 |
|
|
|
89.5 |
|
|
|
117.7 |
|
Income from continuing operations, per diluted share before
cumulative effect of change in accounting principle |
|
|
2.59 |
|
|
|
2.32 |
|
|
|
1.53 |
|
|
|
1.70 |
|
|
|
2.43 |
|
Discontinued operations per diluted share |
|
|
(1.10 |
) |
|
|
0.40 |
|
|
|
0.11 |
|
|
|
0.04 |
|
|
|
|
|
Cumulative effect of change in accounting principle per
diluted share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(0.15 |
) |
Diluted earnings per share |
|
|
1.49 |
|
|
|
2.72 |
|
|
|
1.64 |
|
|
|
1.74 |
|
|
|
2.28 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
FINANCIAL RATIOS: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit percentage |
|
|
24.6 |
|
|
|
25.4 |
|
|
|
26.4 |
|
|
|
26.3 |
|
|
|
28.4 |
|
Percent of revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling and administrative expenses |
|
|
9.4 |
|
|
|
9.6 |
|
|
|
9.9 |
|
|
|
9.6 |
|
|
|
9.6 |
|
Research and testing expenses |
|
|
5.1 |
|
|
|
5.5 |
|
|
|
6.5 |
|
|
|
8.3 |
|
|
|
8.6 |
|
Return on average shareholders equity (%) |
|
|
6.4 |
|
|
|
12.2 |
|
|
|
7.5 |
|
|
|
9.9 |
|
|
|
14.4 |
|
Debt to capitalization (%) |
|
|
47.8 |
|
|
|
51.8 |
|
|
|
56.5 |
|
|
|
28.6 |
|
|
|
31.0 |
|
Current ratio |
|
|
2.9 |
|
|
|
2.4 |
|
|
|
2.4 |
|
|
|
3.1 |
|
|
|
3.0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OTHER INFORMATION: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dividends declared per share |
|
$ |
1.04 |
|
|
$ |
1.04 |
|
|
$ |
1.04 |
|
|
$ |
1.04 |
|
|
$ |
1.04 |
|
Average common shares outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
|
68.7 |
|
|
|
67.9 |
|
|
|
55.7 |
|
|
|
51.7 |
|
|
|
51.5 |
|
Diluted |
|
|
69.3 |
|
|
|
68.8 |
|
|
|
56.0 |
|
|
|
51.9 |
|
|
|
51.8 |
|
Capital expenditures - Continuing Operations |
|
|
125.7 |
|
|
|
121.9 |
|
|
|
122.6 |
|
|
|
88.2 |
|
|
|
65.0 |
|
Depreciation expense - Continuing Operations |
|
|
133.4 |
|
|
|
139.4 |
|
|
|
123.8 |
|
|
|
93.7 |
|
|
|
90.1 |
|
27
Historical Summary (as restated) - continued
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In Millions, Except Shareholders, Employees and Per-Share Data) |
|
2006 |
|
2005 |
|
2004* |
|
2003** |
|
2002** |
|
At year end: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets |
|
$ |
4,390.9 |
|
|
$ |
4,371.2 |
|
|
$ |
4,571.1 |
|
|
$ |
1,944.9 |
|
|
$ |
1,860.2 |
|
Total debt |
|
|
1,541.7 |
|
|
|
1,670.8 |
|
|
|
1,972.3 |
|
|
|
389.6 |
|
|
|
401.9 |
|
Total shareholders equity |
|
$ |
1,683.1 |
|
|
$ |
1,551.9 |
|
|
$ |
1,508.5 |
|
|
$ |
941.0 |
|
|
$ |
860.1 |
|
Shareholders equity per basic share |
|
|
24.39 |
|
|
|
22.81 |
|
|
|
22.58 |
|
|
|
18.24 |
|
|
|
16.71 |
|
Common share price |
|
|
50.13 |
|
|
|
43.43 |
|
|
|
36.86 |
|
|
|
32.52 |
|
|
|
30.50 |
|
Number of shareholders |
|
|
3,265 |
|
|
|
3,500 |
|
|
|
3,698 |
|
|
|
3,903 |
|
|
|
4,081 |
|
Number of employees |
|
|
6,746 |
|
|
|
7,515 |
|
|
|
7,725 |
|
|
|
5,032 |
|
|
|
5,231 |
|
|
|
|
* |
|
The 2004 results include the revenues and expenses of Noveon International, Inc. since June 3,
2004, the date of acquisition. |
|
** |
|
Amounts derived from previously issued financial statements have been restated to include
the effects of the restatement as described in the Explanatory Note contained in the front section
of this annual report on Form 10-K/A for the year ended December 31, 2006. |
|
*** |
|
Includes restructuring and impairment charges of $51.9 million in 2006, $15.9 million in 2005,
$38.1 million in 2004 and $22.5 million in 2003. Also includes the write-off of acquired
in-process research and development of $34.0 million in 2004. |
Total debt reported in the Historical Summary includes the following amounts classified as
long-term at December 31: $1,538.0 million in 2006, $1,662.9 million in 2005, $1,964.1 million in
2004, $386.7 million in 2003 and $384.8 million in 2002.
28
ITEM 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
This Managements Discussion and Analysis of Financial Condition and Results of Operations should
be read in conjunction with the consolidated financial statements, the notes thereto and the
historical summary appearing elsewhere in this annual report. Historical results and percentage
relationships set forth in the consolidated financial statements, including trends that might
appear, should not be taken as indicative of future operations. The following discussion contains
forward-looking statements that involve risks and uncertainties. Our actual results may differ
materially from those discussed in such forward-looking statements as a result of various factors,
including those described under the section Cautionary Statements for Safe Harbor Purposes
included elsewhere in this annual report.
RESTATEMENT OF CONSOLIDATED FINANCIAL STATEMENTS
On October 22, 2007, we concluded to restate our previously issued financial statements because of
reporting errors relating to five postemployment employee benefit plans in three foreign countries.
Accordingly, we have restated our consolidated balance sheets as of December 31, 2006 and 2005 and
our consolidated statements of income, consolidated statements of cash flows and consolidated
statements of shareholders equity for fiscal years 2006, 2005 and 2004. The effects of the
restatement are reflected in this Managements Discussion and Analysis of Financial Condition and
Results of Operations and we have not modified or updated disclosures except as required to
reflect the effects of the restatement.
See the Explanatory Note included in the front section
of the annual report on Form 10-K/A and Note 20 - Restatement of Consolidated Financial Statements contained in the Notes to
Financial Statements for more information regarding the restatement and changes to previously
issued financial statements.
The impact of the restatement decreased income from continuing operations and net income for 2006
by $2.0 million or 1.1% and 1.9%, respectively, for 2005 by $2.1 million or 1.3% and 1.1%,
respectively, and for 2004 by $1.7 million or 1.9% and 1.8%, respectively, from amounts previously
reported. The restatement had no effect on our previously reported revenues or net cash flows.
The cumulative effect of the errors decreased shareholders equity as of December 31, 2006 by
$24.3 million or 0.6% of total liabilities and shareholders equity and 1.4% of total shareholders
equity. The cumulative effect of the errors decreased shareholders equity as of December 31,
2005 by $15.3 million or less than one-half percent of total liabilities and shareholders equity
and 1.0% of total shareholders equity.
The errors primarily arose in three different postemployment employee benefit plans at a wholly
owned subsidiary and in postemployment employee benefit plans for employees at two of our consolidated
joint ventures. Four of these postemployment employee benefit plans had been accounted for
inappropriately on a cash basis rather than an accrual basis as required by U.S. generally accepted
accounting principles (U.S. GAAP), while the accrual recorded in the financial statements for the
fifth plan was not calculated in accordance with U.S. GAAP. The cumulative effect of the errors
resulted in an understatement of postemployment employee benefit plan liabilities of $38.9 million
and $27.1 million at December 31, 2006 and 2005, respectively.
29
OVERVIEW
General
We are an innovative specialty chemical company that produces and supplies technologies that
improve the quality and performance of our customers products in the global transportation,
industrial and consumer markets. Our business is founded on technological leadership. Innovation
provides opportunities for us in growth markets as well as advantages over our competitors. From a
base of approximately 1,700 patents, we use our product development and formulation expertise to
sustain our leading market positions and fuel our future growth. We create additives, ingredients,
resins and compounds that enhance the performance, quality and value of our customers products,
while minimizing their environmental impact. Our products are used in a broad range of
applications, and are sold into stable markets such as those for engine oils, specialty driveline
lubricants and metalworking fluids, as well as higher-growth markets such as personal care and
over-the-counter pharmaceutical products and performance coatings and inks. Our engineered
polymers products also are used in a variety of industries, including the construction, sporting
goods, medical products and automotive industries. We are an industry leader in many of the
markets in which our product lines compete.
We are geographically diverse, with an extensive global manufacturing, supply chain, technical and
commercial infrastructure. We operate facilities in 29 countries, including production facilities
in 20 countries and laboratories in 13 countries, in key regions around the world through the
efforts of more than 6,700 employees. We sell our products in more than 100 countries and believe
that our customers value our ability to provide customized, high-quality, cost-effective
performance formulations and solutions worldwide. We also believe that our customers value our
global supply chain capabilities.
As part of our corporate goal to enhance our one company identity and to reflect more accurately
our positioning in the marketplace, we completed a corporate identity review in the fourth quarter
of 2006. We made a final determination in January 2007 that the trade name Noveon no longer
would be used to describe the specialty chemicals business segment of our company and that its use
would be discontinued except in connection with the consumer specialties product line. We acquired
the rights to the Noveon trade name in June 2004 when we acquired Noveon International, Inc.
(Noveon International). At the time of acquisition, an appraised value was attached to the Noveon
trade name. We recorded a pretax charge of $41.2 million ($25.4 million after-tax) to reduce the
related asset to its estimated fair value. This charge was reflected in the fourth quarter of 2006
as we believed at that time we would more likely than not discontinue the use of the Noveon trade
name, except in the limited context of our consumer specialties product line.
In addition, we made a decision to change the names of our business segments. We believe that
these names are a better fit with the corporate brand that we are presenting to our markets. These
name changes do not change the way we manage our segments or the product lines included in the
segments.
Following are the name changes to our segments:
|
|
|
Former
Name |
|
New
Name |
Lubricant Additives
|
|
Lubrizol Additives |
Specialty Chemicals
|
|
Lubrizol Advanced Materials |
On February 7, 2007, we completed the acquisition of a broad line of additive products used in the
metalworking markets worldwide from Lockhart Chemical Company (Lockhart), a private company with
headquarters in Gibsonia, Pennsylvania. Lockhart is recognized in the metalworking industry for
its application and formulation capabilities and quality products. We purchased Lockharts entire
metalworking product line, which includes: natural, synthetic and gelled sulfonates; emulsifier
packages; corrosion inhibitors and lubricity agents; grease additives; oxidates; esters; soap;
semi-finished coatings; and rust preventatives. In 2006, these product lines had annualized
revenues of approximately $20.0 million.
In May 2006, we sold the food ingredients and industrial specialties business (FIIS) and the active
pharmaceutical ingredients and intermediate compounds business (A&I), both of which were included
in the Lubrizol Advanced Materials segment. A&I and almost all of the FIIS divestiture reported
into the Noveon consumer specialties product line, while a small portion of the FIIS divestiture
reported into the performance coatings product line. We recorded a
30
$15.9 million after-tax loss on
the sale of these divested businesses. During the first quarter of 2006 and in connection with the
held-for-sale classification, we performed an impairment test resulting in a $60.6 million
after-tax impairment charge in the first quarter of 2006. We have reflected the results of these
divested businesses in the discontinued operations - net of tax line item in the consolidated
statements of income for all periods presented.
In February 2006, we sold certain assets and liabilities of our Telene® resins business
(Telene), which was included in the Lubrizol Advanced Materials segment. We have reflected the
results of Telene in the discontinued operations - net of
tax line item in the consolidated statements of income for all periods presented, including an
after-tax loss on the sale of $0.7 million.
In December 2005, we sold certain assets, liabilities and stock of our Engine Control Systems (ECS)
business and, in September 2005, we sold certain assets and liabilities of our U.S. and U.K.
Lubrizol Performance Systems (LPS) operations, both of which were included in the Lubrizol
Additives segment. We have reflected the results of these businesses in the discontinued
operations - net of tax line item in the consolidated statements of income for 2005 and 2004.
On June 3, 2004, we completed the acquisition of Noveon International, a leading global producer
and marketer of technologically advanced consumer specialties, engineered polymers and performance
coatings used in the industrial and consumer markets. We acquired Noveon International for cash of
$920.2 million (inclusive of certain seller expenses of $32.9 million) plus transaction costs of
$11.4 million and less cash acquired of $103.0 million. In addition, we assumed $1,103.1 million
of long-term indebtedness from Noveon International.
In connection with the acquisition of Noveon International, we targeted non-core businesses with
total revenues of approximately $500.0 million for disposition. All disposition activities related
to these businesses were completed by the end of 2006.
LUBRIZOL ADDITIVES SEGMENT
Challenging industry market forces and conditions continue to influence the Lubrizol Additives
business. A key factor is the low global growth rate for this market, which we believe is in the
range of approximately 0% to 1% per year. Additional characteristics of this market are:
|
|
|
Consolidation of the additive industry and capacity reductions in recent years, which
has tightened the supply of lubricant additive components and packages. |
|
|
|
|
Frequent product specification changes primarily driven by original equipment
manufacturers (OEMs) and the impact of environmental and fuel economy regulations on the
OEMs. The specification changes require us to incur product development and testing costs,
but also enable us to apply our technology know-how to create products and solve problems.
We believe our technology, and our expertise in applying it, are key strengths. |
|
|
|
|
Improved engine design, which can result in longer lubricant drain intervals. Longer
drain intervals reduce demand for finished lubricants. |
|
|
|
|
New vehicle production levels, which affect our driveline fluids in particular because
the initial factory fill is an important market factor in that product line. |
|
|
|
|
In recent years, a general tightening of supplies leading to significant increases in
raw material and energy costs. |
We believe we are the market leader in lubricant additives and intend to remain the leader by
continuing to invest in this business. Our strategy is to continue to optimize our product line
mix with existing production capacity. Our Lubrizol Additives segment represents approximately 64%
of consolidated revenues.
LUBRIZOL ADVANCED MATERIALS SEGMENT
Our Lubrizol Advanced Materials segments growth strategy involves a combination of internal growth
and acquisitions. Since 2000 and prior to the Noveon International acquisition, we made eight
acquisitions with aggregate annual revenues at the time of acquisition of approximately $200.0
million.
31
We have a strategy to continue to achieve internal growth in the Lubrizol Advanced Materials
segment by using our strengths, including our technology, formulating skills and broad geographic
infrastructure, to develop and invest in new performance technologies in higher-growth industrial
and consumer markets. Key factors to our success continue to be the introduction of new products,
development of new applications for existing products, cross-selling of products, the integration
of acquisitions and geographic expansion. Our Lubrizol Advanced Materials segment represents
approximately 36% of consolidated revenues.
PRIMARY FACTORS AFFECTING 2006 RESULTS FROM CONTINUING OPERATIONS
The factors that most affected our consolidated 2006 results from continuing operations were:
|
|
|
Our ability to raise selling prices to recover raw material cost increases from 2006 and
prior years. |
|
|
|
|
Volume increases of 6% in the Lubrizol Advanced Materials segment and just under
one-half percent in the Lubrizol Additives segment. |
|
|
|
|
Increased operating costs due to general salary and benefit cost increases and the
hiring of growth resources, costs associated with a newly commenced project to implement a
common information systems platform primarily in the Lubrizol Advanced Materials segment,
the impact of variable accounting for some of our liability-based incentive compensation
plans, the adoption of Statement of Financial Accounting Standards (SFAS) No. 123R
Share-Based Payment for the accounting of stock-based awards, and a $2.9 million pension
settlement charge for a non-qualified plan distribution. |
|
|
|
|
Pretax impairment charges of $41.2 million associated with the impairment of the Noveon
trade name and $10.7 million related to plant and line closures in both the Lubrizol
Additives and Lubrizol Advanced Materials segments. |
|
|
|
|
Reduced interest expense - net of $17.7 million as a result of higher interest income of
$12.3 million associated with greater cash and short-term investment balances, primarily
related to the cash proceeds from the 2006 divestitures and lower interest expense of $5.4
million associated with reduced debt levels. |
|
|
|
|
Increased other income of $6.7 million primarily from legal settlements with suppliers. |
|
|
|
|
Reduced effective tax rate primarily due to the favorable provision impacts of foreign
operations. |
Raw material costs increased 14% in 2006 after increasing 18% excluding the impact of acquisitions
in 2005. Our results were affected by how quickly and the extent to which we were able to raise
selling prices in response to raw material, utility and other operating cost increases. Both the
Lubrizol Additives and Lubrizol Advanced Materials segments implemented price increases throughout
2006 in response to continuing increases in these costs. However, we have not yet recovered the
full effect of the cumulative cost increases.
2006 RESULTS OF OPERATIONS COMPARED WITH 2005
Income from continuing operations increased $20.4 million to $179.8 million for 2006 compared to
$159.4 million for 2005. The increase in earnings from continuing operations primarily was
attributable to improvements in the combination of price and product mix, higher volume and reduced
interest expense - net, which more than offset higher raw material and utility costs, higher
restructuring and impairment charges and higher selling, technology, administrative and research
(STAR) expenses.
We recorded restructuring and impairment charges that reduced income from continuing operations by
$0.47 per diluted share in 2006, which primarily related to a pretax impairment charge associated
with the Noveon trade name and the phase-out of a manufacturing facility located in Bromborough,
United Kingdom. We incurred restructuring and impairment charges of $0.15 per diluted share in
2005, which primarily related to the phase-out of manufacturing facilities located in Bromborough,
United Kingdom; Linden, New Jersey; and Mountaintop, Pennsylvania, as well as other workforce
reductions.
Net income for 2006 includes the factors described above for income from continuing operations and
the impact of discontinued operations. Loss from discontinued operations - net was $76.2 million
in 2006 compared to income from discontinued operations - net of $27.8 million in 2005. The loss
from discontinued operations - net in 2006
32
primarily related to a $60.6 million after-tax
impairment charge recorded in the first quarter of 2006 to reflect the FIIS business at its fair
value and a $16.6 million after-tax loss on the sale of divested businesses.
ANALYSIS OF REVENUES The changes in consolidated revenues are summarized as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In Millions of Dollars) |
|
2006 |
|
|
2005 |
|
|
$ Change |
% Change |
Net sales |
|
|
$ 4,036.4 |
|
|
|
$ 3,618.8 |
|
|
|
$ 417.6 |
|
|
|
12 |
% |
Royalties and other revenues |
|
|
4.4 |
|
|
|
3.4 |
|
|
|
1.0 |
|
|
|
29 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues |
|
|
$ 4,040.8 |
|
|
|
$ 3,622.2 |
|
|
|
$ 418.6 |
|
|
|
12 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The increase in revenues in 2006 compared to 2005 primarily was due to a 10% improvement in the
combination of price and product mix and a 2% increase in volume. We experienced volume gains in
all geographic zones except Europe.
|
|
ANALYSIS OF VOLUME - 2006 VS. 2005 Volume patterns vary in different geographic zones. The
following table shows our 2006 volume by geographic zone as well as the changes compared with 2005:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2006 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Volume |
% Change |
North America |
|
|
|
|
|
|
|
|
|
|
46% |
|
1 |
% |
Europe |
|
|
|
|
|
|
|
|
|
|
27% |
|
(1 |
%) |
Asia-Pacific / Middle East |
|
|
|
|
|
|
|
|
|
|
22% |
|
6 |
% |
Latin America |
|
|
|
|
|
|
|
|
|
|
5% |
|
11 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
|
|
|
|
|
|
|
|
100% |
|
2 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment volume variances by geographic zone, as well as the factors explaining the changes in
segment revenues for 2006 compared with 2005, are contained under the Segment Analysis section.
|
|
ANALYSIS OF COSTS AND EXPENSES
|
|
|
|
(In Millions of Dollars) |
|
2006 |
|
2005 |
|
$ Change |
% Change |
Cost of sales |
|
|
$ 3,045.2 |
|
|
|
$ 2,700.1 |
|
|
$ 345.1 |
|
|
13 |
% |
Selling and administrative expenses |
|
|
381.7 |
|
|
|
348.4 |
|
|
33.3 |
|
|
10 |
% |
Research, testing and development expenses |
|
|
205.5 |
|
|
|
198.9 |
|
|
6.6 |
|
|
3 |
% |
Amortization of intangible assets |
|
|
23.7 |
|
|
|
23.5 |
|
|
0.2 |
|
|
1 |
% |
Restructuring and impairment charges |
|
|
51.9 |
|
|
|
15.9 |
|
|
36.0 |
|
|
* |
|
|
|
|
|
|
|
|
|
|
|
|
Total costs and expenses |
|
|
$ 3,708.0 |
|
|
|
$ 3,286.8 |
|
|
$ 421.2 |
|
|
13 |
% |
|
|
|
|
|
|
|
|
|
|
|
The increase in cost of sales for 2006 compared to 2005 primarily was due to higher average raw
material cost and higher manufacturing expenses. Average raw material cost increased 14% in 2006
compared to 2005 primarily due to higher petrochemical raw material cost. Total manufacturing
expenses increased 4% in 2006 compared to 2005, primarily due to higher salaries and benefits,
higher utility costs and increased volume. On a per-unit-sold basis, manufacturing costs increased
2% in 2006 compared to 2005.
Gross profit (net sales less cost of sales) increased $72.5 million, or 8%, in 2006 compared to
2005. The increase primarily was due to improvement in the combination of price and product mix
and higher volume partially offset by higher average raw material cost. In addition, gross profit
was impacted unfavorably by higher salaries and benefits, an increase in utility costs and an
unfavorable currency impact in 2006 when compared to 2005. Although we were successful in raising
selling prices to offset higher cost of sales, our 2006 gross profit percentage (gross profit
divided by net sales) decreased to 24.6% compared to 25.4% in 2005 due to the increase in net sales
from our pricing responses to escalating raw material costs.
Selling and administrative expenses increased $33.3 million, or 10%, in 2006 compared to 2005. The
increase primarily reflects an increase in salaries and benefits including the addition of growth
resources, an increase of $4.5 million
33
associated with a newly commenced project to implement a
common information systems platform primarily in the Lubrizol Advanced Materials segment, the
unfavorable impact of variable accounting for some of our liability-based incentive plans, a $2.9
million pension settlement charge for a non-qualified pension plan distribution and incremental
stock-based compensation expense of $2.4 million associated with the adoption of SFAS No. 123R.
The timing and amount of research, testing and development expenses (technology expenses) are
affected by lubricant additives product standards, which change periodically to meet new emissions,
efficiency, durability and other performance factors as OEMs improve engine and transmission
designs. Technology expenses increased $6.6 million, or 3%, in 2006 compared to 2005 primarily due
to increases in annual salaries and benefits. During 2006 and 2005, approximately 87% of our
technology costs were incurred in company-owned facilities and approximately 13% were incurred at
third-party facilities.
In 2006, we recorded aggregate restructuring and impairment charges of $51.9 million, or $0.47 per
diluted share, primarily related to the write-down of a trade name in the Lubrizol Advanced
Materials segment and the phase-out of a manufacturing facility in the Lubrizol Additives segment.
The components of the 2006 restructuring and impairment charges are detailed as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Asset |
|
Other Plant |
|
|
|
|
(In Millions of Dollars) |
|
Impairments |
|
Exit Costs |
|
Severance |
|
Total |
Noveon trade name impairment |
|
|
$ 41.2 |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ 41.2 |
|
Bromborough, U.K. closure |
|
|
|
|
|
|
4.8 |
|
|
|
1.9 |
|
|
|
6.7 |
|
Lubrizol Advanced Materials plant and line closures
and workforce reductions |
|
|
3.3 |
|
|
|
0.2 |
|
|
|
0.6 |
|
|
|
4.1 |
|
Other |
|
|
|
|
|
|
|
|
|
|
(0.1 |
) |
|
|
(0.1 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total restructuring and impairment charges |
|
|
$ 44.5 |
|
|
|
$ 5.0 |
|
|
|
$ 2.4 |
|
|
|
$ 51.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As part of our corporate goal to enhance our one company identity and to reflect more accurately
our positioning in the marketplace, we completed a corporate identity review in the fourth quarter
of 2006. We made a final determination in January 2007 that the trade name Noveon no longer
would be used to describe the specialty chemicals business segment of our company and that its use
would be discontinued except in connection with the consumer specialties product line. We acquired
the rights to the Noveon trade name in June 2004 when we acquired Noveon International. At the
time of acquisition, an appraised value was attached to the Noveon trade name. We calculated a
pretax charge of $41.2 million ($25.4 million after-tax) to reduce the related asset to its
estimated fair value. This charge was reflected in the fourth quarter of 2006 as we believed at
that time we would more likely than not discontinue the use of the Noveon trade name, except in the
limited context of the consumer specialties product line.
In September 2006, we entered into an agreement to sell the manufacturing facility located in
Bromborough, United Kingdom. The sale closed in January 2007. In connection with the sale, we
received net cash proceeds of $5.9 million and recorded a pretax gain of $2.9 million during the
first quarter of 2007. The gain will be classified as a restructuring credit associated with
closure of the facility. Production from the Bromborough facility was transferred to
higher-capacity Lubrizol facilities in France and the United States. The sale of the facility will
avoid approximately $3.0 million to $5.0 million in restructuring costs that would have been
associated with demolition of the plant facilities on the site. On January 17, 2005, we announced
our plans to phase-out production at the Bromborough facility by the end of 2006. At that time, we
estimated that total restructuring costs, including employee severance and other plant closure
costs (including planned demolition costs), would be approximately $15.0 million. Cumulative
pretax charges of approximately $12.8 million were incurred through 2006, of which $6.7 million
were incurred in 2006, to satisfy severance and retention obligations, plant dismantling, site
restoration and other site environmental evaluation costs.
We have invested approximately $15.3 million in capital related to the Bromborough closure through
December 31, 2006 for capacity upgrades in France and the United States. We expect to invest an
additional $4.0 million related to these capacity upgrades through the first quarter of 2007.
In the first quarter of 2005, we decided to close two Lubrizol Advanced Materials performance
coatings production facilities in the United States. One facility, located in Mountaintop,
Pennsylvania, was closed in October 2005 and sold in January 2006. We recorded an additional $0.8
million in asset impairments and other exit costs and $0.6 million in severance obligations in 2006
relating to the other facility located in Linden, New Jersey, which was closed in the third quarter
of
34
2006. Additional
asset impairment charges of $2.7 million were recorded in 2006, which primarily related to the planned closure of a performance coatings production line in
the first quarter of 2007.
In addition, we expect these workforce reductions, facility closures and transfers of production to
more efficient manufacturing locations to generate annual pretax savings of approximately $5.3
million for the Lubrizol Advanced Materials segment and approximately $12.0 million for the
Lubrizol Additives segment. Approximately $8.4 million of these savings were realized in 2006.
The charges for these cost reduction initiatives and impairments are reported as a separate line
item in the consolidated statements of income, entitled Restructuring and impairment charges and
are included in the Total cost and expenses subtotal on the consolidated statements of income.
ANALYSIS OF OTHER ITEMS AND NET INCOME
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In Millions of Dollars) |
|
2006 |
|
2005 |
|
$ Change |
% Change |
Other income - net |
|
|
$ 8.5 |
|
|
|
$ 1.8 |
|
|
|
$ 6.7 |
|
|
|
* |
|
Interest expense - net |
|
|
79.3 |
|
|
|
97.0 |
|
|
|
(17.7 |
) |
|
|
(18 |
%) |
Income from continuing operations before income taxes |
|
|
262.0 |
|
|
|
240.2 |
|
|
|
21.8 |
|
|
|
9 |
% |
Provision for income taxes |
|
|
82.2 |
|
|
|
80.8 |
|
|
|
1.4 |
|
|
|
2 |
% |
Income from continuing operations |
|
|
179.8 |
|
|
|
159.4 |
|
|
|
20.4 |
|
|
|
13 |
% |
Discontinued operations - net of tax |
|
|
(76.2 |
) |
|
|
27.8 |
|
|
|
(104.0 |
) |
|
|
* |
|
Net income |
|
|
$ 103.6 |
|
|
|
$ 187.2 |
|
|
|
$ (83.6 |
) |
|
|
(45 |
%) |
|
|
|
|
|
* Calculation not meaningful |
The increase in other income - net for 2006 compared to 2005 primarily was due to the favorable
legal settlements of insurance and commercial matters of $10.4 million and an increase in the net
gain on the sale of property of $1.3 million, partially offset by an increase in currency
transaction losses of $2.4 million and an increase in the elimination of minority interest of $2.4
million due to higher profitability of our joint ventures.
The decrease in interest expense - net for 2006 compared to 2005 primarily was due to an increase
in interest income of $12.3 million as a result of our increased cash and short-term investments
from the divestiture proceeds and a decrease in interest expense of $5.4 million due to a reduction
in our long-term debt balances.
Our effective tax rate was 31.4% in 2006 compared to 33.6% in 2005. The decrease in the effective
tax rate primarily was due to the favorable provision impacts of foreign operations.
Primarily as a result of the above factors, income from continuing operations per diluted share was
$2.59 in 2006 compared to $2.32 in 2005. Loss from discontinued operations per diluted share was
$1.10 in 2006 compared to income from discontinued operations per diluted share of $0.40 in 2005.
The loss from discontinued operations per diluted share of $1.10 in 2006 consisted of operating
income of $0.01 per diluted share, excluding an $0.87 per diluted share impairment charge and a
$0.24 per diluted share loss on the sale of divested businesses.
2005 RESULTS OF OPERATIONS COMPARED WITH 2004
Our 2005 revenues as compared to 2004, excluding the impact of acquisitions, increased primarily
due to improvements in the combination of price and product mix, offset by a slight decrease in
volume. The increased revenues partially were offset by higher raw material costs and higher
utility costs. Primarily as a result of these factors and the impact of acquisitions, gross profit
increased 22% in 2005 compared with 2004. Excluding the impact of acquisitions, gross profit
increased 4% in 2005 compared to 2004.
35
ANALYSIS OF REVENUES The changes in consolidated revenues are summarized as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Excluding the Impact |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
of Acquisitions |
(In Millions of Dollars) |
|
2005 |
|
2004 |
|
$ Change |
|
% Change |
|
|
$ Change |
|
% Change |
Net sales |
|
|
$ 3,618.8 |
|
|
|
$ 2,860.5 |
|
|
|
$ 758.3 |
|
|
|
27% |
|
|
|
$ 333.0 |
|
|
12% |
Royalties and other revenues |
|
|
3.4 |
|
|
|
3.9 |
|
|
|
(0.5 |
) |
|
|
(13%) |
|
|
|
(0.5 |
) |
|
(13%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues |
|
|
$ 3,622.2 |
|
|
|
$ 2,864.4 |
|
|
|
$ 757.8 |
|
|
|
26% |
|
|
|
$ 332.5 |
|
|
12% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The 2004 acquisitions contributed $425.3 million toward the increase in 2005 consolidated revenues
compared with 2004. Acquisitions in 2004 included Noveon International and the hyperdispersants
business purchased from Avecia.
|
|
Excluding the impact of acquisitions, the increase in consolidated revenues in 2005 compared to
2004 was due to a 12% increase in the combination of price and product mix.
|
|
ANALYSIS OF VOLUME - 2005 VS. 2004 Volume patterns vary in different geographic zones. The
following table shows our 2005 volume by geographic zone as well as the changes compared with 2004:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Excluding the Impact |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2005 |
|
|
|
|
|
of Acquisitions |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Volume |
|
% Change |
|
% Change |
North America |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
46% |
|
|
6% |
|
|
(6% |
) |
Europe |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28% |
|
|
8% |
|
|
3% |
|
Asia-Pacific / Middle East |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21% |
|
|
13% |
|
|
8% |
|
Latin America |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5% |
|
|
6% |
|
|
2% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
100% |
|
|
8% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment volume variances by geographic zone, as well as the factors explaining the changes in
segment revenues for 2005 compared with 2004, are contained under the Segment Analysis section.
|
|
ANALYSIS OF COSTS AND EXPENSES
|
|
|
|
(In Millions of Dollars) |
|
|
|
|
|
|
|
|
|
|
2005 |
|
|
|
2004 |
|
|
$ Change |
% Change |
Cost of sales |
|
|
|
|
|
|
|
|
|
|
$ 2,700.1 |
|
|
|
$ 2,104.6 |
|
|
|
$ 595.5 |
|
|
|
28 |
% |
Selling and administrative expenses |
|
|
|
|
|
|
|
|
|
|
348.4 |
|
|
|
284.8 |
|
|
|
63.6 |
|
|
|
22 |
% |
Research, testing and development
expenses |
|
|
|
|
|
|
|
|
|
|
198.9 |
|
|
|
184.8 |
|
|
|
14.1 |
|
|
|
8 |
% |
Amortization of intangible assets |
|
|
|
|
|
|
|
|
|
|
23.5 |
|
|
|
16.9 |
|
|
|
6.6 |
|
|
|
39 |
% |
Write-off of acquired in-process research
and development |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
34.0 |
|
|
|
(34.0 |
) |
|
|
* |
|
Restructuring and impairment charges |
|
|
|
|
|
|
|
|
|
|
15.9 |
|
|
|
38.1 |
|
|
|
(22.2 |
) |
|
|
* |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total costs and expenses |
|
|
|
|
|
|
|
|
|
|
$ 3,286.8 |
|
|
|
$ 2,663.2 |
|
|
|
$ 623.6 |
|
|
|
23 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* Calculation not meaningful |
Cost of sales increased due to acquisitions, higher average raw material cost and higher
manufacturing expenses. Excluding the impact of acquisitions, average raw material cost increased
18% in 2005 compared with 2004. The increase in the material costs during the latter half of 2005
largely was driven by supply disruptions caused by the U.S. Gulf coast hurricanes. Material cost,
including acquisitions, also included inventory step-up adjustments associated with the increased
valuation of inventory of $12.5 million in 2004 for the Noveon International and hyperdispersants
36
acquisitions. The Noveon International portion of the inventory step-up adjustment was $9.8
million, or $0.11 per diluted share.
Total manufacturing expenses increased 19% (5% excluding the impact of acquisitions) in 2005
compared with 2004. Excluding the impact of acquisitions, the increase primarily was due to an
increase in utility costs as well as an unfavorable currency impact. On a per-unit-sold basis,
manufacturing costs increased 5% in 2005 compared to 2004, excluding the impact of acquisitions.
Gross profit increased $162.8 million, or 22% ($29.2 million, or 4%, excluding the impact of
acquisitions), in 2005 compared with 2004. Excluding the impact of acquisitions, the increase
primarily was due to higher average selling price, partially offset by higher unit average raw
material cost and higher utility costs. Our 2005 gross profit percentage decreased to 25.4% (24.6%
excluding the impact of acquisitions) compared to 26.4% in 2004. The decrease primarily was due to
higher raw material costs outpacing our ability to raise selling prices sufficiently to sustain
gross profit percentages.
Selling and administrative expenses increased $63.6 million, or 22% ($9.1 million, or 3%, excluding
the impact of acquisitions), in 2005 compared with 2004. The increase in selling and
administrative expenses, excluding the impact of acquisitions, primarily was due to an increase in
salaries and incentive compensation expense, offset partially by non-recurring litigation expense
of $1.9 million incurred in 2004.
Technology expenses, excluding the impact of acquisitions, decreased 3% in 2005 compared with 2004.
The decrease primarily was due to the 2004 reduction in workforce. During 2005 and 2004,
approximately 87% of our technology costs were incurred in company-owned facilities and
approximately 13% were incurred at third-party facilities.
The increased amortization expense in 2005 compared with 2004 primarily was due to the Noveon
International and hyperdispersants acquisitions in 2004. These two acquisitions resulted in an
increase in gross amortizable intangible assets of approximately $320.3 million with useful lives
ranging between 3 and 20 years.
We included a one-time, non-cash charge of $34.0 million, or $0.39 per share, in total costs and
expenses in 2004 to write-off the estimated fair value of acquired in-process research and
development (IPR&D) projects associated with the Noveon International acquisition. Costs to
acquire IPR&D projects that have no alternative future use and that have not yet reached
technological feasibility at the date of acquisition are expensed upon acquisition. We obtained
appraisals to determine the estimated fair value of IPR&D projects. There were approximately nine
projects acquired in the Noveon International transaction in several different product lines. The
projects were at varying stages of completeness ranging from the early development stage to
prototype testing at the time of acquisition. No further adjustments were made in 2005 to the
valuation in connection with the completion of the Noveon International purchase accounting.
In 2005, we recorded restructuring and impairment charges aggregating $15.9 million, or $0.15 per
diluted share, primarily related to the decision to close three manufacturing facilities, as well
as other workforce reductions.
The components of the 2005 restructuring and impairment charges are detailed as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Asset |
|
Other Plant |
|
|
|
|
(In Millions of Dollars) |
|
Impairments |
|
Exit Costs |
|
Severance |
|
Total |
Lubrizol Advanced Materials plant closures and
workforce reductions |
|
|
$ 4.2 |
|
|
|
$ 1.0 |
|
|
|
$ 3.8 |
|
|
|
$ 9.0 |
|
Bromborough, U.K. closure |
|
|
0.7 |
|
|
|
1.7 |
|
|
|
3.7 |
|
|
|
6.1 |
|
Corporate / other workforce reductions |
|
|
|
|
|
|
|
|
|
|
0.7 |
|
|
|
0.7 |
|
Noveon International restructuring liabilities assumed |
|
|
|
|
|
|
|
|
|
|
0.1 |
|
|
|
0.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total restructuring and impairment charges |
|
|
$ 4.9 |
|
|
|
$ 2.7 |
|
|
|
$ 8.3 |
|
|
|
$ 15.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In May 2005, we announced the reorganization of the Lubrizol Advanced Materials performance
coatings product line. This product line includes businesses acquired from Noveon International as
well as businesses included in our legacy operations. In connection with the reorganization, we
eliminated 26 positions in North America and Europe. These reductions were completed during 2005
and resulted in a severance charge of $1.9 million in 2005.
In the first quarter of 2005, we made the decision and the announcement to close two Lubrizol
Advanced Materials performance coatings production facilities in the United States. The aggregate
restructuring charge recorded for these
37
closures for the year ended December 31, 2005 was $6.6 million, comprised of $4.2 million in asset impairments, $0.9 million in exit costs and $1.5
million in severance costs. We recorded an impairment charge for both plants in the first quarter
of 2005 to reduce the related assets to their estimated fair values. The estimated fair value of
the assets was determined primarily from third-party appraisals. Production from these sites was
transferred to other facilities in the United States. One facility, located in Mountaintop,
Pennsylvania, was closed in October 2005 and sold in January 2006, while the other facility,
located in Linden, New Jersey, was closed in the third quarter of 2006. These closures resulted in
a workforce reduction of 62 employees. We also recorded European-related restructuring charges in
the Lubrizol Advanced Materials segment of $0.4 million in severance costs and $0.1 million in
other exit costs during the fourth quarter of 2005.
In December 2004, we decided to close the Lubrizol Additives manufacturing facility in Bromborough,
United Kingdom. We announced this decision in January 2005. A $17.0 million impairment charge was
recorded in December 2004 to reduce the related assets to their estimated fair values. Production
phase-out of this site began in the third quarter of 2005 and was completed in the third quarter of
2006. During this phase-out, U.K. production was transferred to facilities in France and the
United States. There were 70 employees impacted by this closure. The aggregate restructuring
charge recorded for this closure through December 31, 2005 was $6.1 million. Total 2005 charges
were comprised of $0.7 million in asset impairments, $1.7 million in exit costs and $3.7 million in
severance costs.
In the second quarter of 2005, we continued a process of identifying further opportunities to
increase efficiency and productivity, reduce costs and support our integration strategy of the
Noveon International acquisition. As a result, we reduced headcount in the general and
administrative area of our Ohio headquarters. Through these restructuring efforts, we eliminated
seven positions resulting in a severance-related charge of $0.7 million in 2005. All of the
affected employees had left their positions by June 30, 2005 and the remaining personnel-related
costs were paid by the end of 2006.
In addition, we realized approximately $18.3 million of pretax savings in 2005 relating to the 2004
restructuring programs.
The charges for these cost reduction initiatives and impairments are reported as a separate line
item in the consolidated income statements, entitled Restructuring and impairment charges and are
included in the Total cost and expenses subtotal on the consolidated statements of income.
ANALYSIS OF OTHER ITEMS AND NET INCOME
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Excluding the Impact of |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acquisitions |
(In Millions of Dollars) |
|
2005 |
|
2004 |
|
$ Change |
|
% Change |
|
$ Change |
|
% Change |
Other income - net |
|
|
$ 1.8 |
|
|
|
$ 5.6 |
|
|
|
$ (3.8 |
) |
|
|
* |
|
|
|
$ (4.5 |
) |
|
|
* |
|
Interest expense - net |
|
|
97.0 |
|
|
|
72.3 |
|
|
|
24.7 |
|
|
|
* |
|
|
|
(8.8 |
) |
|
|
* |
|
Income from continuing operations before
income taxes |
|
|
240.2 |
|
|
|
134.5 |
|
|
|
105.7 |
|
|
|
79 |
% |
|
|
86.8 |
|
|
|
65 |
% |
Provision for income taxes |
|
|
80.8 |
|
|
|
49.0 |
|
|
|
31.8 |
|
|
|
65 |
% |
|
|
28.0 |
|
|
|
57 |
% |
Income from continuing operations |
|
|
159.4 |
|
|
|
85.5 |
|
|
|
73.9 |
|
|
|
86 |
% |
|
|
58.8 |
|
|
|
69 |
% |
Discontinued operations - net of tax |
|
|
27.8 |
|
|
|
6.3 |
|
|
|
21.5 |
|
|
|
* |
|
|
|
8.7 |
|
|
|
* |
|
Net income |
|
|
$ 187.2 |
|
|
|
$ 91.8 |
|
|
|
$ 95.4 |
|
|
|
104 |
% |
|
|
$ 67.5 |
|
|
|
74 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
*
Calculation not meaningful
The change in other income - net in 2005 predominantly was due to the non-recurring 2004 gain of
$6.4 million on a currency forward contract to purchase pound sterling related to the acquisition
of the hyperdispersants business. We secured the forward contract in December 2003 and completed
the acquisition at the end of January 2004.
The increase in interest expense - net in 2005, compared with 2004, primarily was due to the Noveon
International pretax acquisition-related financing costs of $82.0 million, or $0.77 per diluted
share, in 2005 compared to $56.7 million, or $0.66 per diluted share, in 2004. These costs were
comprised of the interest incurred relating to the permanent financing as well as interest on the
bridge loan and assumed Noveon International debt not repaid at the time of the acquisition of
$42.6 million, amortization of bridge loan fees of $11.2 million and termination of an interest
rate swap of $2.9 million. We obtained permanent financing for the Noveon International
acquisition in the third quarter of 2004.
38
We had an effective tax rate of 33.6% in 2005 as compared with 36.4% in 2004. Items driving the
decrease in tax rate included reduced tax costs associated with actual and planned foreign
dividends, the more favorable impact of foreign tax rate differences and higher U.S. tax benefits
on exports. These factors partially were offset by increased state income taxes and lower
non-taxable currency gains as compared to 2004.
As of December 31, 2005, we had U.S. net operating loss carryforwards (NOLs) of $178.4 million.
These NOLs are a combination of NOLs acquired from Noveon International, as well as those generated
in 2004 primarily as a result of transaction-related costs.
Primarily as a result of the above factors, our income from continuing operations per diluted share
was $2.32 in 2005 compared to $1.53 in 2004. Income from discontinued operations per diluted share
was $0.40 in 2005 compared to $0.11 in 2004. Income from discontinued operations in 2005 included
$0.28 per diluted share of operating income from the FIIS and A&I businesses, $0.10 per diluted
share related to LPS and ECS, of which $0.04 was attributable to the gain on sale, and $0.02 per
diluted share in operating income related to the Telene resins business. Restructuring and
impairment charges recorded in 2005 reduced earnings by $0.15 per diluted share. Earnings in 2004
included a one-time write-off for IPR&D projects from the Noveon International acquisition of $0.38
per diluted share, a purchase adjustment associated with the increased valuation of Noveon
International-acquired inventory of $0.11 per diluted share, restructuring charges of $0.46 per
diluted share, acquisition-related financing costs of $0.66 per diluted share and a gain on a
foreign currency forward contract of $0.07 per diluted share.
SEGMENT ANALYSIS
We primarily evaluate performance and allocate resources based on segment operating income, defined
as revenues less expenses identifiable to the product lines included within each segment, as well
as projected future returns. Segment operating income will reconcile to consolidated income from
continuing operations before income taxes by deducting corporate expenses and corporate other
income (expense) that are not attributable to the operating segments, restructuring and impairment
charges and net interest expense.
The proportion of consolidated revenues and segment operating income attributed to each segment was
as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2006 |
|
2005 |
|
|
2004 |
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
Lubrizol Additives |
|
|
64 |
% |
|
63% |
|
|
70% |
Lubrizol Advanced Materials |
|
|
36 |
% |
|
37% |
|
|
30% |
|
|
|
|
|
|
|
|
|
|
|
|
Segment Operating Income: |
|
|
|
|
|
|
|
|
|
|
|
Lubrizol Additives |
|
|
64 |
% |
|
64% |
|
|
75% |
Lubrizol Advanced Materials |
|
|
36 |
% |
|
36% |
|
|
25% |
39
OPERATING RESULTS BY SEGMENT
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2005 vs. 2004 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Excluding the Impact of |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2006 vs. 2005 |
|
|
Acquisitions |
(In Millions of Dollars) |
|
2006 |
|
2005 |
|
2004 |
|
|
$ Change |
|
% Change |
|
|
$ Change |
|
% Change |
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Lubrizol Additives |
|
|
$ 2,600.5 |
|
|
|
$ 2,280.0 |
|
|
|
$ 1,998.6 |
|
|
|
$ 320.5 |
|
|
14% |
|
|
$ 281.4 |
|
|
14% |
Lubrizol Advanced Materials |
|
|
1,440.3 |
|
|
|
1,342.2 |
|
|
|
865.8 |
|
|
|
98.1 |
|
|
7% |
|
|
51.1 |
|
|
6% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
$ 4,040.8 |
|
|
|
$ 3,622.2 |
|
|
|
$ 2,864.4 |
|
|
|
$ 418.6 |
|
|
12% |
|
|
$ 332.5 |
|
|
12% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross Profit: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Lubrizol Additives |
|
|
$ 578.0 |
|
|
|
$ 527.7 |
|
|
|
$ 505.5 |
|
|
|
$ 50.3 |
|
|
10% |
|
|
$ 23.0 |
|
|
5% |
Lubrizol Advanced Materials |
|
|
413.2 |
|
|
|
391.0 |
|
|
|
250.4 |
|
|
|
22.2 |
|
|
6% |
|
|
6.2 |
|
|
2% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
$ 991.2 |
|
|
|
$ 918.7 |
|
|
|
$ 755.9 |
|
|
|
$ 72.5 |
|
|
8% |
|
|
$ 29.2 |
|
|
4% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating Income: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Lubrizol Additives |
|
|
$ 303.0 |
|
|
|
$ 263.3 |
|
|
|
$ 238.2 |
|
|
|
$ 39.7 |
|
|
15% |
|
|
$ 25.9 |
|
|
11% |
Lubrizol Advanced Materials |
|
|
167.6 |
|
|
|
150.9 |
|
|
|
78.6 |
|
|
|
16.7 |
|
|
11% |
|
|
18.1 |
|
|
23% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
$ 470.6 |
|
|
|
$ 414.2 |
|
|
|
$ 316.8 |
|
|
|
$ 56.4 |
|
|
14% |
|
|
$ 44.0 |
|
|
14% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LUBRIZOL ADDITIVES SEGMENT
2006 COMPARED WITH 2005 Revenues increased 14% in 2006 when compared to 2005. The increase
primarily was due to improvement in the combination of price and product mix, while a slight
increase in volume was offset by a slight unfavorable impact of currency.
Volume patterns vary in different geographic zones. The following table shows our volume by
geographic zone in 2006 as well as the changes compared with 2005:
|
|
|
|
|
|
|
|
|
|
|
2006 |
|
|
|
|
Volume |
|
% Change |
North America |
|
|
38 |
% |
|
|
1 |
% |
Europe |
|
|
30 |
% |
|
|
(3 |
%) |
Asia-Pacific / Middle East |
|
|
26 |
% |
|
|
2 |
% |
Latin America |
|
|
6 |
% |
|
|
6 |
% |
|
|
|
|
|
|
|
|
|
Total |
|
|
100 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
Volume increased slightly in 2006 compared to 2005; however, excluding the impact of nonrecurring,
temporary business gains in 2005, volume increased 2% in 2006 compared to 2005.
The decrease in volume in Europe was due in part to a change in a customer sourcing from Europe to
North America. The volume growth in the Asia-Pacific / Middle East region primarily resulted from
growth in China, which represents our third largest country in terms of volume sold despite the
fact that a majority of the 2005 temporary business gains occurred in this region. The volume growth in Latin America primarily was driven by stronger
demand by our major international customers.
Segment gross profit increased 10% in 2006 compared to 2005 as we continued to recover from margin
erosion that occurred in 2005 and prior years. The Lubrizol Additives segment implemented a series
of price increases in 2006 and 2005 in response to continued raw material and utility cost
increases. The effective dates of the selling price increases varied by geographic zone. The
gross profit increase primarily was due to an improvement in the combination of price and product
mix partially offset by a 19% increase in average material cost in 2006 as compared to 2005.
Manufacturing costs on a per-unit-sold basis increased 3% in 2006 compared to 2005. The increase
was due in part to higher utility costs as well as higher operating supplies and outside services
partially offset by lower depreciation expense, employee benefits and a reclassification of certain
expenses from manufacturing to STAR due to a change in organization structure in our European
operations. In addition, manufacturing costs were impacted favorably by approximately $5.2 million
in
40
2006 as we curtailed production activity at our Bromborough, U.K. plant in accordance with our
previously announced timetable to close this facility.
The gross profit percentage declined
to 22.3% in 2006 compared with 23.2% in 2005. The decline in
gross profit percentage primarily was due to continuing raw material cost increases throughout most
of 2006 outpacing the timing of price increases.
STAR expenses increased 7% in 2006 compared to 2005. This increase primarily was due to an
increase in selling and administrative expenses of $14.8 million. The higher selling and
administrative costs primarily resulted from the impact of reclassifying to STAR certain expenses
that previously were classified as manufacturing resulting from a change in organization structure
in our European operations, increases in base and variable compensation and a change in the timing
of annual salary increases. The balance of the change in STAR expenses was due to an increase in
technical expenses of $3.5 million primarily associated with technical programs within our
driveline and industrial oils additives packages.
Other income was impacted favorably by $11.7 million primarily due to legal settlements of
insurance and commercial matters as well as the gain on sale of certain properties.
Segment operating income (revenues less expenses attributable to the product lines aggregated
within each segment) increased 15% in 2006 compared to the prior year due to the factors discussed
above.
2005 COMPARED WITH 2004 Segment revenues increased 14% in 2005 compared to 2004, due to a 12%
improvement from the combination of price and product mix, and a 1% increase in both volume and
currency.
Volume patterns vary in different geographic zones. The following table shows our volume by
geographic zone in 2005 as well as the changes compared with 2004:
|
|
|
|
|
|
|
|
|
|
|
2005 |
|
|
|
|
Volume |
|
% Change |
North America |
|
|
38 |
% |
|
|
(5 |
%) |
Europe |
|
|
31 |
% |
|
|
3 |
% |
Asia-Pacific / Middle East |
|
|
25 |
% |
|
|
9 |
% |
Latin America |
|
|
6 |
% |
|
|
2 |
% |
|
|
|
|
|
|
|
|
|
Total |
|
|
100 |
% |
|
|
1 |
% |
|
|
|
|
|
|
|
|
|
Total volume increased 1% in 2005 compared to 2004. Our results reflect some spot business or
temporary business gains during 2005. This increase partially was offset by the final piece of
lost business of a major international customer in the second half of 2004 and the impact on
volumes of the higher concentration associated with the new passenger car technical standard GF-4
as compared to GF-3. Excluding these three specific factors, volume increased 3% globally and 1%
in North America compared to 2004.
Higher volume in Europe in 2005 compared with 2004 primarily was due to increases in our engine
additives product line due to improved product mix and market share gains. The Asia-Pacific /
Middle East region benefited from overall expanded growth in that market, particularly China, as
well as spot business gains. Excluding the spot business gains, volumes increased 5% in
Asia-Pacific / Middle East.
The Lubrizol Additives segment implemented a series of price increases in 2005 in response to
continued raw material cost increases as well as higher prices for natural gas and electricity used
in our plants. The effective dates of the price increases varied by geographic zone.
Segment gross profit increased $23.0 million, or 5%, in 2005 compared to 2004. The increase
primarily was due to the cumulative impact of the selling price increases as well as an increase in
volume, largely offset by higher average raw material cost and to a lesser extent, higher utility costs. In 2005, average unit raw material
cost increased 22% compared to 2004. Manufacturing expenses increased 3% in 2005; however, on a
per-unit-sold basis, manufacturing expenses increased only 2% as compared to the prior year. The
increase in manufacturing expenses was driven by higher utilities and maintenance costs in 2005
partially offset by lower employee benefit expense and lower environmental accruals.
41
Gross profit as a percentage of net
sales for the segment was 23.2% for 2005 compared with 25.3% in
2004. The decline primarily was due to the time lag between the effective date of selling price
increases in the wake of continuing raw material cost increases and raw material costs rising
proportionally faster than selling prices.
STAR expenses decreased 1% in 2005 compared to 2004, primarily due to lower technical expenses of
$3.1 million. The decrease in technical expenses primarily was due to lower outside technical
expenses impacted by delays in the industry specifications for new lubricant additive programs.
Segment operating income increased 11% in 2005 compared with 2004 due to the factors discussed
above.
LUBRIZOL ADVANCED MATERIALS SEGMENT
2006 COMPARED WITH 2005 Revenues for the Lubrizol Advanced Materials segment increased 7% in 2006
compared with 2005. The increase was due to a 6% increase in volume and a 1% improvement in the
combination of price and product mix. The improvement in the combination of price and product mix
primarily occurred in our Noveon consumer specialties product line.
Volume patterns vary in different geographic zones. The following table shows our volume by
geographic zone in 2006 as well as the changes compared with 2005:
|
|
|
|
|
|
|
|
|
|
|
2006 |
|
|
|
|
Volume |
|
% Change |
North America |
|
|
65 |
% |
|
|
1 |
% |
Europe |
|
|
18 |
% |
|
|
4 |
% |
Asia-Pacific / Middle East |
|
|
13 |
% |
|
|
28 |
% |
Latin America |
|
|
4 |
% |
|
|
32 |
% |
|
|
|
|
|
|
|
|
|
Total |
|
|
100 |
% |
|
|
6 |
% |
|
|
|
|
|
|
|
|
|
Our engineered polymers and Noveon consumer specialties product lines both had increases in volume
in North America in 2006 compared to 2005. The increase in our engineered polymers product line
was due to increased customer demand in both our Estane® thermoplastic polyurethane
business (Estane) and our TempRite® engineered polymers business (TempRite). TempRite
benefited from continued conversions from metals to plastics. The increase in the Noveon consumer
specialties product line primarily was due to increased customer demand in our personal care and
home care business and tolling sales to the buyer of our FIIS business. Our performance coatings
product line had a slight decrease in volume in North America in 2006 compared to 2005, which we
believe primarily was due to the continued migration of the textile industry from North America to
China.
Our engineered polymers and performance coatings product lines had increases in Europe in 2006
compared to 2005. The increase in our performance coatings product line primarily was due to
customer demand and market share gains in the textiles market and customer demand in the paints and
coatings market. The increase in our engineered polymers product line was due to market-share
gains in our Estane business and business gains in our TempRite business resulting from continued
conversions from metals to plastics. Our Noveon consumer specialties product line had a decrease
in volume in Europe in 2006 compared to 2005 primarily attributable to our AMPS®
specialty monomers business. The increase in Asia-Pacific / Middle East volume for 2006
primarily was due to higher customer demand and market-share gains in both our Estane business and
performance coatings product line, predominately in the textiles market, and higher customer demand
in our Noveon consumer specialties product line. We also experienced higher customer demand in the
TempRite business, particularly in the Middle East and India.
Segment gross profit increased $22.2 million, or 6%, in 2006 compared to 2005. The increase in
segment gross profit in 2006 primarily was the result of higher revenues due to the increase in
volume and improvement in the combination of price and product mix partially offset by higher
average raw material cost and manufacturing costs. Average raw material cost increased 4% in 2006
compared to 2005. Manufacturing costs primarily were higher due to increased utility costs, the
impact of reclassifying certain expenses from STAR to manufacturing as a result of a change in
organizational structure in our European operations and higher volume.
The gross profit percentage for this segment was 28.7% in 2006 compared to 29.1% in 2005. The
decrease in gross profit percentage in 2006 was due to higher average raw material cost partially
offset by an improvement in the combination of price and product mix.
42
STAR expenses increased $9.0 million, or 4%, in 2006 compared to 2005. The increase in STAR was
due to higher salaries and incentive compensation and increased hiring to support growth
initiatives partially offset by the impact of reclassifying certain expenses from STAR to
manufacturing as a result of a change in organizational structure in our European operations and
reductions in bad debt expense.
Segment operating income increased $16.7 million in 2006 compared to 2005. The increase in segment
operating income primarily was due to the increase in segment gross profit as described above,
partially offset by the increase in STAR expenses.
2005 COMPARED WITH 2004 In 2005, revenues for the Lubrizol Advanced Materials segment increased
55% compared with 2004 primarily due to the 2004 acquisitions of Noveon International and the
hyperdispersants business. Excluding the impact of acquisitions, segment revenues increased 6% in
2005 compared with 2004 due to a 10% improvement in the combination of price and product mix
partially offset by a 4% decrease in volume. The improvements in price and product mix occurred
relatively evenly across all three of our product lines as we had implemented price increases to
offset rising raw material costs.
Volume patterns vary in different geographic zones. The following table shows our volume by
geographic zone in 2005 as well as the changes compared with 2004:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Excluding the Impact |
|
|
2005 |
|
|
|
|
|
of Acquisitions |
|
|
Volume |
|
% Change |
|
% Change |
North America |
|
|
68 |
% |
|
|
28 |
% |
|
|
(7 |
%) |
Europe |
|
|
19 |
% |
|
|
40 |
% |
|
|
2 |
% |
Asia-Pacific / Middle East |
|
|
10 |
% |
|
|
44 |
% |
|
|
(3 |
%) |
Latin America |
|
|
3 |
% |
|
|
32 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
100 |
% |
|
|
31 |
% |
|
|
(4 |
%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Excluding the impact of acquisitions, all three product lines showed volume decreases in North
America. These decreases primarily were due to our exiting certain low-margin business,
deterioration in the textiles market and some market-share loss as a result of competitive activity
in response to our price increases. The volume increase in Europe primarily was in our Noveon
consumer specialties product line and was due to increased sales in our AMPS specialty monomers
business.
Segment gross profit increased $140.5 million, or 56% (increased $6.2 million, or 2%, excluding the
impact of acquisitions), in 2005 compared with 2004. Excluding the impact of acquisitions, the
increase in segment gross profit in 2005 resulted from higher revenues due to an improvement in the
combination of price and product mix partially offset by lower volume and higher raw material costs
and utility expenses. Average raw material cost increased 12% in 2005 compared with 2004. Raw
material cost for 2004 included the impact of $7.5 million of inventory step-up amortization from
acquisition accounting. Excluding the impact of the step-up in 2004, average raw material cost
increased 13% in 2005 compared with 2004. Manufacturing expenses increased 9% in 2005 compared
with 2004 primarily due to higher spending related to utilities. Average unit manufacturing
expense increased 14% due to the combination of lower volumes and higher utility and operating
expenses.
Gross profit as a percentage of net sales was 29.1% (28.0% excluding the impact of acquisitions) in
2005 compared with 29.0% in 2004. Excluding the impact of the inventory step-up amortization, the
gross profit percentage for 2004 was 29.8%. The decrease in gross profit percentage in 2005 was
due to higher average raw material cost and higher manufacturing costs partially offset by an
improvement in the combination of price and product mix.
STAR expenses increased $62.9 million, or 40%, in 2005 (decreased $11.4 million, or 7%, excluding
the impact of acquisitions) compared with 2004. Excluding the impact of acquisitions, the decrease
in STAR expenses primarily was due to reduced corporate administrative and technical services
provided to the segment, the consolidation of some segment administrative functions into corporate
functions and savings from a restructuring in our performance coatings product line.
43
Segment operating income increased $72.3 million in 2005 (increased $18.1 million, excluding the
impact of acquisitions) compared with segment operating income of $78.6 million in 2004. Excluding
the impact of acquisitions, the increase in segment operating income primarily was due to the
increase in segment gross profit and lower STAR expenses.
RETURN ON AVERAGE SHAREHOLDERS EQUITY
Return on average shareholders equity was 6.4% in 2006, 12.2% in 2005 and 7.5% in 2004. The return
on average shareholders equity is calculated as current year net income divided by the rolling
12-month average of shareholders equity for the current and prior years. The earnings (loss)
impact of discontinued operations, restructuring and impairment charges
and the write-off of acquired IPR&D in 2004 lowered the return on average shareholders equity by
approximately 5.8%, 1.0% and 3.8% in 2006, 2005 and 2004, respectively.
WORKING CAPITAL, LIQUIDITY AND CAPITAL RESOURCES
SELECTED MEASURES OF LIQUIDITY AND CAPITAL RESOURCES The following table summarizes our financial
performance indicators of liquidity:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2006 |
|
|
2005 |
|
Cash and short-term investments (in millions of dollars) |
|
|
|
|
|
$ |
575.7 |
|
|
$ |
262.4 |
|
Working capital (in millions of dollars) |
|
|
|
|
|
$ |
1,201.9 |
|
|
$ |
906.6 |
|
Current ratio |
|
|
|
|
|
|
2.9 |
|
|
|
2.4 |
|
Debt as a % of capitalization |
|
|
|
|
|
|
47.8 |
% |
|
|
51.8 |
% |
Net debt as a % of capitalization |
|
|
|
|
|
|
36.5 |
% |
|
|
47.5 |
% |
|
SUMMARY OF CASH FLOWS The following table summarizes the major components of cash flows: |
|
|
|
(In Millions of Dollars) |
|
2006 |
|
2005 |
|
2004 |
Cash provided by (used for): |
|
|
|
|
|
|
|
|
|
|
|
|
Operating activities |
|
$ |
334.8 |
|
|
$ |
362.2 |
|
|
$ |
331.6 |
|
Investing activities |
|
|
151.4 |
|
|
|
(106.8 |
) |
|
|
(1,088.8 |
) |
Financing activities |
|
|
(183.9 |
) |
|
|
(312.8 |
) |
|
|
808.5 |
|
Effect of exchange-rate changes on cash |
|
|
11.0 |
|
|
|
(16.1 |
) |
|
|
25.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash and short-term investments |
|
$ |
313.3 |
|
|
$ |
(73.5 |
) |
|
$ |
77.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
OPERATING ACTIVITIES
The decrease in cash provided by operating activities in 2006 compared with 2005 primarily relates
to a decrease in payables and accrued expenses, including the payment of accounts payable of
approximately $27.0 million that were retained at the closing of the FIIS divestiture and
unfavorable timing of accounts payable disbursements in 2006 compared to 2005. In addition, we
experienced higher inventory levels due to increased raw material costs, as well as an increase in
finished goods inventory caused by lower year-end shipment volumes.
We manage our levels of inventories and accounts receivable on the basis of average days sales in
inventory and average days sales in receivables. We establish our target for accounts receivable
by taking into consideration the weighted average of our various terms of trade for each segment.
We establish our target for days sales in inventory with the goal of minimizing our investment in
inventories while at the same time ensuring adequate supply for our customers. Despite the
increase in working capital due to higher average selling price and higher inventory costs, we
improved our days outstanding in accounts receivable and days in inventory.
INVESTING ACTIVITIES
Our capital expenditures in 2006 were $130.9 million, as compared with $136.7 million and $133.2
million in 2005 and 2004, respectively. Capital expenditures for the Lubrizol Additives segment
primarily are made to maintain existing manufacturing capacity. Approximately 30% of the capital
expenditures in the Lubrizol Advanced Materials segment
44
related to increasing capacity. In 2007,
we estimate annual capital expenditures will be approximately $175.0 million to $180.0 million.
The higher level of estimated capital expenditures in 2007 is driven by our plans to build
production capacity for our Lubrizol Advanced Materials product lines in China, North America and
Europe to meet growing demand, as well as to bring both segments onto a common information systems
platform.
The sales of FIIS and A&I were completed on May 1, 2006 and May 23, 2006, respectively. In
consideration for these divested businesses, we received net cash proceeds of approximately $254.8
million and $10.4 million, respectively. The FIIS sale resulted in a taxable gain, which was
offset by our remaining net operating loss carryforwards. The sale of Telene was completed in
February 2006 for net cash proceeds of $6.2 million.
FINANCING ACTIVITIES
Cash used for financing activities of $183.9 million in 2006 primarily consisted of repayments of
long-term debt and the payment of dividends, partially offset by proceeds from the exercise of
stock options. This compares to $312.8 million used for financing activities in 2005, which
primarily consisted of net repayments of long-term debt of $280.4 million and the payment of
dividends, partially offset by borrowings under our euro revolving credit facility and proceeds
from the exercise of stock options.
Other than the 85.0 million outstanding under our euro revolving credit facility, we have no
other debt that is prepayable without incurring a penalty.
CAPITALIZATION AND CREDIT FACILITIES
At December 31, 2006, our total debt outstanding of $1,541.7 million consisted of 67% fixed-rate
debt and 33% variable-rate debt, including $400.0 million of fixed-rate debt that effectively has
been swapped to a variable rate. Our weighted-average interest rate as of December 31, 2006 was
approximately 5.8%.
Our net debt to capitalization ratio at December 31, 2006 was 36.5%. Net debt represents total
short-term and long-term debt, excluding original issue discounts and unrealized gains and losses
on derivative instruments designated as fair-value hedges of fixed-rate debt, reduced by cash and
short-term investments. Capitalization is calculated as shareholders equity plus net debt. Total
debt as a percent of capitalization was 47.8% at December 31, 2006.
Our ratio of current assets to current liabilities was 2.9 and 2.4 at December 31, 2006 and 2005,
respectively.
On September 20, 2006, we amended our five-year unsecured committed U.S. bank credit agreement to
reduce the revolving credit facility from $500.0 million to $350.0 million and extend the maturity
date to September 2011. In addition, as of September 20, 2006, our direct and indirect domestic
subsidiaries were released as guarantors under the credit agreement, and we no longer are subject
to any investment or acquisition restrictions. This credit facility allows us to borrow at
variable rates based upon the U.S. prime rate or LIBOR plus a specified credit spread. As of
December 31, 2006, we had no outstanding borrowings under this agreement.
In addition, at December 31, 2006, two of our wholly owned foreign subsidiaries had a 250.0
million revolving credit facility that matures in September 2010. This credit agreement permits
these foreign subsidiaries to borrow at variable rates based on EURIBOR plus a specified credit
spread. We have guaranteed all obligations of the borrowers under the credit agreement. On
September 20, 2006, we amended this credit agreement such that we no longer are subject to any
investment or acquisition restrictions. No other terms or conditions of the agreement were
modified. As of December 31, 2006, we had outstanding borrowings of 85.0 million under this
agreement.
The cash and short-term investments balance of $575.7 million at December 31, 2006 will be used to fund ongoing operations,
pay down debt, pursue acquisition opportunities and buy back shares sufficient to offset future
dilution from our stock-based incentive compensation plans. Given the call premium on our
long-term debt, it is unlikely that we will reduce debt significantly before our next scheduled
maturity in late 2008. Therefore, it is possible that we will carry excess cash until our next
scheduled maturity.
45
CONTRACTUAL CASH OBLIGATIONS
The following table shows our contractual cash obligations under debt agreements, leases,
non-cancelable purchase commitments and other long-term liabilities at December 31, 2006:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments Due by Period |
(In Millions of Dollars) |
|
Total |
|
2007 |
|
2008 - 2009 |
|
2010 - 2011 |
|
2012 and After |
Total debt (1) |
|
|
$ 1,549.1 |
|
|
|
$ 3.7 |
|
|
|
$ 582.6 |
|
|
|
$ 112.7 |
|
|
|
$ 850.1 |
|
Interest (2) |
|
|
954.6 |
|
|
|
80.9 |
|
|
|
150.1 |
|
|
|
103.0 |
|
|
|
620.6 |
|
Operating leases |
|
|
62.3 |
|
|
|
17.1 |
|
|
|
23.0 |
|
|
|
13.6 |
|
|
|
8.6 |
|
Non-cancelable purchase commitments (3) |
|
|
178.0 |
|
|
|
77.9 |
|
|
|
86.6 |
|
|
|
9.2 |
|
|
|
4.3 |
|
Other long-term liabilities (4)(5) |
|
|
90.8 |
|
|
|
66.1 |
|
|
|
8.6 |
|
|
|
0.6 |
|
|
|
15.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total contractual cash obligations |
|
|
$ 2,834.8 |
|
|
|
$ 245.7 |
|
|
|
$ 850.9 |
|
|
|
$ 239.1 |
|
|
|
$ 1,499.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Total debt includes both the current and long-term portions of debt as reported in Note
7 to the consolidated financial statements, excluding original issue discounts and
unrealized gains on derivative instruments designated as fair-value hedges of fixed-rate
debt. |
|
(2) |
|
Represents estimated contractual interest payments for fixed-rate debt only. We are
not able to estimate reasonably the cash payments for interest associated with
variable-rate debt due to the significant estimation required relating to both market
interest rates as well as projected principal payments. |
|
(3) |
|
Non-cancelable purchase commitments primarily include raw materials purchased under
take-or-pay contracts, drumming, warehousing and service contracts, utility purchase
agreements, terminal agreements and toll processing arrangements. |
|
(4) |
|
Other long-term liabilities disclosed in the table represent long-term liabilities
reported in our consolidated balance sheet at December 31, 2006 under noncurrent
liabilities, excluding pension, postretirement, postemployment, environmental and other
non-contractual liabilities. |
|
(5) |
|
We are required to make minimum contributions to our U.S. defined benefit pension plans
pursuant to the minimum funding requirements of the Internal Revenue Code of 1986, as
amended, and the Employee Retirement Income Security Act of 1974, as amended. Funding
requirements for plans outside the United States are subject to applicable local
regulations. In 2007, we expect to make employer contributions of approximately $59.5
million to the qualified plans to satisfy these minimum statutory funding requirements. In
2007, we expect to make payments of approximately $1.8 million relating to our unfunded
pension plans. The expected payments associated with the unfunded plans represent an
actuarial estimate of future assumed payments based upon retirement and payment patterns.
Actual amounts paid could differ from this estimate. In addition, non-pension
postretirement benefit payments are expected to approximate $4.8 million in 2007. We have
included these expected contributions of $66.1 million in the above table. Due to
uncertainties regarding significant assumptions involved in estimating future required
contributions to our defined benefit pension and other plans, such as interest rate levels,
the amount and timing of asset returns and future restructurings, if any, we are not able
to reasonably estimate our contributions beyond 2007. |
In addition, at December 31, 2006, we had $45.7 million of contingent obligations under standby
letters of credit issued in the ordinary course of business to financial institutions, customers
and insurance companies to secure short-term support for a variety of commercial transactions,
insurance and benefit programs.
We had $1,541.7 million of debt outstanding at December 31, 2006 compared to $1,670.8 million
outstanding at December 31, 2005. Our total debt as a percent of capitalization has decreased from
51.8% at December 31, 2005 to 47.8% at December 31, 2006. We believe our future operating cash
flows will be sufficient to cover our debt repayments, other contractual obligations, capital
expenditures and dividends. In addition, we have untapped borrowing capacity that can provide us
with additional financial resources. We currently have a shelf registration statement filed with
the Securities and Exchange Commission (SEC) under which $359.8 million of debt securities,
preferred shares or common shares may be issued. In addition, as of December 31, 2006, we
maintained cash and short-term investment balances of $575.7 million and had $304.3 million
available under our U.S. revolving credit facility and 165.0 million available under our euro
revolving credit facility.
46
GUARANTEES
On May 1, 2006, we sold the FIIS business to SPM Group Holdings, LLC, now known as Emerald
Performance Materials, LLC (Emerald). As a result of the sale, Emerald became responsible for a
supplier contract with SK Corporation (SK). We have provided a guarantee to SK for the timely
performance of Emeralds payment obligations. SK may make a demand for payment of outstanding
obligations under this guarantee, which extends to January 31, 2008, provided they are unable to
collect payment from Emerald using commercially reasonable efforts. The guarantee is revocable by
us upon 60 days prior written notice. Because of the existing revocation clause, we estimate that
the maximum liability under the guarantee would be approximately $15.2 million. However, we
believe that it is highly unlikely that an event would occur requiring us to pay any monies
pursuant to the guarantee. Accordingly, no liability has been reflected in our consolidated
balance sheet at December 31, 2006.
INDEMNIFICATIONS
In connection with the sale of the FIIS business, we have provided indemnifications to Emerald with
respect to the business sold. These indemnifications have been associated with the price and
quantity of raw material purchases, permit costs, costs incurred due to the inability to obtain
permits and environmental matters. We believe that losses incurred in any of these matters would
not have a material effect on our business, financial condition or results of operations. For
those indemnification agreements where a payment by us is probable and estimable, a liability has
been recorded as of December 31, 2006.
CRITICAL ACCOUNTING POLICIES
The preparation of financial statements and related disclosures in accordance with accounting
principles generally accepted in the United States of America requires us to make judgments,
assumptions and estimates at a specific point in time that affect the amounts reported in the
accompanying consolidated financial statements and related notes. In preparing these financial
statements, we have utilized available information including our past history, industry standards
and the current economic environment, among other factors, in forming our estimates and judgments
of certain amounts included in the
consolidated financial statements, giving due consideration to materiality. It is possible that
the ultimate outcome as anticipated by management in formulating our estimates inherent in these
financial statements may not materialize. Application of the critical accounting policies
described below involves the exercise of judgment and the use of assumptions as to future
uncertainties and, as a result, actual results could differ from these estimates. In addition,
other companies may utilize different estimates, which may impact the comparability of our results
of operations to similar businesses.
ACCOUNTING FOR RESERVES AND CONTINGENCIES
Our accounting policies for reserves and contingencies cover a wide variety of business activities,
including reserves for potentially uncollectible receivables, slow-moving or obsolete inventory,
legal and environmental exposures and tax exposures. We accrue these reserves when our assessments
indicate that it is probable that a liability has been incurred or an asset will not be recovered
and an amount can be reasonably estimated. We review these estimates quarterly based on currently
available information. Actual results may differ from our estimates and our estimates may be
revised upward or downward, depending upon the outcome or changed expectations based on the facts
surrounding each exposure. We discuss annually with the audit committee of our board of directors
our reserves and contingencies, as well as our policies and processes for evaluating them.
ACCOUNTING FOR SALES DISCOUNTS AND REBATES
Sales discounts and rebates are offered to certain customers to promote customer loyalty and to
encourage greater product sales. These rebate programs provide that upon the attainment of
pre-established volumes or the attainment of revenue milestones for a specified period, the
customer receives credits against purchases. We estimate the provision for rebates based upon the
specific terms in each agreement at the time of shipment and an estimate of the customers
achievement of the respective revenue milestones. Customer claims, returns and allowances and
discounts are accrued based upon our history of claims and sales returns and allowances. The
estimated provisions significantly could be affected if future occurrences and claims differ from
these assumptions and historical trends.
DETERMINATION OF NET PERIODIC PENSION COST
Each year we review with our actuaries the actuarial assumptions used in the determination of net
periodic pension cost, as prescribed by SFAS No. 87, Employers Accounting for Pensions. The
determination of net periodic pension cost is based upon a number of actuarial assumptions. The
two most critical assumptions are the expected return on plan assets and the
47
discount rate for determining the funded status. Other assumptions include the rate of
compensation increase and demographic factors such as retirement age, mortality and turnover. We
review the critical assumptions for our U.S. pension plans with the audit committee of our board of
directors. Our net periodic pension cost for all pension plans was $52.9 million in 2006, $43.5
million in 2005 and $37.7 million in 2004. The net periodic pension cost included a settlement
loss of $2.9 million, $0.3 million and $7.7 million in 2006, 2005 and 2004, respectively. In
accordance with generally accepted accounting principles, actual results that differ from the
assumptions are accumulated and amortized over future periods and, therefore, affect expense
recognized and obligations recorded in future periods.
In developing our assumption for the expected long-term rate of return on plan assets, we
considered historical returns and the future expectations for returns for each asset class, as well
as the target asset allocation of the pension portfolio. In 2006, we lowered our assumption for
the U.S. pension plans by 25 basis points to 8.25% (7.48% on a weighted-average basis for all
plans) based on our investment mix and projected market conditions. We believe 8.25% represents a
reasonable return that could be achieved over the long term using our current asset allocation. At
December 31, 2006, our U.S. pension plans assets had an investment mix that approximated 73% in
equity securities and 27% in debt securities.
A change in the rate of return of 100 basis points would have the following effects on 2007 net
periodic pension cost:
|
|
|
|
|
|
|
|
|
|
|
|
|
100 Basis Point |
(In Millions of Dollars) |
|
Increase |
|
Decrease |
U.S. pension plans |
|
|
$ |
(2.7 |
) |
|
|
$ |
2.7 |
|
International pension plans |
|
|
|
(1.9 |
) |
|
|
|
1.9 |
|
|
|
|
|
|
|
|
|
|
All pension plans |
|
|
$ |
(4.6 |
) |
|
|
$ |
4.6 |
|
|
|
|
|
|
|
|
|
|
The selection of a discount rate for pension plans is required to determine the value of future
pension obligations and represents our best estimate of our cost in the marketplace to settle all
pension obligations through annuity purchases. We determined the discount rate based upon current
market indicators, including yields from dedicated bond portfolios that provide for a general
matching of bond maturities with the projected benefit cash flows from our plans. The dedicated
bond portfolios consist of non-callable corporate bonds that are at least AA- quality. The 2006
year-end discount rate assumption for our U.S. pension plans was set at 6.25%, which is an increase
from 5.75% used in 2005. On a worldwide basis, the 2006 weighted-average discount rate utilized
increased to 5.63% from 5.25% used in 2005.
A change in the discount rate of 100 basis points would have the following effects on 2007 net
periodic pension cost:
|
|
|
|
|
|
|
|
|
|
|
|
|
100 Basis Point |
|
(In Millions of Dollars) |
|
Increase |
|
Decrease |
U.S. pension plans |
|
|
$ |
(3.0 |
) |
|
|
$ |
7.0 |
|
International pension plans |
|
|
|
(5.3 |
) |
|
|
|
3.6 |
|
|
|
|
|
|
|
|
|
|
All pension plans |
|
|
$ |
(8.3 |
) |
|
|
$ |
10.6 |
|
|
|
|
|
|
|
|
|
|
The accumulated benefit obligation for all pension plans worldwide exceeds the value of plan assets
by $83.3 million. This represents a $44.3 million improvement in funded status from the $127.6
million in the total unfunded accumulated benefit obligation reported in 2005. The accumulated
benefit obligation exceeded the plan assets for the U.S. pension plans by $30.3 million and the
non-U.S. plans by $53.0 million in 2006. The primary driver behind the $44.3 million decrease in
the unfunded benefit obligations was a result of favorable investment returns during 2006.
Changes in pension plan assumptions are expected to decrease pension expense for most pension plans
worldwide in 2007. The 2007 pension expense is expected to be approximately $42.7 million,
excluding the impact of any settlement charges. The expected decrease in pension expense in 2007,
excluding the impact of settlement charges, primarily is due to an increase in expected returns on
assets due to the increase in fair value of plan assets at December 31, 2006, a reduction in the
amortization of actuarial losses and the increase in the discount rate for all plans, offset by an
increase in interest cost associated with an increase in the projected benefit obligation.
48
DETERMINATION OF POSTRETIREMENT BENEFIT COST
Annually, we review with our actuaries the key economic assumptions used in calculating
postretirement benefit cost as prescribed by SFAS No. 106, Employers Accounting for
Postretirement Benefits Other than Pensions. Postretirement benefits include health care and life
insurance plans. The determination of postretirement benefit cost is based upon a number of
actuarial assumptions, including the discount rate for determining the accumulated postretirement
benefit obligation, the assumed health care cost trend rates and the ultimate health care trend
rate. Except for the U.S. plans, the same discount rate selected for the pension plans generally
is used for calculating the postretirement benefit obligation by country. Net non-pension
postretirement benefit (credit) cost was ($0.1) million in 2006, $3.4 million in 2005 and $6.8
million in 2004.
A change in the discount rate of 100 basis points would have the following effects on 2007
postretirement benefit cost:
|
|
|
|
|
|
|
|
|
|
|
|
|
100 Basis Point |
(In Millions of Dollars) |
|
Increase |
|
Decrease |
U.S. postretirement plans |
|
|
$ |
(0.4 |
) |
|
|
$ |
0.4 |
|
International postretirement plans |
|
|
|
(0.3 |
) |
|
|
|
0.4 |
|
|
|
|
|
|
|
|
|
|
All postretirement plans |
|
|
$ |
(0.7 |
) |
|
|
$ |
0.8 |
|
|
|
|
|
|
|
|
|
|
|
A change in the assumed health care cost trend rate of 100 basis points would have the following
effects on 2007 postretirement benefit cost: |
|
|
|
100 Basis Point |
(In Millions of Dollars) |
|
Increase |
|
Decrease |
U.S. postretirement plans |
|
|
$ |
1.1 |
|
|
|
$ |
(1.0 |
) |
International postretirement plans |
|
|
|
0.7 |
|
|
|
|
(0.5 |
) |
|
|
|
|
|
|
|
|
|
All postretirement plans |
|
|
$ |
1.8 |
|
|
|
$ |
(1.5 |
) |
|
|
|
|
|
|
|
|
|
ACCOUNTING FOR BUSINESS COMBINATIONS
We allocate the purchase price of business combinations to assets acquired and liabilities assumed
based on their relative fair value at the date of acquisition pursuant to the provisions of SFAS
No. 141, Business Combinations. In estimating the fair value of the tangible and intangible
assets and liabilities acquired, we consider information obtained during our due diligence process
and utilize various valuation methods including market prices, where available, appraisals,
comparisons to transactions for similar assets and liabilities and present value of estimated
future cash flows. We are required to make subjective estimates in connection with these
valuations and allocations.
ACCOUNTING FOR IMPAIRMENT OF LONG-LIVED ASSETS
We review the carrying value of our long-lived assets, including property and equipment, whenever
events or changes in circumstances indicate that the carrying value of the assets may not be
recoverable. An impairment loss exists when estimated undiscounted future cash flows expected to
result from the use of the asset, including disposition, are less than the carrying value of the
asset. The measurement of the impairment loss to be recognized is based on the difference between
the fair value and the carrying amounts of the assets. Fair value generally is determined based
upon a discounted cash flow analysis. In order to determine if an asset has been impaired, assets
are grouped and tested at the lowest level for which identifiable, independent, cash flows are
available.
The determination of both undiscounted and discounted cash flows requires us to make significant
estimates and considers the expected course of action at the balance sheet date. Subsequent
changes in estimated undiscounted and discounted cash flows arising from changes in anticipated
actions could impact the determination of whether an impairment exists, the amount of the
impairment charge recorded and whether the effects could materially impact our consolidated
financial statements.
49
DISCONTINUED OPERATIONS
The results of a component of our business that either has been disposed of or is classified as
held for sale are reported in discontinued operations in accordance with the requirements of SFAS
No. 144. We classify a component of our business as held for sale if it meets the following
criteria as of each balance sheet date:
|
|
|
We commit to a plan to sell the disposal group. |
|
|
|
|
The disposal group is available for immediate sale in its present condition, subject
only to the terms that are usual and customary for sales of such disposal groups. |
|
|
|
|
An active program to locate a buyer and other actions required to complete the plan to
sell have been initiated. |
|
|
|
|
The sale of the disposal group is probable and the transfer is expected to qualify for
recognition as a completed sale within one year. |
|
|
|
|
The disposal group is being marketed actively for sale at a price that is reasonable in
relation to its current fair value. |
|
|
|
|
Actions necessary to complete the plan indicate that it is unlikely that significant
changes to the plan will be made or that the plan will be withdrawn. |
The results of operations of all entities that have been disposed of or are classified as held for
sale have been classified in the (loss) income from discontinued operations - net of tax line item
in the consolidated statements of income for all periods presented. The 2006, 2005 and 2004 cash
flow statements are presented on a consolidated basis, including both continuing operations and
discontinued operations.
ACCOUNTING FOR IMPAIRMENT OF GOODWILL AND INTANGIBLE ASSETS
Goodwill represents the excess of purchase price and related costs over the value assigned to the
net tangible and identifiable intangible assets of businesses acquired. In accordance with SFAS
No. 142, Goodwill and Other Intangible Assets, goodwill is to be tested annually and between
annual tests if events occur or circumstances change that would more likely than not reduce the
fair value of an operating segment below its carrying amount. We have elected October 1 as the
annual evaluation date to test for potential goodwill impairment. The annual goodwill impairment
test requires us to make a number of assumptions and estimates concerning future levels of earnings
and cash flow, which are based upon our strategic plans. The combination of a discounted cash flow
analysis and terminal value model is used to determine the fair value of each reporting unit.
While we use available information to prepare estimates and to perform the impairment evaluation,
actual results could differ significantly resulting in future impairment and losses related to
recorded goodwill balances. No impairment of goodwill was identified in the annual impairment test
completed in 2006. (See Note 6 to the consolidated financial statements.)
Intangible assets resulting from business acquisitions, including customer lists, purchased
technology, trademarks, patents, land-use rights and non-compete agreements, are amortized on a
straight-line method over periods ranging from 3 to 40 years. Under SFAS No. 142, intangible
assets determined to have indefinite lives are not amortized, but are tested for impairment at
least annually. We have elected October 1 as the annual evaluation date to test for potential
impairment of indefinite lived intangible assets. The combination of a discounted cash flow
analysis and terminal value model is used to determine whether the fair value of an intangible
asset exceeds its carrying amount. As part of the annual impairment test, the non-amortized
intangible assets are reviewed to determine if the indefinite status remains appropriate.
We completed a corporate identity review in the fourth quarter of 2006 and made a final
determination in January 2007 that the trade name Noveon no longer would be used to describe the
specialty chemicals business segment of our company and that its use would be discontinued except
in connection with the consumer specialties product line. As a result, an impairment charge for
the Noveon trade name was recognized in accordance with SFAS No. 142. We calculated a pretax
charge of $41.2 million ($25.4 million after-tax) to reduce the related asset to its estimated fair
value. This charge was reflected in the fourth quarter of 2006 as we believed at that time we
would more likely than not discontinue the use of the Noveon trade name, except in the limited
context of the consumer specialties product line.
ASSET-RETIREMENT OBLIGATIONS
We account for asset retirement obligations in accordance with SFAS No. 143, Accounting for Asset
Retirement Obligations and Financial Accounting Standards Board (FASB) Interpretation (FIN) No.
47, Accounting for Conditional Asset-Retirement Obligations - an interpretation of FASB Statement
No. 143. FIN No. 47 requires the recognition of a liability for the fair value of a legal
obligation to perform asset-retirement obligations (AROs)
50
that are conditional on a future event if
the amount can be reasonably estimated. We have identified AROs related to certain of our leased
facilities and to asbestos remediation activities that may be required at other company-owned
facilities in the future. We record liabilities for AROs at the time that they are identified and
when they can be reasonably estimated. Due to the long-term, productive nature of some of our
manufacturing operations, absent plans or expectation of plans to initiate asset retirement
activities, we are unable to reasonably estimate the fair value of such asbestos remediation
liabilities since the potential settlement dates cannot be determined at this time.
NEW ACCOUNTING STANDARDS
SFAS No. 158
In September 2006, the FASB issued SFAS No. 158, Employers Accounting for Defined Benefit Pension
and Other Postretirement Plans - an amendment of FASB Statements No. 87, 88, 106, and 132(R).
This statement requires an employer to recognize a plans funded status in its statement of
financial position, measure a plans assets and obligations as of the end of the employers fiscal
year and recognize the changes in a plans funded status in comprehensive income in the year in
which the changes occur. SFAS No. 158s requirement to recognize a plans funded status and new
disclosure requirements are effective for us as of December 31, 2006. The requirement to measure
plan assets and benefit obligations as of the date of our fiscal year-end statement of financial
position is effective for fiscal years ending after
December 15, 2008. Currently, we measure plan assets and benefit obligations as of the date of our
fiscal year-end. We adopted the required provisions of SFAS No. 158 on December 31, 2006.
The incremental effects of adopting SFAS No. 158 on our consolidated balance sheet at December 31,
2006 were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance Before |
|
|
|
|
|
Balance After |
|
|
Applying |
|
SFAS No. 158 |
|
Applying |
|
|
SFAS No. 158 |
|
Adjustments |
|
SFAS No. 158 |
Current assets: |
|
|
|
|
|
|
|
|
|
|
|
|
Other current assets |
|
$ |
104.9 |
|
|
$ |
(6.9 |
) |
|
$ |
98.0 |
|
Noncurrent assets: |
|
|
|
|
|
|
|
|
|
|
|
|
Other assets |
|
$ |
65.5 |
|
|
$ |
1.2 |
|
|
$ |
66.7 |
|
Intangible assets - net |
|
$ |
329.2 |
|
|
$ |
(6.4 |
) |
|
$ |
322.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets |
|
$ |
4,403.0 |
|
|
$ |
(12.1 |
) |
|
$ |
4,390.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
Accrued expenses and other current liabilities |
|
$ |
287.2 |
|
|
$ |
3.0 |
|
|
$ |
290.2 |
|
Noncurrent liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
Pension obligations |
|
$ |
149.1 |
|
|
$ |
88.8 |
|
|
$ |
237.9 |
|
Other postretirement health care obligations |
|
$ |
104.7 |
|
|
$ |
(11.2 |
) |
|
$ |
93.5 |
|
Deferred income taxes |
|
$ |
110.3 |
|
|
$ |
(29.9 |
) |
|
$ |
80.4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities |
|
$ |
2,605.8 |
|
|
$ |
50.7 |
|
|
$ |
2,656.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated other comprehensive income (loss) |
|
$ |
2.0 |
|
|
$ |
(62.8 |
) |
|
$ |
(60.8 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total shareholders equity |
|
$ |
1,745.9 |
|
|
$ |
(62.8 |
) |
|
$ |
1,683.1 |
|
SFAS No. 157
In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements. This statement defines
fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP and
expands disclosure about fair value measurements. SFAS No. 157 does not expand the use of fair
value measures in financial statements, but simplifies and codifies related guidance within U.S.
GAAP. SFAS No. 157 establishes a fair value hierarchy using observable market data as the highest
level and an entitys own fair value assumptions as the lowest level. SFAS No. 157 is effective
for
51
fiscal years beginning after November 15, 2007 and interim periods within those years. SFAS
No. 157 requires adoption prospectively as of the beginning of the fiscal year in which this
statement is initially applied, with the exception of certain financial instruments in which
adoption is applied retrospectively as of the beginning of the fiscal year in which this statement
is initially applied. We currently are evaluating the impact of this recently issued standard on
our consolidated financial statements.
SAB No. 108
In September 2006, the SEC released Staff Accounting Bulletin (SAB) No. 108, Considering the
Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial
Statements. This bulletin provides guidance on how the effects of prior-year uncorrected
financial statement misstatements should be considered in quantifying a current-year misstatement.
SAB No. 108 requires registrants to quantify misstatements using both an income statement
(rollover) and balance sheet (iron curtain) approach and evaluate whether either approach results
in a misstatement that, when all relevant quantitative and qualitative factors are considered, is
material. If prior-year errors that previously had been considered immaterial now are considered
material based on either approach, no restatement is required so long as management properly
applied its previous approach and all relevant facts and circumstances were considered. If prior
years are not restated, a cumulative-effect adjustment is recorded in opening accumulated earnings
as of the beginning of the fiscal year of adoption. SAB No. 108 is effective for us for the fiscal
year ending December 31, 2006. Our adoption of this standard did not have an impact on our
consolidated financial statements.
FIN No. 48
In July 2006, the FASB issued FIN No. 48, Accounting for Uncertainty in Income Taxes, that
prescribes a recognition threshold and measurement attribute for the financial statement
recognition and measurement of a tax position taken or expected to be taken in a tax return. Under
FIN No. 48, a contingent tax asset only will be recognized if it is more likely than not that a tax
position ultimately will be sustained. After this threshold is met, a tax position is reported at
the largest amount of benefit that is more likely than not to be realized. FIN No. 48 also
provides guidance on derecognition, classification, interest and penalties, accounting in interim
periods and disclosure. FIN No. 48 is effective for fiscal years beginning after December 15,
2006. FIN No. 48 requires the cumulative effect of applying the provisions to be reported
separately as an adjustment to the opening balance of retained earnings in the year of adoption.
We currently are evaluating the impact of this recently issued Interpretation on our consolidated
financial statements.
SFAS No. 154
In May 2005, the FASB issued SFAS No. 154, Accounting Changes and Error Corrections. This
standard establishes new standards on accounting for changes in accounting principles. Pursuant to
the new rules, all such changes must be accounted for by retrospective application to the financial
statements of prior periods unless it is impracticable to do so. SFAS No. 154 completely replaces
Accounting Principles Board (APB) Opinion No. 20, Accounting Changes, and SFAS No. 3, Reporting
Accounting Changes in Interim Financial Statements, though it carries forward the guidance in
those pronouncements with respect to accounting for changes in estimates, changes in the reporting
entity and the correction of errors. This statement is effective for accounting changes and
corrections of errors beginning January 1, 2006. Our adoption of this standard did not have a
material impact on our consolidated financial statements.
SFAS No. 123R
In December 2004, the FASB issued SFAS No. 123R. This standard requires compensation costs related
to share-based payment transactions to be recognized in the financial statements. With limited
exceptions, the amount of compensation cost is measured based on the grant-date fair value of the
equity or liability instruments issued. In addition, liability awards are remeasured each
reporting period. Compensation cost is recognized over the period that an employee provides
service in exchange for the award. This standard replaces SFAS No. 123, Accounting for
Stock-Based Compensation, and supersedes APB Opinion No. 25, Accounting for Stock Issued to
Employees, and applies to all awards granted, modified, repurchased or cancelled after July 1,
2005. In April 2005, the SEC amended the compliance date of SFAS No. 123R through an amendment of
Regulation S-X. We adopted SFAS No. 123R on January 1, 2006. The adoption of SFAS No. 123R
incrementally increased before-tax compensation expense by approximately $2.4 million during 2006.
SFAS No. 151
In November 2004, the FASB issued SFAS No. 151, Inventory Costs, to clarify the accounting for
abnormal amounts of idle facility expense, freight, handling costs and wasted material. This
standard requires that such items be recognized as current-period charges. The standard also
establishes the concept of normal capacity and requires the allocation of fixed-production
overhead to inventory based on the normal capacity of the production facilities. Any unallocated
52
overhead must be recognized as an expense in the period incurred. This standard was effective for
inventory costs incurred beginning January 1, 2006. The adoption of this standard did not have a
material impact on our consolidated financial statements.
CAUTIONARY STATEMENTS FOR SAFE HARBOR PURPOSES
This Managements Discussion and Analysis of Financial Condition and Results of Operations contains
forward-looking statements within the meaning of the federal securities laws. As a general matter,
forward-looking statements are those focused upon future plans, objectives or performance as
opposed to historical items and include statements of anticipated events or trends and expectations
and beliefs relating to matters not historical in nature. Forward-looking statements are subject
to uncertainties and factors relating to our operations and business environment, all of which are
difficult to predict and many of which are beyond our control. These uncertainties and factors
could cause our actual results to differ materially from those matters expressed in or implied by
any forward-looking statements, although we believe our expectations reflected in those
forward-looking statements are based upon reasonable assumptions. For this purpose, any statements
contained herein that are not statements of historical fact should be deemed to be forward-looking
statements.
We believe that the following factors, among others, could affect our future performance and cause
our actual results to differ materially from those expressed or implied by forward-looking
statements made in this annual report:
|
|
The cost, availability and quality of raw materials, especially petroleum-based products. |
|
|
Our ability to sustain profitability of our products in a competitive environment. |
|
|
The demand for our products as influenced by factors such as the global economic
environment, longer-term technology developments and the success of our commercial development
programs. |
|
|
The risks of conducting business in foreign countries, including the effects of
fluctuations in currency exchange rates upon our consolidated results and political, social,
economic and regulatory factors. |
|
|
The extent to which we are successful in expanding our business in new and existing markets
and in identifying, understanding and managing the risks inherent in those markets. |
|
|
The effect of required principal and interest payments on our ability to fund capital
expenditures and acquisitions and to meet operating needs. |
|
|
Our ability to identify, complete and integrate acquisitions for profitable growth and
operating efficiencies. |
|
|
Our success at continuing to develop proprietary technology to meet or exceed new industry
performance standards and individual customer expectations. |
|
|
Our ability to implement a new common information systems platform primarily into our
Lubrizol Advanced Materials segment successfully, including the management of project costs,
its timely completion and realization of its benefits. |
|
|
Our ability to continue to reduce complexities and conversion costs and modify our cost
structure to maintain and enhance our competitiveness. |
|
|
Our success in retaining and growing the business that we have with our largest customers. |
|
|
The cost and availability of energy, especially natural gas and electricity. |
|
|
The effect of interest rate fluctuations on our net interest expense. |
|
|
The risk of weather-related disruptions to our Lubrizol Additives production facilities
located near the U.S. Gulf coast. |
|
|
Significant changes in government regulations affecting environmental compliance. |
53
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We operate manufacturing and blending facilities, laboratories and offices around the world and
utilize fixed-rate and variable-rate debt to finance our global operations. As a result, we are
subject to business risks inherent in non-U.S. activities, including political and economic
uncertainties, import and export limitations, and market risks related to changes in interest rates
and foreign currency exchange rates. We believe the political and economic risks related to our
foreign operations are mitigated due to the stability of the countries in which our largest foreign
operations are located.
In the normal course of business, we use derivative financial instruments including interest rate
and commodity hedges and forward foreign currency exchange contracts to manage our market risks.
Our objective in managing our exposure to changes in interest rates is to limit the impact of such
changes on our earnings and cash flow. Our objective in managing the exposure to changes in
foreign currency exchange rates is to reduce volatility on our earnings and cash flow associated
with such changes. Our principal currency exposures are the euro, the pound sterling, the Japanese
yen and certain Latin American currencies. Our objective in managing our exposure to changes in
commodity prices is to reduce the volatility on earnings of utility expense. We do not hold
derivatives for trading purposes.
We measure our market risk related to our holdings of financial instruments based on changes in
interest rates, foreign currency rates and commodity prices utilizing a sensitivity analysis. The
sensitivity analysis measures the potential loss in fair value, cash flow and earnings based on a
hypothetical 10% change (increase and decrease) in interest, currency exchange rates and commodity
prices. We use current market rates on our debt and derivative portfolios to perform the
sensitivity analysis. Certain items such as lease contracts, insurance contracts and obligations
for pension and other postretirement benefits are not included in the analysis.
Our primary interest rate exposures relate to our cash and short-term investments, fixed-rate and
variable-rate debt and interest rate swaps. The calculation of potential loss in fair value is
based on an immediate change in the net present values of our interest rate-sensitive exposures
resulting from a 10% change in interest rates. The potential loss in cash flow and income before
tax is based on the change in the net interest income/expense over a one-year period due to an
immediate 10% change in rates. A hypothetical 10% increase in interest rates would have had a
favorable impact and a hypothetical 10% decrease in interest rates would have had an unfavorable
impact on fair values of $41.1 million and $42.7 million at December 31, 2006 and 2005,
respectively. In addition, a hypothetical 10% increase in interest rates would have had an
unfavorable impact and a hypothetical 10% decrease in interest rates would have had a favorable
impact on cash flows and income before tax of $1.6 million and $1.8 million in 2006 and 2005,
respectively.
Our primary currency exchange rate exposures are to foreign currency-denominated debt, intercompany
debt, cash and short-term investments and forward foreign currency exchange contracts. The
calculation of potential loss in fair value is based on an immediate change in the U.S. dollar
equivalent balances of our currency exposures due to a 10% shift in exchange rates. The potential
loss in cash flow and income before tax is based on the change in cash flow and income before tax
over a one-year period resulting from an immediate 10% change in currency exchange rates. A
hypothetical 10% increase in currency exchange rates would have had an unfavorable impact and a
hypothetical 10% decrease in currency exchange rates would have had a favorable impact on fair
values of $3.5 million at December 31, 2006. In addition, a hypothetical 10% increase in currency
exchange rates would have had a favorable impact and a hypothetical 10% decrease in currency
exchange rates would have had an unfavorable impact on fair values of $6.8 million at December 31,
2005. Further, a hypothetical 10% increase in currency exchange rates would have had an
unfavorable impact and a hypothetical 10% decrease in currency exchange rates would have had a
favorable impact on cash flows of $21.1 million and $21.4 million and on income before tax of $4.0
million and $4.4 million in 2006 and 2005, respectively.
Our primary commodity hedge exposures relate to natural gas and electric utility expenses. The
calculation of potential loss in fair value is based on an immediate change in the U.S. dollar
equivalent balances of our commodity exposures due to a 10% shift in the underlying commodity
prices. The potential loss in cash flow and income before tax is based on the change in cash flow
and income before tax over a one-year period resulting from an immediate 10% change in commodity
prices. A hypothetical 10% increase in commodity prices would have had a favorable impact and a
hypothetical 10% decrease in commodity prices would have had an unfavorable impact on fair values,
cash flows and income before tax of $1.3 million and $0.9 million in 2006 and 2005, respectively.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The response to this item is submitted in a separate section of this report following the
signature page.
54
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
Not applicable.
ITEM 9A. CONTROLS AND PROCEDURES
(a) Evaluation of Disclosure Controls and Procedures
As discussed elsewhere in this annual report on Form 10-K/A, we are restating certain of our
previously issued financial statements. See Item 7 - Managements Discussion and Analysis of
Financial Condition and Results of Operations and Note 20 - Restatement of Consolidated Financial
Statements contained in the Notes to Financial Statements for more detailed information
regarding the restatement.
In connection with this restatement, under the direction of our chief executive officer and
chief financial officer, we reevaluated our disclosure controls and procedures. Public Company
Accounting Oversight Board Auditing Standard No. 2 (AS-2) defines a material weakness over
financial reporting as a significant deficiency or a combination of significant deficiencies that
results in more than a remote likelihood that a material misstatement of the annual or interim
financial statements will not be prevented or detected. AS-2 identifies certain circumstances that
are to be regarded as a
significant deficiency and as a strong indicator that a material weakness in internal control
over financial reporting exists. The restatement of previously issued financial statements to
reflect the correction of an error is such an indicator under AS-2. We identified a material
weakness in our internal control over financial reporting with respect to reporting errors for five
postemployment employee benefit plans, as further described below under Managements Annual Report
on Internal Control over Financial Reporting (Restated). Solely as a result of this material
weakness, we concluded that our disclosure controls and procedures were not effective as of
December 31, 2006.
As a result of this material weakness, we have taken steps to remediate the internal control
weakness. Specifically, we contracted a third-party benefits consultant to complete a detailed
benefits review at our wholly owned subsidiary that generated the majority of the reporting errors,
made inquiries and conducted reviews of other international locations and enhanced our training on
the application of U.S. GAAP to postemployment employee benefit plans and other matters at our
non-U.S. subsidiaries and joint ventures.
As previously reported, there were no changes in our internal control over financial reporting
during the fourth quarter of 2006 that have affected materially, or are reasonably likely to
affect materially, our internal control over financial reporting.
(b) Managements Annual Report on Internal Control over Financial Reporting (Restated)
The management of The Lubrizol Corporation and its subsidiaries is responsible for
establishing and maintaining adequate internal control over financial reporting. The Lubrizol
Corporations internal control system was designed to provide reasonable assurance to the company
and board of directors regarding the preparation and fair presentation of published financial
statements. In making this assessment, management used the criteria set forth by the Committee of
Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated
Framework.
All internal control systems, no matter how well designed, have inherent limitations.
Therefore, even those systems determined to be effective can provide only reasonable assurance with
respect to financial statement preparation and presentation.
55
In the companys annual report on Form 10-K for the year ended December 31, 2006, filed on
February 28, 2007, the company concluded that its internal control over financial reporting was
effective as of December 31, 2006. Subsequently, the company identified a material weakness in its
internal control over financial reporting solely with respect to accounting errors related to
postemployment employee benefit plans in some foreign countries.
This
material weakness has resulted in this amendment to the annual report on Form 10-K for the
year ended December 31, 2006 in order to restate the financial statements for the years ended
December 31, 2006, 2005 and 2004 and to restate financial information for the years ended December
31, 2003 and 2002.
Solely as a result of this material weakness, the company has revised its earlier assessment
and now has concluded that its internal control over financial reporting was not effective as of
December 31, 2006.
The companys assessment of the effectiveness of internal control over financial reporting as
of December 31, 2006 has been audited by Deloitte & Touche LLP, an independent registered public
accounting firm, and its report is set forth below.
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Shareholders and Board of Directors of
The Lubrizol Corporation
We have audited managements assessment, included in the accompanying Managements Report on
Internal Control Over Financial Reporting (Restated), that The Lubrizol Corporation and
subsidiaries (the Company) did not maintain effective internal control over financial reporting
as of December 31, 2006, because of the effect of the material weakness identified in managements
assessment based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway
Commission. The Companys management is responsible for maintaining effective internal control
over financial reporting and for its assessment of the effectiveness of internal control over
financial reporting. Our responsibility is to express an opinion on managements assessment and an
opinion on the effectiveness of the Companys internal control over financial reporting based on
our audit.
We conducted our audit in accordance with the standards of the Public Company Accounting Oversight
Board (United States). Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether effective internal control over financial reporting was
maintained in all material respects. Our audit included obtaining an understanding of internal
control over financial reporting, evaluating managements assessment, testing and evaluating the
design and operating effectiveness of internal control, and performing such other procedures as we
considered necessary in the circumstances. We believe that our audit provides a reasonable basis
for our opinions.
A companys internal control over financial reporting is a process designed by, or under the
supervision of, the companys principal executive and principal financial officers, or persons
performing similar functions, and effected by the companys board of directors, management, and
other personnel to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles. A companys internal control over financial reporting includes
those policies and procedures that (1) pertain to the maintenance of records that, in reasonable
detail, accurately and fairly reflect the transactions and dispositions of the assets of the
company; (2) provide reasonable assurance that transactions are recorded as necessary to permit
preparation of financial statements in accordance with generally accepted accounting principles,
and that receipts and expenditures of the company are being made only in accordance with
authorizations of management and directors of the company; and (3) provide reasonable assurance
regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the
companys assets that could have a material effect on the financial statements.
Because of the inherent limitations of internal control over financial reporting, including the
possibility of collusion or improper management override of controls, material misstatements due to
error or fraud may not be prevented or detected on a timely basis. Also, projections of any
evaluation of the effectiveness of the internal control over financial reporting to future periods
are subject to the risk that the controls may become inadequate because of changes in conditions,
or that the degree of compliance with the policies or procedures may deteriorate.
56
In our report dated February 28, 2007, we expressed an unqualified opinion on managements
assessment that the Company maintained effective internal control over financial reporting and an
unqualified opinion on the effectiveness of internal control over financial reporting. As described
in the following paragraph, the Company subsequently identified material misstatements in its 2006
annual financial statements and 2006 interim financial statements which caused such financial
statements to be restated. Management subsequently revised its assessment due to the identification
of a material weakness, described in the following paragraph, which resulted in the financial
statement restatements. Accordingly, our opinion on the effectiveness of the Companys internal
control over financial reporting as of December 31, 2006 expressed herein is different from that
expressed in our initial report dated February 28, 2007.
A material weakness is a deficiency, or a combination of deficiencies in internal control over
financial reporting, such that there is a reasonable possibility that a material misstatement of
the Companys annual or interim financial statements will not be prevented or detected. The
following material weakness has been identified and included in managements restated assessment:
management did not design and maintain adequate controls over the identification and recording of
postemployment benefit plans in accordance
with accounting principles generally accepted in the United States of America, which resulted in a
material misstatement of and subsequent restatement of the consolidated financial statements and
consolidated financial statement schedule for the year ended December 31, 2006. This material
weakness was considered in determining the nature, timing, and extent of audit tests applied in our
audit of the consolidated financial statements and financial statement schedule as of and for the
year ended December 31, 2006 (as restated) and this report does not affect our report on such
restated financial statements.
In our opinion, managements revised assessment that the Company did not maintain effective
internal control over financial reporting as of December 31, 2006, is fairly stated, in all
material respects, based on the criteria established in Internal Control-Integrated Framework
issued by the Committee of Sponsoring Organizations of the Treadway Commission. Also in our
opinion, because of the effect of the material weakness described above on the achievement of the
objectives of the control criteria, the Company has not maintained effective internal control over
financial reporting as of December 31, 2006, based on the criteria established in Internal
Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway
Commission.
We have also audited, in accordance with the standards of the Public Company Accounting Oversight
Board (United States), the consolidated financial statements and consolidated financial statement
schedule of the Company as of and for the year ended December 31, 2006, and our report dated
February 28, 2007 (November 9, 2007 as to the effects of the restatement discussed in Note 20)
expressed an unqualified opinion on those financial statements and financial statement schedule and
included explanatory paragraphs regarding the Companys adoption of new accounting standards and
the restatement discussed in Note 20.
/s/ Deloitte & Touche LLP
Cleveland, Ohio
February 28, 2007 (November 9, 2007 as to the effects of the material weakness
described in Managements Report on Internal Control Over Financial Reporting
(Restated))
ITEM 9B. OTHER INFORMATION
Not applicable.
57
PART III
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
The information contained under the headings Election of Directors and Section 16(a)
Beneficial Ownership Reporting Compliance of our proxy statement for the 2007 Annual Meeting of
Shareholders is incorporated herein by reference. Information relative to executive officers is
contained under Executive Officers of the Registrant in Part I of this annual report on Form
10-K/A. Information regarding the identification of a financial expert on the Audit Committee
contained under the heading Audit Committee in our proxy statement for the 2007 Annual Meeting of
Shareholders is incorporated herein by reference.
We have a code of ethics, entitled the Ethical and Legal Conduct Guidelines, that applies to
our directors and all employees, including our chief executive officer, chief financial officer and
controller. The Ethical and Legal Conduct Guidelines are posted at the company overview area of
our website, www.lubrizol.com.
ITEM 11. EXECUTIVE COMPENSATION
The information relating to executive compensation contained under the headings Director
Compensation, Executive Compensation, Board Committees - Organization and Compensation
Committee and Board Committees - Compensation Committee Report in our proxy statement for the
2007 Annual Meeting of Shareholders is incorporated herein by reference.
ITEM
12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER
MATTERS
The information relating to security ownership set forth under the heading Share Ownership of
Directors, Executive Officers and Large Beneficial Owners in our proxy statement for the 2007
Annual Meeting of Shareholders is incorporated herein by reference.
The following table gives information about our common shares that may be issued under the
companys equity compensation plans as of December 31, 2006.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of Securities |
|
|
|
|
|
|
|
|
|
|
Remaining Available |
|
|
Number of Securities to |
|
Weighted-Average |
|
for Future Issuance under |
|
|
be Issued upon Exercise |
|
Exercise Price of |
|
Equity Compensation Plans |
|
|
of Outstanding Options, |
|
Outstanding Options, |
|
(excluding Securities |
Plan Category |
|
Warrants and Rights |
|
Warrants and Rights |
|
reflected in Column (a)) |
Equity compensation plans
approved by security holders |
|
3,339,329 |
|
|
$ |
32.72 |
|
|
|
3,030,401 |
(1) |
Equity compensation plans not approved by security holders |
|
|
(2) |
|
|
N/A |
|
|
|
|
(2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
3,339,329 |
|
|
$ |
32.72 |
|
|
|
3,030,401 |
(1) |
|
|
|
(1) |
|
The 1991 Stock Incentive Plan was terminated with respect to future grants effective
November 15, 2004. The shares shown are with respect to the 2005 Stock Incentive Plan. In
addition to the shares shown, effective January 1, 2003, pursuant to grants under the 1991
Stock Incentive Plan, Donald W. Bogus, Charles P. Cooley and Stephen F. Kirk each will be
issued 15,000 shares if the officer remains an employee until January 1, 2008. There are no
voting or dividend rights associated with these common shares unless and until they are
issued. |
|
(2) |
|
Under the Executive Council Deferred Compensation Plan, certain executive officers may
defer any amount of their variable pay under the annual incentive pay plan. Deferred amounts
are converted into share units based on the current market price of Lubrizols common shares.
There is a 25% company match. Additional share units are credited for quarterly dividends
paid on Lubrizol common shares. At the end of the deferral period, which is at least three
years, common shares are issued equal to the number of share units in the participants
account. Amounts |
58
attributable to the company match credited after January 1, 2004 will be
paid in cash. As of December 31, 2006, there were 92,523 share units outstanding that are
payable in shares.
Prior to January 1, 2004, under the Deferred Stock Compensation Plan for Outside Directors,
each director who was not a Lubrizol employee received 500 share units on each October 1st and
was credited with additional share units for quarterly dividends paid on Lubrizol common shares.
When a person is no longer a director, Lubrizol common shares are issued equal to the number of
share units in the persons account. As of December 31, 2006, there were 35,563 share units
outstanding that are payable in shares. No additional share units other than those credited for
quarterly dividends have been or will be granted after January 1, 2004.
Under the Deferred Compensation Plan for Directors, each director who is not a Lubrizol
employee may defer all or any portion of his or her yearly fee and meeting attendance fees and
have these amounts credited to various cash investment accounts and/or a share unit account. The
number of share units credited to the share unit account is based on
the price of Lubrizol common shares on the day the share units are credited to the account and includes share units credited
for quarterly dividends paid on Lubrizol common shares. When a person is no longer a director,
Lubrizol shares are issued equal to the number of share units in the persons share unit account.
As of December 31, 2006, there were 65,454 share units outstanding, 31,682 of which must be paid
in Lubrizol shares and the remainder of which may be invested in the various cash investment
accounts at the discretion of the director, and paid in cash.
Under the Senior Management Deferred Compensation Plan, each executive officer may defer all
or any portion of his or her total annual pay and have these amounts credited to various cash
investment accounts and/or a share unit account. The number of share units credited to the share
unit account is based on the price of Lubrizol common shares on the day the share units are
credited to the account and includes share units credited for quarterly dividends paid on
Lubrizol common shares. Upon the distribution date, Lubrizol common shares are issued equal to
the number of share units in the persons share unit account. As of December 31, 2006, there
were 67,747 share units outstanding.
Under the Supplemental Retirement Plan for Donald W. Bogus, 500 share units are credited
each anniversary date of the officers employment to an officers account and includes share
units credited for quarterly dividends paid on Lubrizol common shares. Upon retirement, Mr.
Bogus may elect to receive cash or Lubrizol shares equal to the number of share units in the
account. As of December 31, 2006, there were 2,336 share units outstanding that could be paid in shares. For units credited after January 1, 2004, the payment will be made in cash only.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
The information relating to certain relationships, related transactions and director
independence contained under the headings Director Independence and Related Person Transactions
in our proxy statement for the 2007 Annual Meeting of Shareholders is incorporated herein by
reference.
ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES
The information included under the heading entitled Independent Registered Public Accountant
Fees in our proxy statement for the 2007 Annual Meeting of Shareholders is incorporated herein by
reference.
59
PART IV
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
(a) |
|
Documents filed in a separate section of this annual report on Form 10-K/A: |
|
1. |
|
The following restated consolidated financial statements of the company are
included in a separate section of this report following the signature page: |
Report of Independent Registered Public Accounting Firm.
Consolidated Statements of Income (Restated) for the years ended December 31, 2006, 2005 and
2004.
Consolidated Balance Sheets (Restated) at December 31, 2006 and 2005.
Consolidated Statements of Cash Flows (Restated) for the years ended December 31, 2006, 2005
and 2004.
Consolidated Statements of Shareholders Equity (Restated) for the years ended December 31,
2006, 2005 and 2004.
Notes to Financial Statements.
|
2. |
|
Schedule II - Valuation and Qualifying Accounts |
60
SCHEDULE II - Valuation and Qualifying Accounts
For the years ended December 31, 2006, 2005 and 2004
(in millions of dollars)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Charged |
|
Charged |
|
|
|
|
|
|
|
|
Balance at |
|
/(Credited) |
|
/(Credited) |
|
|
|
|
|
Balance at |
|
|
Beginning |
|
To |
|
to Other |
|
|
|
|
|
End of |
Description |
|
of Year |
|
Expenses |
|
Accounts* |
|
Deductions |
|
Year |
Year ended December 31, 2006 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Allowance for
uncollectible
accounts |
|
$ |
10.1 |
|
|
$ |
0.8 |
|
|
$ |
(1.2 |
) |
|
$ |
2.2 |
|
|
$ |
7.5 |
|
Inventory reserves |
|
$ |
18.2 |
|
|
$ |
9.1 |
|
|
$ |
1.2 |
|
|
$ |
12.4 |
|
|
$ |
16.1 |
|
Deferred tax asset
valuation allowance |
|
$ |
18.1 |
|
|
$ |
(0.1 |
) |
|
$ |
(0.2 |
) |
|
|
|
|
|
$ |
17.8 |
|
Year ended December 31, 2005 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Allowance for uncollectible accounts |
|
$ |
11.0 |
|
|
$ |
1.9 |
|
|
$ |
(0.9 |
) |
|
$ |
1.9 |
|
|
$ |
10.1 |
|
Inventory reserves |
|
$ |
19.1 |
|
|
$ |
10.9 |
|
|
$ |
(2.8 |
) |
|
$ |
9.0 |
|
|
$ |
18.2 |
|
Deferred tax asset valuation allowance |
|
$ |
18.8 |
|
|
$ |
4.0 |
|
|
$ |
(4.7 |
) |
|
|
|
|
|
$ |
18.1 |
|
Year ended December 31, 2004 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Allowance for uncollectible accounts |
|
$ |
4.2 |
|
|
$ |
0.4 |
|
|
$ |
7.7 |
|
|
$ |
1.3 |
|
|
$ |
11.0 |
|
Inventory reserves |
|
$ |
9.0 |
|
|
$ |
5.4 |
|
|
$ |
8.5 |
|
|
$ |
3.8 |
|
|
$ |
19.1 |
|
Deferred tax asset valuation allowance |
|
$ |
1.9 |
|
|
$ |
2.4 |
|
|
$ |
14.5 |
|
|
|
|
|
|
$ |
18.8 |
|
|
|
|
* |
|
Valuation and qualifying accounts of acquired and divested companies. |
All other schedules have been omitted because they are not applicable.
61
3. Exhibits
|
|
|
3.1
|
|
Amended Articles of Incorporation of The Lubrizol Corporation, as adopted
September 23, 1991 (incorporated by reference to Exhibit 3.1 to The Lubrizol
Corporations annual report on Form 10-K for the year ended December 31, 2004). |
|
|
|
3.2
|
|
Regulations of The Lubrizol Corporation, as amended effective April 27, 1992
(incorporated by reference to Exhibit 3.2 to The Lubrizol Corporations annual report
on Form 10-K for the year ended December 31, 2004). |
|
|
|
4.1
|
|
Amendment to Article Fourth of Amended Articles of Incorporation (incorporated
by reference to Exhibit 4.1 to The Lubrizol Corporations annual report on Form 10-K
for the year ended December 31, 2004). |
|
|
|
4.2
|
|
Amended and Restated Rights Agreement between The Lubrizol Corporation and
American Stock Transfer & Trust Company dated as of July 26, 1999 (incorporated by
reference to Exhibit 4.2 to The Lubrizol Corporations annual report on Form 10-K for
the year ended December 31, 2004). |
|
|
|
4.3
|
|
Amended and Restated Indenture dated September 28, 2004 (originally dated June
1, 1995) by and among The Lubrizol Corporation, all of The Lubrizol Corporations
wholly owned direct and indirect domestic subsidiaries, as guarantors, and J.P. Morgan
Trust Company, National Association, as successor trustee (incorporated by reference to
Exhibit 99.1 of the Form 8-K of The Lubrizol Corporation filed with the SEC on
September 29, 2004). |
|
|
|
4.4
|
|
Amended and Restated Indenture dated September 28, 2004 (originally dated
November 25, 1998), by and among The Lubrizol Corporation, all of The Lubrizol
Corporations wholly owned direct and indirect domestic subsidiaries, as guarantors,
and J.P. Morgan Trust Company, National Association, as successor trustee (incorporated
by reference to Exhibit 99.2 of the Form 8-K of The Lubrizol Corporation filed with the
SEC on September 29, 2004). |
|
|
|
4.5
|
|
Form of Indenture for Debt Securities of The Lubrizol Corporation (incorporated
by reference to Exhibit 4.2 of Amendment No. 2 to the Registration Statement on Form
S-3 of The Lubrizol Corporation filed with the SEC on August 24, 2004). |
|
|
|
10.1*
|
|
The Lubrizol Corporation 1991 Stock Incentive Plan, as amended (incorporated
by reference to Exhibit (10)(h) to The Lubrizol Corporations Current Report on Form
8-K filed with the SEC on November 18, 2004). |
|
|
|
10.2*
|
|
The Lubrizol Corporation 2005 Stock Incentive Plan, as amended (incorporated
by reference to Exhibit 10.1 to The Lubrizol Corporations Current Report on Form 8-K
filed with the SEC on December 12, 2006). |
|
|
|
10.3*
|
|
The Lubrizol Corporation Amended Deferred Compensation Plan for Directors
(incorporated by reference to Exhibit (10)(b) to The Lubrizol Corporations Current
Report on Form 8-K filed with the SEC on November 18, 2004). |
|
|
|
10.4*
|
|
The Lubrizol Corporation Deferred Stock Compensation Plan for Outside
Directors, as amended (incorporated by reference to Exhibit (10)(i) to The Lubrizol
Corporations annual report on Form 10-K for the year ended December 31, 2003). |
|
|
|
10.5*
|
|
The Lubrizol Corporation Deferred Compensation Plan for Officers, as amended
(incorporated by reference to Exhibit (10)(k) to The Lubrizol Corporations Current
Report on Form 8-K filed with the SEC on November 18, 2004). |
|
|
|
10.6*
|
|
The Lubrizol Corporation Executive Council Deferred Compensation Plan, as
amended (incorporated by reference to Exhibit (10)(l) to The Lubrizol Corporations
Current Report on Form 8-K filed with the SEC on November 18, 2004). |
62
|
|
|
10.7*
|
|
The Lubrizol Corporation 2005 Deferred Compensation Plan for Directors
(incorporated by reference to Exhibit (10)(v) to The Lubrizol Corporations Current
Report on Form 8-K filed with the SEC on November 18, 2004). |
|
|
|
10.8*
|
|
The Lubrizol Corporation Senior Management Deferred Compensation Plan (fka The
Lubrizol Corporation 2005 Deferred Compensation Plan for Officers) (incorporated by
reference to Exhibit
10.8 to The Lubrizol Corporations Current Report on Form 8-K filed with the SEC on
December 13, 2005). |
|
|
|
10.9*
|
|
The Lubrizol Corporation 2005 Executive Council Deferred Compensation Plan
(incorporated by reference to Exhibit 10.7 to The Lubrizol Corporations Current Report
on Form 8-K filed with the SEC on December 13, 2005). |
|
|
|
10.10*
|
|
The Lubrizol Corporation Excess Defined Benefit Plan, as amended (incorporated by
reference to Exhibit (10)(d) to The Lubrizol Corporations Current Report on Form 8-K
filed with the SEC on December 15, 2004). |
|
|
|
10.11*
|
|
The Lubrizol Corporation Excess Defined Contribution Plan, as amended (incorporated
by reference to Exhibit (10)(e) to The Lubrizol Corporations Current Report on Form
8-K filed with the SEC on December 15, 2004). |
|
|
|
10.12*
|
|
The Lubrizol Corporation Officers Supplemental Retirement Plan, as amended
(incorporated by reference to Exhibit (10)(j) to The Lubrizol Corporations Current
Report on Form 8-K filed with the SEC on December 15, 2004). |
|
|
|
10.13*
|
|
The Lubrizol Corporation 2005 Excess Defined Benefit Plan (incorporated by reference
to Exhibit 10.4 to The Lubrizol Corporations Current Report on Form 8-K filed with the
SEC on December 13, 2005). |
|
|
|
10.14*
|
|
The Lubrizol Corporation 2005 Excess Defined Contribution Plan (incorporated by
reference to Exhibit 10.3 to The Lubrizol Corporations Current Report on Form 8-K
filed with the SEC on December 12, 2006). |
|
|
|
10.15*
|
|
The Lubrizol Corporation 2005 Officers Supplemental Retirement Plan (incorporated by
reference to Exhibit 10.5 to The Lubrizol Corporations Current Report on Form 8-K
filed with the SEC on December 13, 2005). |
|
|
|
10.16*
|
|
Supplemental Retirement for Donald W. Bogus (incorporated by reference to Exhibit
10.6 to The Lubrizol Corporations Current Report on Form 8-K filed with the SEC on
December 13, 2005). |
|
|
|
10.17*
|
|
The Lubrizol Corporation Executive Death Benefit Plan, as amended (incorporated by
reference to Exhibit 10.11 to The Lubrizol Corporations Current Report on Form 8-K
filed with the SEC on December 13, 2005). |
|
|
|
10.18*
|
|
The Lubrizol Corporation Executive Officer Long Term Incentive Plan (incorporated by
reference to Exhibit (10)(n) to The Lubrizol Corporations annual report on Form 10-K
for the year ended December 31, 2003). |
|
|
|
10.19*
|
|
Form of Employment Agreement between The Lubrizol Corporation and certain of its
senior executive officers (incorporated by reference to Exhibit 10.19 to The Lubrizol
Corporations annual report on Form 10-K for the year ended December 31, 2005). |
|
|
|
10.20*
|
|
Employment Agreement effective January 1, 2003, between The Lubrizol Corporation and
Charles P. Cooley (incorporated by reference to Exhibit (10)(o) to The Lubrizol
Corporations Quarterly Report on Form 10-Q for the period ended on March 31, 2003). |
|
|
|
10.21*
|
|
Employment Agreement effective January 1, 2003, between The Lubrizol Corporation and
Stephen F. Kirk (incorporated by reference to Exhibit (10)(p) to The Lubrizol
Corporations Quarterly Report on Form 10-Q for the period ended on March 31, 2003). |
63
|
|
|
10.22*
|
|
Employment Agreement effective January 1, 2003, between The Lubrizol Corporation and
Donald W. Bogus (incorporated by reference to Exhibit (10)(r) to The Lubrizol
Corporations Quarterly Report on Form 10-Q for the period ended on March 31, 2003). |
|
|
|
10.23*
|
|
The Lubrizol Corporation Annual Incentive Pay Plan (incorporated by reference to
Exhibit 10.10 to The Lubrizol Corporations Current Report on Form 8-K filed with the
SEC on December 13, 2005). |
|
|
|
10.24*
|
|
The Lubrizol Corporation Annual Incentive Pay Plan Award Letter, as amended
(incorporated by reference to Exhibit 10.2 to The Lubrizol Corporations Current Report
on Form 8-K filed with the SEC on December 13, 2005). |
|
|
|
10.25*
|
|
The Lubrizol Corporation Financial Planning Program (incorporated by reference to
Exhibit 10.1 to The Lubrizol Corporations Quarterly Report on Form 10-Q for the period
ended on September 30, 2006). |
|
|
|
10.26*
|
|
Form of Indemnification Agreement between The Lubrizol Corporation and certain of its
senior executive officers (incorporated by reference to Exhibit 10.26 to the Lubrizol
Corporations Annual Report on Form 10-K for the period ended December 31, 2006). |
|
|
|
10.27
|
|
Asset Purchase Agreement, dated March 16, 2006, by and among Noveon, Inc.,
Noveon Hilton Davis, Inc., Noveon Kalama, Inc., Noveon Textile Chemicals, Inc.,
Lubrizol Foam Control Additives, Inc., Lubrizol do Brasil Aditivos Ltda., and SPM Group
Holdings LLC (incorporated by reference to Exhibit 10.1 to The Lubrizol Corporations
Current Report on Form 8-K filed with the SEC on May 5, 2006). |
|
|
|
10.28
|
|
Letter of Guarantee dated as of May 19, 2006 by and between Noveon, Inc. and
SK Corporation (incorporated by reference to Exhibit 10.1 to The Lubrizol Corporations
Current Report on Form 8-K filed with the SEC on May 25, 2006). |
|
|
|
10.29
|
|
Credit Agreement dated as of August 24, 2004 among The Lubrizol Corporation,
the Initial Lenders named therein, Citigroup Global Markets Inc. and KeyBanc Capital
Markets, as co-lead arrangers and co-bookrunners, KeyBank National Association and ABN
Amro Bank N.V., as co-syndication agents, Wachovia Bank, National Association, as
documentation agent, and Citicorp North America, Inc., as agent (incorporated by
reference to Exhibit 10.1 to The Lubrizol Corporations Current Report on Form 8-K
filed with the SEC on August 30, 2004). |
|
|
|
10.30
|
|
Amended and Restated Credit Agreement dated as of March 29, 2005 among The
Lubrizol Corporation, the Initial Lenders named therein, Citicorp North America, Inc.,
as administrative agent, and Citigroup Global Markets, Inc., as arranger and
syndication agent (incorporated by reference to Exhibit 10.5 to The Lubrizol
Corporations Quarterly Report on Form 10-Q for the period ended March 31, 2005). |
|
|
|
10.31
|
|
Amendment No. 2 to the Credit Agreement among The Lubrizol Corporation, the
banks, financial institutions and other institutional lenders who are parties to the
Credit Agreement dated as of August 24, 2004, as amended and restated as of March 29,
2005, and as further amended as of August 23, 2005, and Citicorp North America, Inc. as
agent (incorporated by reference to Exhibit 10.1 to The Lubrizol Corporations Current
Report on Form 8-K filed with the SEC on September 22, 2006). |
|
|
|
10.32
|
|
Five Year Credit Agreement dated as of September 14, 2005 among Europe
Chemical Holdings C.V., Noveon Holdings France S.A.S. and Noveon Europe BVBA, The
Lubrizol Corporation, the Initial Lenders named therein, ABN AMRO Bank N.V. as
administrative agent, and ABN AMRO Bank N.V., Calyon, Citigroup Global Markets Inc.,
and Fortis Capital Corp as mandated lead arrangers and bookrunners (incorporated by
reference to Exhibit 10.1 to The Lubrizol Corporations Current Report on Form 8-K
filed with the SEC on September 16, 2005). |
64
|
|
|
10.33
|
|
Letter Amendment dated as of September 20, 2006 among Lubrizol Holdings France
S.A.S. (formerly known as Noveon Holdings France S.A.S.) and Noveon Europe BVBA
(collectively, the Borrowers), The Lubrizol Corporation, the Lenders named therein,
ABN AMRO Bank N.V. as agent, to the Five Year Credit Agreement dated as of September
14, 2005 among the Borrowers, The Lubrizol Corporation, the Initial Lenders named
therein, ABN AMRO Bank N.V., Calyon, Citigroup Global Markets Inc. and Fortis Capital
Corp. (incorporated by reference to Exhibit 10.2 to The Lubrizol Corporations Current
Report on Form 8-K filed with the SEC on September 22, 2006). |
|
|
|
12.1
|
|
Computation of Ratio of Earnings to Fixed Charges. |
|
|
|
21.1
|
|
List of Significant Subsidiaries of The Lubrizol Corporation (incorporated by
reference to Exhibit 21.1 to The Lubrizol Corporations Annual Report on Form 10-K for
the period ended December 31, 2006). |
|
|
|
23.1
|
|
Consent of Independent Registered Public Accounting Firm. |
|
|
|
24.1
|
|
Powers of Attorney. |
|
|
|
31.1
|
|
Rule 13a-14(a) Certification of the Chief Executive Officer, as created by
Section 302 of the Sarbanes-Oxley Act of 2002. |
|
|
|
31.2
|
|
Rule 13a-14(a) Certification of the Chief Financial Officer, as created by
Section 302 of the Sarbanes-Oxley Act of 2002. |
|
|
|
32.1
|
|
Certification of Chief Executive Officer and Chief Financial Officer of The
Lubrizol Corporation pursuant to 18 U.S.C. Section 1350, as created by Section 906 of
the Sarbanes-Oxley Act of 2002. |
|
|
|
* Indicates management contract or compensatory plan or arrangement. |
65
SIGNATURES
Pursuant to the requirements of Section 13 of the Securities Exchange Act of 1934, the
Registrant has duly caused this annual report on Form 10-K/A to be signed on November 9, 2007, on
its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
THE LUBRIZOL CORPORATION
|
|
|
BY |
/s/ James L. Hambrick
|
|
|
|
James L. Hambrick, President and |
|
|
|
Chief Executive Officer |
|
|
|
Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been
signed below on November 9, 2007, by the following persons on behalf of the Registrant and in the
capacities indicated.
|
|
|
|
|
/s/ James L. Hambrick
|
|
Chairman of the Board, President and Chief Executive Officer |
|
|
|
(Principal
Executive Officer) |
|
|
|
|
|
/s/ Charles P. Cooley
|
|
Sr. Vice President, Treasurer and Chief Financial Officer |
|
|
|
(Principal
Financial Officer) |
|
|
|
|
|
/s/ W. Scott Emerick
|
|
Corporate Controller |
|
|
|
(Chief
Accounting Officer) |
|
|
|
|
|
|
|
Director |
|
|
|
|
|
|
|
|
|
|
|
Director |
|
|
|
|
|
|
|
|
* |
/s/ Forest J. Farmer, Sr.
|
|
Director |
|
|
|
|
|
|
|
|
* |
/s/ Gordon D. Harnett
|
|
Director |
|
|
|
|
|
|
|
|
* |
/s/ William P. Madar
|
|
Director |
|
|
|
|
|
|
|
|
* |
/s/ Dominic J. Pileggi
|
|
Director |
|
|
|
|
|
|
|
|
* |
/s/ Harriet Tee Taggart
|
|
Director |
|
|
|
|
|
|
|
|
* |
/s/ James E. Sweetnam
|
|
Director |
|
|
|
|
|
|
|
|
|
* By:
|
|
/s/ Charles P. Cooley |
|
|
|
|
Charles P. Cooley
|
|
|
|
|
Attorney-in-Fact |
|
|
66
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Shareholders and Board of Directors of
The Lubrizol Corporation
We have audited the accompanying consolidated balance sheets of The Lubrizol Corporation and
subsidiaries (the Company) as of December 31, 2006 and 2005, and the related consolidated
statements of income, shareholders equity, and cash flows for each of the three years in the
period ended December 31, 2006. Our audits also included the consolidated financial statement
schedule listed in the Index at Item 15. These financial statements and financial statement
schedule are the responsibility of the Companys management. Our responsibility is to express an
opinion on the financial statements and financial statement schedule based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight
Board (United States). Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement. An
audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the
financial statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall financial statement
presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, such consolidated financial statements present fairly, in all material respects,
the financial position of The Lubrizol Corporation and subsidiaries at December 31, 2006 and 2005,
and the results of their operations and their cash flows for each of the three years in the period
ended December 31, 2006, in conformity with accounting principles generally accepted in the United
States of America. Also, in our opinion, such consolidated financial statement schedule, when
considered in relation to the basic consolidated financial statements taken as a whole, presents
fairly, in all material respects, the information set forth therein.
As discussed in Notes 2 and 16 to the consolidated financial statements, the Company changed its
method of accounting for stock-based compensation with the adoption of Statement of Financial
Accounting Standards (SFAS) No. 123R, Share-Based Payment effective January 1, 2006. Also, as
discussed in Note 13 to the consolidated financial statements, the Company changed its method of
accounting for defined pension and other postretirement plans with the adoption of SFAS No. 158,
Employers Accounting for Defined Benefit Pension and Other Postretirement Plans effective
December 31, 2006.
As discussed in Note 20 to the consolidated financial statements, the accompanying consolidated
financial statements have been restated.
We have also audited, in accordance with the standards of the Public Company Accounting Oversight
Board (United States), the effectiveness of the Companys internal control over financial reporting
as of December 31, 2006, based on the criteria established in Internal Control-Integrated Framework
issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated
February 28, 2007 (November 9, 2007 as to the effects of the material weakness described in
Managements Report on Internal Control Over Financial Reporting (Restated)) expressed an
unqualified opinion on managements assessment of the effectiveness of the Companys internal
control over financial reporting and an adverse opinion on the effectiveness of the Companys
internal control over financial reporting.
|
|
|
|
|
/s/ |
|
Deloitte & Touche LLP |
|
|
|
|
|
|
|
Cleveland, Ohio
February 28, 2007 (November 9, 2007 as to the effects
of the restatement discussed in Note 20)
67
THE
LUBRIZOL CORPORATION
CONSOLIDATED STATEMENTS OF INCOME
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31 |
(In Millions of Dollars Except Per Share Data) |
|
2006 |
|
2005 |
|
2004 |
|
|
(as restated, |
|
(as restated, |
|
(as restated, |
|
|
see Note 20) |
|
see Note 20) |
|
see Note 20) |
Net sales |
|
|
$ 4,036.4 |
|
|
|
$ 3,618.8 |
|
|
|
$ 2,860.5 |
|
Royalties and other revenues |
|
|
4.4 |
|
|
|
3.4 |
|
|
|
3.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues |
|
|
4,040.8 |
|
|
|
3,622.2 |
|
|
|
2,864.4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales |
|
|
3,045.2 |
|
|
|
2,700.1 |
|
|
|
2,104.6 |
|
Selling and administrative expenses |
|
|
381.7 |
|
|
|
348.4 |
|
|
|
284.8 |
|
Research, testing and development expenses |
|
|
205.5 |
|
|
|
198.9 |
|
|
|
184.8 |
|
Amortization of intangible assets |
|
|
23.7 |
|
|
|
23.5 |
|
|
|
16.9 |
|
Write-off of acquired in-process research and development |
|
|
|
|
|
|
|
|
|
|
34.0 |
|
Restructuring and impairment charges |
|
|
51.9 |
|
|
|
15.9 |
|
|
|
38.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total costs and expenses |
|
|
3,708.0 |
|
|
|
3,286.8 |
|
|
|
2,663.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income - net |
|
|
8.5 |
|
|
|
1.8 |
|
|
|
5.6 |
|
Interest income |
|
|
20.4 |
|
|
|
8.1 |
|
|
|
4.8 |
|
Interest expense |
|
|
(99.7 |
) |
|
|
(105.1 |
) |
|
|
(77.1 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before income taxes |
|
|
262.0 |
|
|
|
240.2 |
|
|
|
134.5 |
|
Provision for income taxes |
|
|
82.2 |
|
|
|
80.8 |
|
|
|
49.0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations |
|
|
179.8 |
|
|
|
159.4 |
|
|
|
85.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Loss) income from discontinued operations - net of tax |
|
|
(76.2 |
) |
|
|
27.8 |
|
|
|
6.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
|
$ 103.6 |
|
|
|
$ 187.2 |
|
|
|
$ 91.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic earnings (loss) per share: |
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations |
|
|
$ 2.62 |
|
|
|
$ 2.35 |
|
|
|
$ 1.54 |
|
Discontinued operations |
|
|
(1.11 |
) |
|
|
0.41 |
|
|
|
0.11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share, basic |
|
|
$ 1.51 |
|
|
|
$ 2.76 |
|
|
|
$ 1.65 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings (loss) per share: |
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations |
|
|
$ 2.59 |
|
|
|
$ 2.32 |
|
|
|
$ 1.53 |
|
Discontinued operations |
|
|
(1.10 |
) |
|
|
0.40 |
|
|
|
0.11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share, diluted |
|
|
$ 1.49 |
|
|
|
$ 2.72 |
|
|
|
$ 1.64 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dividends paid per share |
|
|
$ 1.04 |
|
|
|
$ 1.04 |
|
|
|
$ 1.04 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these consolidated financial statements.
68
THE
LUBRIZOL CORPORATION
CONSOLIDATED
BALANCE SHEETS
|
|
|
|
|
|
|
|
|
|
|
December 31 |
(In Millions of Dollars Except Share Data) |
|
2006 |
|
2005 |
|
|
(as restated, |
|
(as restated, |
|
|
see Note 20) |
|
see Note 20) |
ASSETS |
|
|
|
|
|
|
|
|
Cash and short-term investments |
|
|
$ 575.7 |
|
|
|
$ 262.4 |
|
Receivables |
|
|
573.6 |
|
|
|
585.6 |
|
Inventories |
|
|
589.0 |
|
|
|
586.0 |
|
Other current assets |
|
|
98.0 |
|
|
|
138.3 |
|
|
|
|
|
|
|
|
|
|
Total current assets |
|
|
1,836.3 |
|
|
|
1,572.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Property and equipment - at cost |
|
|
2,546.0 |
|
|
|
2,621.5 |
|
Less accumulated depreciation |
|
|
1,464.7 |
|
|
|
1,437.1 |
|
|
|
|
|
|
|
|
|
|
Property and equipment - net |
|
|
1,081.3 |
|
|
|
1,184.4 |
|
|
|
|
|
|
|
|
|
|
Goodwill |
|
|
1,076.1 |
|
|
|
1,138.8 |
|
Intangible assets - net |
|
|
322.8 |
|
|
|
407.2 |
|
Investments in non-consolidated companies |
|
|
7.7 |
|
|
|
7.6 |
|
Other assets |
|
|
66.7 |
|
|
|
60.9 |
|
|
|
|
|
|
|
|
|
|
TOTAL |
|
|
$ 4,390.9 |
|
|
|
$ 4,371.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS EQUITY |
|
|
|
|
|
|
|
|
Short-term debt and current portion of long-term debt |
|
|
$ 3.7 |
|
|
|
$ 7.9 |
|
Accounts payable |
|
|
340.5 |
|
|
|
372.2 |
|
Accrued expenses and other current liabilities |
|
|
290.2 |
|
|
|
285.6 |
|
|
|
|
|
|
|
|
|
|
Total current liabilities |
|
|
634.4 |
|
|
|
665.7 |
|
|
|
|
|
|
|
|
|
|
Long-term debt |
|
|
1,538.0 |
|
|
|
1,662.9 |
|
Pension obligations |
|
|
237.9 |
|
|
|
140.6 |
|
Other postretirement benefit obligations |
|
|
93.5 |
|
|
|
109.5 |
|
Noncurrent liabilities |
|
|
72.3 |
|
|
|
82.8 |
|
Deferred income taxes |
|
|
80.4 |
|
|
|
107.7 |
|
|
|
|
|
|
|
|
|
|
Total liabilities |
|
|
2,656.5 |
|
|
|
2,769.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Minority interest in consolidated companies |
|
|
51.3 |
|
|
|
50.1 |
|
|
|
|
|
|
|
|
|
|
Contingencies and commitments |
|
|
|
|
|
|
|
|
Preferred stock without par value - unissued |
|
|
|
|
|
|
|
|
Common shares without par value - 69,020,569 and 68,043,241
outstanding shares at December 31, 2006 and 2005,
respectively |
|
|
710.1 |
|
|
|
663.7 |
|
Retained earnings |
|
|
1,033.8 |
|
|
|
1,001.7 |
|
Accumulated other comprehensive loss |
|
|
(60.8 |
) |
|
|
(113.5 |
) |
|
|
|
|
|
|
|
|
|
Total shareholders equity |
|
|
1,683.1 |
|
|
|
1,551.9 |
|
|
|
|
|
|
|
|
|
|
TOTAL |
|
|
$ 4,390.9 |
|
|
|
$ 4,371.2 |
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these consolidated financial statements.
69
THE
LUBRIZOL CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31 |
(In Millions of Dollars) |
|
2006 |
|
2005 |
|
2004 |
|
|
(as restated, |
|
(as restated, |
|
(as restated, |
|
|
see Note 20) |
|
see Note 20) |
|
see Note 20) |
CASH PROVIDED BY (USED FOR): |
|
|
|
|
|
|
|
|
|
|
|
|
OPERATING ACTIVITIES |
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
|
$ 103.6 |
|
|
|
$ 187.2 |
|
|
|
$ 91.8 |
|
Adjustments to reconcile net income to cash
provided by operating activities: |
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
161.8 |
|
|
|
179.8 |
|
|
|
154.7 |
|
Write-off of acquired in-process research and development |
|
|
|
|
|
|
|
|
|
|
34.0 |
|
Deferred income taxes |
|
|
28.6 |
|
|
|
9.1 |
|
|
|
4.9 |
|
Deferred compensation |
|
|
19.5 |
|
|
|
16.3 |
|
|
|
3.4 |
|
Restructuring and impairment charges |
|
|
105.6 |
|
|
|
11.1 |
|
|
|
27.5 |
|
Loss (gain) from divestitures and sales of property and
equipment |
|
|
9.6 |
|
|
|
(3.9 |
) |
|
|
3.1 |
|
Change in current assets and liabilities, net of
acquisitions and divestitures: |
|
|
|
|
|
|
|
|
|
|
|
|
Receivables |
|
|
(3.4 |
) |
|
|
(52.9 |
) |
|
|
(38.4 |
) |
Inventories |
|
|
(56.2 |
) |
|
|
(47.5 |
) |
|
|
(50.0 |
) |
Accounts payable, accrued expenses and other current
liabilities |
|
|
(57.1 |
) |
|
|
56.1 |
|
|
|
80.7 |
|
Other current assets |
|
|
3.4 |
|
|
|
6.9 |
|
|
|
2.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(113.3 |
) |
|
|
(37.4 |
) |
|
|
(5.2 |
) |
Change in noncurrent liabilities |
|
|
8.5 |
|
|
|
8.6 |
|
|
|
11.6 |
|
Other items - net |
|
|
10.9 |
|
|
|
(8.6 |
) |
|
|
5.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating activities |
|
|
334.8 |
|
|
|
362.2 |
|
|
|
331.6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
INVESTING ACTIVITIES |
|
|
|
|
|
|
|
|
|
|
|
|
Capital expenditures |
|
|
(130.9 |
) |
|
|
(136.7 |
) |
|
|
(133.2 |
) |
Acquisitions - net of cash received and liabilities assumed |
|
|
|
|
|
|
|
|
|
|
(958.4 |
) |
Net proceeds from divestitures and sales of property and equipment |
|
|
281.9 |
|
|
|
30.1 |
|
|
|
3.0 |
|
Other items - net |
|
|
0.4 |
|
|
|
(0.2 |
) |
|
|
(0.2 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total investing activities |
|
|
151.4 |
|
|
|
(106.8 |
) |
|
|
(1,088.8 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
FINANCING ACTIVITIES |
|
|
|
|
|
|
|
|
|
|
|
|
Changes in short-term debt - net |
|
|
(0.6 |
) |
|
|
(4.0 |
) |
|
|
(72.6 |
) |
Repayments of long-term debt |
|
|
(143.4 |
) |
|
|
(512.2 |
) |
|
|
(1,193.0 |
) |
Proceeds from the issuance of long-term debt |
|
|
|
|
|
|
235.8 |
|
|
|
1,743.3 |
|
Dividends paid |
|
|
(71.2 |
) |
|
|
(70.4 |
) |
|
|
(57.6 |
) |
Proceeds from sale of common shares, net of underwriting
commissions and offering expenses of $20.2 million |
|
|
|
|
|
|
|
|
|
|
470.0 |
|
Payment of debt issuance costs |
|
|
|
|
|
|
(0.8 |
) |
|
|
(16.8 |
) |
Payment of treasury rate lock upon settlement |
|
|
|
|
|
|
|
|
|
|
(73.9 |
) |
Payment on termination of interest rate swaps |
|
|
|
|
|
|
|
|
|
|
(2.9 |
) |
Proceeds from the exercise of stock options |
|
|
31.3 |
|
|
|
38.8 |
|
|
|
12.0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total financing activities |
|
|
(183.9 |
) |
|
|
(312.8 |
) |
|
|
808.5 |
|
|
Effect of exchange rate changes on cash |
|
|
11.0 |
|
|
|
(16.1 |
) |
|
|
25.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash and short-term investments |
|
|
313.3 |
|
|
|
(73.5 |
) |
|
|
77.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and short-term investments at the beginning of year |
|
|
262.4 |
|
|
|
335.9 |
|
|
|
258.7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and short-term investments at the end of year |
|
|
$ 575.7 |
|
|
|
$ 262.4 |
|
|
|
$ 335.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these consolidated financial statements.
70
THE
LUBRIZOL CORPORATION
CONSOLIDATED STATEMENTS OF SHAREHOLDERS EQUITY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders Equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated |
|
|
|
|
Number of |
|
|
|
|
|
|
|
|
|
|
Other |
|
|
|
|
Shares |
|
Common |
|
Retained |
|
|
Comprehensive |
|
|
(In Millions) |
|
Outstanding |
|
|
Shares |
|
|
|
Earnings |
|
|
|
(Loss) Income |
|
|
Total |
BALANCE, JANUARY 1, 2004, AS PREVIOUSLY
REPORTED |
|
|
51.6 |
|
|
|
$ 123.8 |
|
|
|
$ 865.5 |
|
|
|
$ (36.0 |
) |
|
|
$ 953.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restatement adjustments, see Note 20 |
|
|
|
|
|
|
|
|
|
|
(10.5 |
) |
|
|
(1.8 |
) |
|
|
(12.3 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BALANCE, JANUARY 1, 2004, AS RESTATED |
|
|
51.6 |
|
|
|
123.8 |
|
|
|
855.0 |
|
|
|
(37.8 |
) |
|
|
941.0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income 2004 |
|
|
|
|
|
|
|
|
|
|
91.8 |
|
|
|
|
|
|
|
91.8 |
|
Other comprehensive income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50.5 |
|
|
|
50.5 |
|
Total comprehensive income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
142.3 |
|
Dividends declared |
|
|
|
|
|
|
|
|
|
|
(61.6 |
) |
|
|
|
|
|
|
(61.6 |
) |
Common shares - issued in public offerings |
|
|
14.7 |
|
|
|
470.0 |
|
|
|
|
|
|
|
|
|
|
|
470.0 |
|
Deferred stock compensation |
|
|
|
|
|
|
3.4 |
|
|
|
|
|
|
|
|
|
|
|
3.4 |
|
Common shares - treasury: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares issued upon exercise of
stock options and awards |
|
|
0.5 |
|
|
|
13.4 |
|
|
|
|
|
|
|
|
|
|
|
13.4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BALANCE, DECEMBER 31, 2004, AS RESTATED |
|
|
66.8 |
|
|
|
610.6 |
|
|
|
885.2 |
|
|
|
12.7 |
|
|
|
1,508.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income 2005 |
|
|
|
|
|
|
|
|
|
|
187.2 |
|
|
|
|
|
|
|
187.2 |
|
Other comprehensive loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(126.2 |
) |
|
|
(126.2 |
) |
Total comprehensive income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
61.0 |
|
Dividends declared |
|
|
|
|
|
|
|
|
|
|
(70.7 |
) |
|
|
|
|
|
|
(70.7 |
) |
Deferred stock compensation |
|
|
|
|
|
|
8.8 |
|
|
|
|
|
|
|
|
|
|
|
8.8 |
|
Common shares - treasury: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares issued upon exercise of
stock options and awards |
|
|
1.2 |
|
|
|
44.3 |
|
|
|
|
|
|
|
|
|
|
|
44.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BALANCE, DECEMBER 31, 2005, AS RESTATED |
|
|
68.0 |
|
|
|
663.7 |
|
|
|
1,001.7 |
|
|
|
(113.5 |
) |
|
|
1,551.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income 2006 |
|
|
|
|
|
|
|
|
|
|
103.6 |
|
|
|
|
|
|
|
103.6 |
|
Other comprehensive income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
115.5 |
|
|
|
115.5 |
|
Total comprehensive income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
219.1 |
|
Adjustment to recognize pension and other
postretirement benefit plans funded status |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(62.8 |
) |
|
|
(62.8 |
) |
Dividends declared |
|
|
|
|
|
|
|
|
|
|
(71.5 |
) |
|
|
|
|
|
|
(71.5 |
) |
Deferred stock compensation |
|
|
|
|
|
|
11.2 |
|
|
|
|
|
|
|
|
|
|
|
11.2 |
|
Common shares - treasury: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares issued upon exercise of
stock options and awards |
|
|
1.0 |
|
|
|
35.2 |
|
|
|
|
|
|
|
|
|
|
|
35.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BALANCE, DECEMBER 31, 2006, AS RESTATED |
|
|
69.0 |
|
|
|
$ 710.1 |
|
|
|
$ 1,033.8 |
|
|
|
$ (60.8 |
) |
|
|
$ 1,683.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these consolidated financial statements.
71
Notes to Financial Statements
(In Millions Except Per Share Data)
Note 1 - NATURE OF OPERATIONS
The Lubrizol Corporation (the company) is an innovative specialty chemical company that produces
and supplies technologies that improve the quality and performance of its customers products in
the global transportation, industrial and consumer markets. These technologies include lubricant
additives for engine oils, other transportation-related fluids and industrial lubricants, as well
as additives for gasoline and diesel fuel. In addition, the company makes ingredients and
additives for personal care products and pharmaceuticals; engineered polymers, including plastics
technology; and performance coatings in the form of specialty resins and additives.
The company is organized into two operating and reporting segments: Lubrizol Additives (formerly
known as the Lubricant Additives segment) and Lubrizol Advanced Materials (formerly known as the
Specialty Chemicals segment). Refer to Note 15 for a further description of the nature of the
companys operations, the product lines within each of the operating segments, segment operating
income and related financial disclosures for the reportable segments.
Note 2 - SIGNIFICANT ACCOUNTING POLICIES
CONSOLIDATION - The consolidated financial statements include the accounts of the company and its
consolidated subsidiaries. The company consolidates certain entities in which it owns less than a
100% equity interest if it is either deemed to be the primary beneficiary in a variable interest
entity, as defined in Financial Accounting Standards Board (FASB) Interpretation (FIN) No. 46
(revised December 2003), Consolidation of Variable Interest Entities or where its ownership
interest is at least 50% and the company has effective management control. The equity method of
accounting is applied to non-consolidated entities in which the company can exercise significant
influence over the entity with respect to its operations and major decisions. The book value of
investments carried on the equity method was $6.3 million and $6.1 million at December 31, 2006 and
2005, respectively. Investments carried at cost were $1.4 million and $1.5 million at December 31,
2006 and 2005, respectively.
DISCONTINUED OPERATIONS - The results of a component of the company that either has been disposed
of or is classified as held for sale are reported in discontinued operations in accordance with the
requirements of Statement of Financial Accounting Standards (SFAS) No. 144, Accounting for the
Impairment or Disposal of Long-Lived Assets. A component of an entity is classified as held for
sale when the transaction has been approved by the appropriate level of management and there are no
known significant contingencies outstanding that would prevent the sale from closing within one
year. The results of operations of all entities that have been disposed of or that are classified
as held for sale in 2006 and 2005 have been classified as discontinued operations in all periods
presented in the consolidated statements of income. The 2006, 2005 and 2004 cash flow statements
are presented on a consolidated basis, including both continuing operations and discontinued
operations.
USE OF ESTIMATES - The preparation of consolidated financial statements in conformity with
accounting principles generally accepted in the United States of America requires management to
make estimates and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. Actual results could differ
from those estimates.
CASH EQUIVALENTS - The company invests its excess cash in short-term investments with various banks
and financial institutions. Short-term investments are cash equivalents, as they are part of the
cash management activities of the company and are comprised of investments having maturities of
three months or less when purchased.
INVENTORIES - Inventories are stated at the lower of cost or market value. Cost of inventories is
determined by either the first-in, first-out (FIFO) method or the moving-average method, except in
the United States for chemical inventories, which primarily are valued using the last-in, first-out
(LIFO) method.
The company accrues volume discounts on purchases from vendors where it is probable that the
required volume will be attained and the amount can be reasonably estimated. The company records
the discount as a reduction in the cost of the purchase (generally raw materials), based on
projected purchases over the purchase agreement period.
72
In November 2004, the FASB issued SFAS No. 151, Inventory Costs, to clarify the accounting for
abnormal amounts of idle facility expense, freight, handling costs and wasted material. This
standard requires that such items be recognized as current-period charges. The standard also
establishes the concept of normal capacity and requires the allocation of fixed production
overhead to inventory based on the normal capacity of the production facilities. Any unallocated
overhead must be recognized as an expense in the period incurred. This standard was effective for
inventory costs incurred beginning on January 1, 2006. The companys adoption of this standard did
not have a material impact on its financial position, results of operations or cash flows.
PROPERTY AND EQUIPMENT - Property and equipment are carried at cost. Repair and maintenance costs
are charged against income while renewals and betterments are capitalized as additions to the
related assets. Costs incurred for computer software developed or obtained for internal use are
capitalized for application development activities and immediately expensed for preliminary project
activities or post-implementation activities. Accelerated depreciation methods, which are used in
computing depreciation on certain machinery and equipment, comprised approximately 6% of the
depreciable assets at December 31, 2006 and 2005. The remaining assets are depreciated using the
straight-line method. The estimated useful lives are 10 to 40 years for buildings and improvements
for buildings and land. Estimated useful lives range from 3 to 20 years for machinery and
equipment.
IMPAIRMENT OR DISPOSAL OF LONG-LIVED ASSETS - The company reviews the carrying value of its
long-lived assets, including property and equipment, whenever events or changes in circumstances
indicate that the carrying value of the assets may not be recoverable. An impairment loss exists
when estimated undiscounted future cash flows expected to result from the use of the asset,
including disposition, are less than the carrying value of the asset. The measurement of the
impairment loss to be recognized is based on the difference between the fair value and the carrying
amounts of the assets. Fair value is generally determined based on a discounted cash flow
analysis. In order to determine if an asset has been impaired, assets are grouped and tested at
the lowest level for which identifiable, independent, cash flows are available.
GOODWILL AND INTANGIBLE ASSETS - Goodwill represents the excess of purchase price and related costs
over the value assigned to the net tangible and identifiable intangible assets of businesses
acquired and is not amortized in accordance with SFAS No. 142, Goodwill and Other Intangible
Assets. Goodwill is tested for impairment annually, and between annual tests if an event occurs
or circumstances change that indicates the carrying amount may be impaired. The company has
elected to perform its annual tests for potential impairment of goodwill and indefinite-lived
intangible assets as of October 1 of each year. Impairment testing is performed at the reporting
unit level. An impairment loss generally would be recognized when the carrying amount of the
reporting units net assets exceeds the estimated fair value of the reporting unit. The estimated
fair value of a reporting unit is determined through a combination of discounted cash flow analysis
and terminal value calculations.
Intangible assets resulting from business acquisitions, including customer lists, purchased
technology, trademarks, patents, land-use rights and non-compete agreements, are amortized on a
straight-line method over periods ranging from 3 to 40 years. Under SFAS No. 142, intangible
assets determined to have indefinite lives are not amortized, but are tested for impairment at
least annually. As part of the annual impairment test, the non-amortized intangible assets are
reviewed to determine if the indefinite status remains appropriate.
DEFERRED FINANCING COSTS - Costs incurred with the issuance of debt and credit facilities are
capitalized and amortized over the life of the associated debt as a component of interest expense
using the effective interest method of amortization. In June 2004, the company initially financed
the Noveon International, Inc. acquisition with a temporary bridge facility. Fees associated with
the bridge facility were capitalized and amortized over the bridge financing period. A total of
$11.2 million was incurred in bridge facility fees in June 2004. These fees were expensed ratably
through September 2004 when the bridge facility was repaid in full. In September 2004, the
company incurred $16.8 million in debt issuance costs and fees relating to the issuance of $1,150.0
million in senior notes and debentures, and a $1,075.0 million five-year credit facility. Such
costs are being amortized under the effective interest method over the respective terms of the
debt. Net deferred financing costs were $15.7 million and $18.3 million at December 31, 2006 and
2005, respectively. Amortization expense incurred in 2006, 2005 and 2004 was $2.9 million, $3.6
million and $1.6 million, respectively.
ENVIRONMENTAL LIABILITIES - The company accrues for expenses associated with environmental
remediation obligations when such expenses are probable and reasonably estimable, based upon
current law and existing technologies. These accruals are adjusted as further information develops
or circumstances change. Costs of future expenditures for environmental remediation obligations
are not discounted to their present value.
73
SHARE REPURCHASES - The company uses the par-value method of accounting for its treasury shares.
Under this method, the cost to reacquire shares in excess of paid-in capital related to those
shares is charged against retained earnings.
FOREIGN CURRENCY TRANSLATION - The assets and liabilities of the companys international
subsidiaries are translated into U.S. dollars at exchange rates in effect at the balance sheet
date, while revenues and expenses are translated at weighted-average exchange rates in effect
during the period. Unrealized translation adjustments are recorded as a component of accumulated
other comprehensive income or loss in the consolidated statements of shareholders equity, except
for subsidiaries for which the functional currency is other than the local currency, where
translation adjustments are recognized in income. Transaction gains or losses that arise from
exchange rate changes on transactions denominated in a currency other than the functional currency,
except those transactions that function as a hedge of an identifiable foreign currency commitment
or as a hedge of a foreign currency investment, are included in income as incurred.
REVENUE RECOGNITION - Revenues are recognized at the time of shipment of products to customers, or
at the time of transfer of title, if later, and when collection is reasonably assured. All amounts
in a sales transaction billed to a customer related to shipping and handling are reported as
revenues.
Provisions for sales discounts and rebates to customers are recorded, based upon the terms of sales
contracts, in the same period the related sales are recorded, as a deduction to the sale. Sales
discounts and rebates are offered to certain customers to promote customer loyalty and encourage
greater product sales. These rebate programs provide that upon the attainment of pre-established
volumes or the attainment of revenue milestones for a specified period, the customer receives
credits against purchases. The company estimates the provision for rebates based on the specific
terms in each agreement at the time of shipment and an estimate of the customers achievement of
the respective revenue milestones.
COMPONENTS OF COST OF SALES - Cost of sales is comprised of raw material costs including freight
and duty, inbound handling costs associated with the receipt of raw materials, direct production,
maintenance and utility costs, plant and engineering overhead, terminals and warehousing costs, and
outbound shipping and handling costs.
RESEARCH, TESTING AND DEVELOPMENT - Research, testing and development costs are expensed as
incurred. Research and development expenses, excluding testing, were $135.3 million in 2006,
$128.1 million in 2005 and $103.7 million in 2004. Costs to acquire in-process research and
development (IPR&D) projects that have no alternative future use and that have not yet reached
technological feasibility at the date of acquisition are expensed upon acquisition.
INCOME TAXES - The company provides for income taxes in accordance with SFAS No. 109, Accounting
for Income Taxes. SFAS No. 109 requires the recognition of deferred tax assets and liabilities
for the expected future tax consequences of temporary differences between the financial statement
carrying amounts and the tax bases of the assets and liabilities.
In June 2006, the FASB issued FIN No. 48, Accounting for Uncertainty in Income Taxes, that
prescribes a recognition threshold and measurement attribute for the financial statement
recognition and measurement of a tax position taken or expected to be taken in a tax return. Under
FIN No. 48, a contingent tax asset only will be recognized if it is more likely than not that a tax
position ultimately will be sustained. After this threshold is met, a tax position is reported at
the largest amount of benefit that is more likely than not to be realized. FIN No. 48 also
provides guidance on derecognition, classification, interest and penalties, accounting in interim
periods and disclosure. FIN No. 48 is effective for fiscal years beginning after December 15,
2006. This Interpretation requires the cumulative effect of applying the provisions to be reported
separately as an adjustment to the opening balance of retained earnings in the year of adoption.
The company currently is evaluating the impact of this recently issued Interpretation on its
consolidated financial statements.
74
PER SHARE AMOUNTS - Net income per share is computed by dividing net income by average common
shares outstanding during the period, including contingently issuable shares. Net income per
diluted share includes the dilutive impact resulting from outstanding stock options and awards.
Per share amounts are computed as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2006 |
|
|
|
2005 |
|
|
|
2004 |
Numerator: |
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations |
|
|
$ 179.8 |
|
|
|
$ 159.4 |
|
|
|
$ 85.5 |
(Loss) income from discontinued
operations - net of tax |
|
|
(76.2 |
) |
|
|
27.8 |
|
|
|
6.3 |
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
|
$ 103.6 |
|
|
|
$ 187.2 |
|
|
|
$ 91.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator: |
|
|
|
|
|
|
|
|
|
|
|
Weighted-average common shares outstanding |
|
|
68.7 |
|
|
|
67.9 |
|
|
|
55.7 |
Dilutive effect of stock options and awards |
|
|
0.6 |
|
|
|
0.9 |
|
|
|
0.3 |
|
|
|
|
|
|
|
|
|
|
|
|
Denominator for net income per share, diluted |
|
|
69.3 |
|
|
|
68.8 |
|
|
|
56.0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic earnings (loss) per share: |
|
|
|
|
|
|
|
|
|
|
|
Continuing operations |
|
|
$ 2.62 |
|
|
|
$ 2.35 |
|
|
|
$ 1.54 |
Discontinued operations |
|
|
(1.11 |
) |
|
|
0.41 |
|
|
|
0.11 |
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share, basic |
|
|
$ 1.51 |
|
|
|
$ 2.76 |
|
|
|
$ 1.65 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings (loss) per share: |
|
|
|
|
|
|
|
|
|
|
|
Continuing operations |
|
|
$ 2.59 |
|
|
|
$ 2.32 |
|
|
|
$ 1.53 |
Discontinued operations |
|
|
(1.10 |
) |
|
|
0.40 |
|
|
|
0.11 |
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share, diluted |
|
|
$ 1.49 |
|
|
|
$ 2.72 |
|
|
|
$ 1.64 |
|
|
|
|
|
|
|
|
|
|
|
|
There were no shares excluded from the diluted earnings per share calculations because they were
antidilutive in 2006 and 2005. There were 1.1 million weighted-average shares issuable upon the
exercise of stock options and awards that were excluded from the diluted earnings per share
calculation because they were antidilutive in 2004.
ACCOUNTING FOR DERIVATIVE INSTRUMENTS - Derivative financial instruments are recognized on the
balance sheet as either assets or liabilities and are measured at fair value. Derivatives that are
not hedges are adjusted to fair value through income. Depending upon the nature of the hedge,
changes in fair value of the derivative are either offset against the change in fair value of
assets, liabilities or firm commitments through earnings or recognized in other comprehensive
income or loss until the hedged item is recognized in earnings. The ineffective portion of a
derivatives change in value is recognized immediately in earnings. The company only uses
derivative financial instruments to manage well-defined interest rate, foreign currency and
commodity price risks. The company does not use derivatives for trading purposes.
COSTS ASSOCIATED WITH EXIT OR DISPOSAL ACTIVITIES - Liabilities for costs associated with exit or
disposal activities are recognized and measured initially at fair value when the liability is
incurred pursuant to the requirements of SFAS No. 146, Accounting for Costs Associated with Exit
or Disposal Activities.
ASSET-RETIREMENT OBLIGATIONS - The company accounts for asset retirement obligations in accordance
with SFAS No. 143, Accounting for Asset Retirement Obligations and FIN No. 47, Accounting for
Conditional Asset-Retirement Obligations - an interpretation of FASB Statement No. 143. FIN No.
47 requires the recognition of a liability for the fair value of a legal obligation to perform
asset-retirement obligations (AROs) that are conditional on a future event
if the amount can be reasonably estimated. The company has identified AROs related to certain of
its leased facilities and to asbestos remediation activities that may be required in the future.
However, due to the long-term, productive nature of the companys manufacturing operations, absent
plans or expectation of plans to initiate asset retirement activities, the company is unable to
reasonably estimate the fair value of such asbestos remediation liabilities since the potential
settlement dates cannot be determined at this time.
75
GUARANTEES - FIN No. 45, Guarantors Accounting and Disclosure Requirements for Guarantees,
Including Indirect Guarantees of Indebtedness of Others requires the recognition of a liability
for any guarantees entered into or modified. At December 31, 2006, the company had guaranteed the
timely performance of payment obligations under supplier contracts by a third-party purchaser of
the companys food ingredients and industrial specialties (FIIS) business. The company believes
that it is highly unlikely that an event would occur requiring the company to pay any monies
pursuant to the guarantee. Accordingly, no liability has been reflected in the accompanying
consolidated balance sheet at December 31, 2006 (see Note 18). The company did not have any other
material guarantees within the scope of FIN No. 45 at December 31, 2006 and 2005, respectively.
STOCK-BASED COMPENSATION - Effective January 1, 2006, the company adopted the fair value
recognition provisions of SFAS No. 123R, Share-Based Payment, using the modified prospective
transition method and therefore has not restated results for prior periods. Under this transition
method, stock-based compensation expense for 2006 includes compensation expense for all stock-based
compensation awards granted prior to, but not yet vested as of, January 1, 2006, based on the
grant-date fair value estimated in accordance with the original provisions of SFAS No. 123,
Accounting for Stock-Based Compensation. Stock-based compensation expense for all stock-based
compensation awards granted after January 1, 2006 is based on the grant-date fair value estimated
in accordance with the provisions of SFAS No. 123R. The company recognizes these compensation
costs, net of a forfeiture rate, on a straight-line basis over the requisite service period of the
award, which generally is the option vesting term of three years with the options becoming
exercisable 50% one year after date of grant, 75% after two years and 100% after three years. The
company estimates the forfeiture rate based on its historical experience during the preceding 10
years.
The following table shows the pro forma effect on net income and earnings per share if the company
had applied the fair-value recognition provisions of SFAS No. 123, Accounting for Stock-Based
Compensation, to stock-based employee compensation for 2005 and 2004. There is no pro forma
presentation necessary after December 31, 2005 as the company adopted the fair value recognition
provisions of SFAS No. 123R on January 1, 2006.
|
|
|
|
|
|
|
|
|
|
|
|
2005 |
|
|
|
2004 |
|
Reported net income |
|
|
$ 187.2 |
|
|
|
$ 91.8 |
|
Plus: Stock-based employee compensation
(net of tax) included in net income |
|
|
5.5 |
|
|
|
2.1 |
|
Less: Stock-based employee compensation
(net of tax) using the fair value method |
|
|
(6.5 |
) |
|
|
(6.0 |
) |
|
|
|
|
|
|
|
|
|
Pro forma net income |
|
|
$ 186.2 |
|
|
|
$ 87.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reported net income per share, basic |
|
|
$ 2.76 |
|
|
|
$ 1.65 |
|
|
|
|
|
|
|
|
|
|
Pro forma net income per share, basic |
|
|
$ 2.74 |
|
|
|
$ 1.58 |
|
|
|
|
|
|
|
|
|
|
Reported net income per share, diluted |
|
|
$ 2.72 |
|
|
|
$ 1.64 |
|
|
|
|
|
|
|
|
|
|
Pro forma net income per share, diluted |
|
|
$ 2.71 |
|
|
|
$ 1.57 |
|
|
|
|
|
|
|
|
|
|
FAIR VALUE MEASUREMENTS - In September 2006, the FASB issued SFAS No. 157, Fair Value
Measurements. This statement defines fair value, establishes a framework for measuring fair value
in accordance with U.S. generally accepted accounting principles (U.S. GAAP) and expands disclosure
about fair value measurements. SFAS No. 157 does not expand the use of fair value measures in
financial statements, but simplifies and codifies related guidance within U.S. GAAP. SFAS No. 157
establishes a fair value hierarchy from observable market data as the highest level to fair value
based on an entitys own fair value assumptions as the lowest level. SFAS No. 157 is effective for
fiscal years beginning after November 15, 2007 and interim periods within those years. SFAS No.
157 requires adoption prospectively as of the beginning of the fiscal year in which this statement
is initially applied, with the exception of certain financial instruments, in
which adoption is applied retrospectively as of the beginning of the fiscal year in which this
statement is initially applied. The company is currently evaluating the impact of this recently
issued standard on its consolidated financial statements.
ACCOUNTING CHANGES AND ERROR CORRECTIONS - In September 2006, the Securities and Exchange
Commission (SEC) released Staff Accounting Bulletin (SAB) No. 108, Considering the Effects of
Prior Year
76
Misstatements when Quantifying Misstatements in Current Year Financial Statements. SAB
No. 108 provides guidance on how the effects of prior-year uncorrected financial statement
misstatements should be considered in quantifying a current-year misstatement. SAB No. 108
requires registrants to quantify misstatements using both an income statement (rollover) and
balance sheet (iron curtain) approach and evaluate whether either approach results in a
misstatement that, when all relevant quantitative and qualitative factors are considered, is
material. If prior-year errors that previously had been considered immaterial now are considered
material based on either approach, no restatement is required so long as management properly
applied its previous approach and all relevant facts and circumstances were considered. If prior
years are not restated, a cumulative-effect adjustment is recorded in opening accumulated earnings
as of the beginning of the fiscal year of adoption. SAB No. 108 is effective for the company for
the fiscal year ended December 31, 2006. The companys adoption of this standard did not have a
material impact on its consolidated financial statements.
In May 2005, the FASB issued SFAS No. 154, Accounting Changes and Error Corrections. This
standard establishes new standards on accounting for changes in accounting principles. Pursuant to
the new rules, all such changes must be accounted for by retrospective application to the financial
statements of prior periods unless it is impracticable to do so. SFAS No. 154 completely replaces
Accounting Principles Board (APB) Opinion No. 20 and SFAS No. 3, though it carries forward the
guidance in those pronouncements with respect to accounting for changes in estimates, changes in
the reporting entity, and the correction of errors. This statement is effective for accounting
changes and corrections of errors beginning January 1, 2006. The companys adoption of this
standard did not have a material impact on its consolidated financial statements.
RECLASSIFICATIONS - Certain prior period amounts have been reclassified to conform to the current
year presentation.
Note 3 - ACQUISITIONS
On February 7, 2007, the company completed the acquisition of a broad line of additive products
used in the metalworking markets worldwide from Lockhart Chemical Company (Lockhart), a private
company with headquarters in Gibsonia, Pennsylvania. Lockhart is recognized in the metalworking
industry for its application and formulation capabilities and quality products. The company
purchased Lockharts entire metalworking product line, which includes: natural, synthetic and
gelled sulfonates; emulsifier packages; corrosion inhibitors and lubricity agents; grease
additives; oxidates; esters; soap; semi-finished coatings; and rust preventatives. In 2006, these
product lines had annualized revenues of approximately $20.0 million.
On June 3, 2004, the company completed the acquisition of Noveon International for cash of $920.2
million (inclusive of $32.9 million in certain seller expenses) plus transaction costs of $11.4
million and less cash acquired of $103.0 million. In addition, the company assumed $1,103.1
million of long-term indebtedness from Noveon International.
The acquisition and related costs initially were financed with the proceeds of a $2,450.0 million
364-day bridge credit facility. Shortly after the acquisition, the company repaid substantially
all of the assumed long-term debt of Noveon International with proceeds of the temporary bridge
loan. In addition, the temporary bridge loan was repaid in full in September 2004 with the
proceeds from the permanent financing obtained by the issuance of senior notes, debentures and
equity and the borrowing of $575.0 million of bank term loans, resulting in proceeds of
approximately $2,170.0 million, net of underwriting commissions, discounts and transaction costs.
The company recorded the various assets acquired and liabilities assumed, primarily working capital
accounts, of Noveon International at their estimated fair values determined as of the acquisition
date under the purchase method of accounting. Actuarial valuations were completed for the
projected pension and other post-employment benefit obligations and were reflected in the purchase
price allocation. Appraisals of long-lived assets and identifiable intangible assets, including an
evaluation of IPR&D projects, also were obtained.
The purchase price included the estimated fair value of IPR&D projects totaling $34.0 million that,
as of the acquisition date, had not yet reached technological feasibility and had no alternative
future use. As a result, the full amount allocated to IPR&D was expensed in 2004. There were nine
projects acquired in the Noveon International transaction in several different product lines. The
projects were at varying stages of completeness ranging from the early development stage to
prototype testing at the time of acquisition. The inventory step-up to fair value totaled $24.2
million, of which $9.8 million was expensed in 2004. As the remaining step-up relates to
inventories accounted for on the LIFO method of accounting, the company does not anticipate that
additional amounts of step-up will be expensed in the near term.
The 2004 historical results of the company include revenues and expenses of Noveon International
since the date of acquisition.
77
In January 2004, the company completed the acquisition of the coatings hyperdispersants business
from Avecia for cash totaling $129.7 million, including transaction costs of $2.2 million. This
business is headquartered in Blackley, United Kingdom and develops, manufactures and markets
high-value additives that are based on polymeric dispersion technology and used in coatings and
inks.
Note 4 - DIVESTITURES
In May 2006, the company sold the FIIS business and the active pharmaceutical ingredients and
intermediate compounds business (A&I), both of which were included in the Lubrizol Advanced
Materials segment. A&I and almost all of FIIS were included in the Noveon consumer specialties
product line. A small portion of the FIIS divestiture was included in the performance coatings
product line. In consideration for the FIIS and A&I businesses, the company received net cash
proceeds of approximately $254.8 million and $10.4 million, respectively. The company recorded a
$10.4 million pretax ($15.9 million after-tax) loss on the sale of these divested businesses. The
tax charge of $5.5 million primarily related to the difference in book and tax basis in goodwill.
The net charge of $76.2 million recorded in discontinued operations in 2006 also reflected a $60.6
million after-tax goodwill impairment charge in the first quarter of 2006 to reduce the FIIS
business to its carrying value. The company performed the impairment test on the FIIS business in
connection with its classification as held for sale and estimated its fair value based on expected
proceeds from the sale, less transaction costs. In addition, a charge of $4.4 million pretax ($2.9
million after-tax) was recorded in the fourth quarter of 2006 to write-off an intangible asset
associated with the FIIS business.
The company performed a SFAS No. 144 impairment test of the FIIS business at December 31, 2005 and
determined that the estimated fair value of the FIIS business exceeded its carrying value. The
company calculated the fair value using a probability-weighted assessment based on selling the
businesses versus continuing operations of the businesses. Based on the results of this impairment
analysis, an impairment charge was not warranted at December 31, 2005.
In February 2006, the company sold certain assets and liabilities of its Telene® resins
business (Telene), which was included in the Lubrizol Advanced Materials segment. The company
received net cash proceeds of $6.2 million for the sale of Telene.
The results of the FIIS, A&I and the Telene businesses were reflected in the (loss) income from
discontinued operations - net of tax line item in the consolidated statements of income for 2006,
2005 and 2004, respectively.
In December 2005, the company sold certain assets, liabilities and stock of its Engine Control
Systems (ECS) business and, in September 2005, the company sold certain assets and liabilities of
its U.S. and U.K. Lubrizol Performance Systems (LPS) operations, both of which were included in the
Lubrizol Additives segment. The company reflected the results of these businesses in the (loss)
income from discontinued operations - net of tax line item in the consolidated statements of income
for 2005 and 2004, respectively.
Revenues from discontinued operations were $143.8 million, $476.7 million and $295.1 million in
2006, 2005 and 2004, respectively. Loss from discontinued operations - net of tax was $76.2
million in 2006 and primarily related to a $60.6 million after-tax goodwill impairment charge on
the FIIS business recorded in the first quarter of 2006 and a $16.6 million after-tax loss on the
sale of divested businesses. Loss from discontinued operations - net of tax in 2006 includes
income tax expense of $9.4 million. Income from discontinued operations - net of tax in 2005 was
$27.8 million and includes income tax expense of $15.5 million. Income from discontinued
operations - net of tax in 2004 was $6.3 million and includes income tax expense of $3.1 million.
The companys consolidated balance sheet at December 31, 2006 does not reflect any businesses
classified as discontinued operations as all activities related to discontinued operations were
fully completed during 2006. The companys consolidated balance sheet at December 31, 2005
included $132.1 million in current assets, $115.6 million in net property and equipment, $87.6
million in goodwill, $24.8 million in net intangible assets, $0.6 million in other current assets,
$8.5 million in current liabilities and $6.4 million in long-term liabilities pertaining to
businesses reflected as discontinued operations.
78
Note 5 - INVENTORIES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2006 |
|
|
|
2005 |
Finished products |
|
|
$ |
315.0 |
|
|
|
$ |
319.6 |
|
Products in process |
|
|
|
108.2 |
|
|
|
|
86.9 |
|
Raw materials |
|
|
|
138.2 |
|
|
|
|
151.2 |
|
Supplies and engine test parts |
|
|
|
27.6 |
|
|
|
|
28.3 |
|
|
|
|
|
|
|
|
|
|
Total inventory |
|
|
$ |
589.0 |
|
|
|
$ |
586.0 |
|
|
|
|
|
|
|
|
|
|
Inventories valued using the LIFO method were 40% and 42% of consolidated inventories at
December 31, 2006 and 2005, respectively. The current replacement cost of these inventories
exceeded the LIFO cost at December 31, 2006 and 2005 by $132.8 million and $121.5 million,
respectively.
Note 6
- GOODWILL AND INTANGIBLE ASSETS
Goodwill
Goodwill is tested for impairment at the reporting unit level as of October 1 of each year or if
events or circumstances occur that would more likely than not reduce the fair value of a reporting
unit below its carrying amount. No impairment of goodwill was identified in connection with the
2006, 2005 or 2004 annual impairment test.
The carrying amount of goodwill by reporting segment follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Lubrizol |
|
|
|
|
|
|
|
|
|
|
|
Advanced |
|
Lubrizol |
|
|
|
|
|
|
|
Materials |
|
Additives |
|
|
Total |
|
Balance, January 1, 2005 |
|
|
$ |
1,052.9 |
|
|
|
$ |
100.9 |
|
|
|
$ |
1,153.8 |
|
Goodwill acquired |
|
|
|
32.9 |
|
|
|
|
|
|
|
|
|
32.9 |
|
Translation & other adjustments |
|
|
|
(42.8 |
) |
|
|
|
(5.1 |
) |
|
|
|
(47.9 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, December 31, 2005 |
|
|
|
1,043.0 |
|
|
|
|
95.8 |
|
|
|
|
1,138.8 |
|
Goodwill of divestitures |
|
|
|
(87.6 |
) |
|
|
|
|
|
|
|
|
(87.6 |
) |
Translation & other adjustments |
|
|
|
22.9 |
|
|
|
|
2.0 |
|
|
|
|
24.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, December 31, 2006 |
|
|
$ |
978.3 |
|
|
|
$ |
97.8 |
|
|
|
$ |
1,076.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The decrease in the carrying amount of goodwill from December 31, 2005 to December 31, 2006
primarily reflects the elimination of the goodwill of divestitures in the Lubrizol Advanced
Materials segment of $87.6 million, of which $85.1 million was associated with the FIIS business
sold in the second quarter of 2006 and $2.5 million related to the Telene business sold during the
first quarter of 2006. The $85.1 million goodwill reduction related to the FIIS business includes
an impairment charge of $60.6 million reflected in the first quarter of 2006 and a $24.5 million
disposition of the residual balance at the time of sale (see Note 4).
Intangible Assets
The major components of the companys identifiable intangible assets are customer lists,
technology, trademarks, patents, land-use rights and non-compete agreements. Definite-lived
intangible assets are amortized over their useful lives, which range between 3 and 40 years. The
companys indefinite-lived intangible assets consist of certain trademarks which are tested for
impairment each year as of October 1 or more frequently if impairment indicators arise.
Indefinite-lived trademarks are assessed for impairment separately from goodwill. No impairment of
indefinite-lived trademarks was identified in connection with the 2006, 2005 or 2004 annual
impairment test. However, the decrease in gross intangible assets from December 31, 2005 to
December 31, 2006 primarily was due to a $41.2 million write-down of the Noveon trade name in the
Lubrizol Advanced Materials segment during the fourth quarter of 2006 (see Note 17) and intangible
assets associated with the FIIS business sold during the second quarter of 2006.
79
The following table shows the components of identifiable intangible assets as of December 31, 2006
and 2005:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2006 |
|
2005 |
|
|
Gross |
|
|
|
|
|
|
Gross |
|
|
|
|
|
|
|
Carrying |
|
Accumulated |
|
Carrying |
|
Accumulated |
|
|
Amount |
|
Amortization |
|
Amount |
|
Amortization |
|
Amortized intangible assets: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Customer lists |
|
|
$ 145.0 |
|
|
|
|
$ 24.0 |
|
|
|
$ 151.5 |
|
|
|
|
$ 15.8 |
|
Technology |
|
|
139.8 |
|
|
|
|
44.9 |
|
|
|
144.4 |
|
|
|
|
35.6 |
|
Trademarks |
|
|
20.7 |
|
|
|
|
5.5 |
|
|
|
24.5 |
|
|
|
|
4.2 |
|
Patents |
|
|
14.0 |
|
|
|
|
4.2 |
|
|
|
11.8 |
|
|
|
|
2.5 |
|
Land-use rights |
|
|
7.5 |
|
|
|
|
1.2 |
|
|
|
7.3 |
|
|
|
|
1.0 |
|
Non-compete agreements |
|
|
8.2 |
|
|
|
|
7.2 |
|
|
|
9.1 |
|
|
|
|
5.9 |
|
Other |
|
|
0.9 |
|
|
|
|
0.7 |
|
|
|
8.0 |
|
|
|
|
0.7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total amortized intangible assets |
|
|
336.1 |
|
|
|
|
87.7 |
|
|
|
356.6 |
|
|
|
|
65.7 |
|
Non-amortized trademarks |
|
|
74.4 |
|
|
|
|
|
|
|
|
116.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
$ 410.5 |
|
|
|
|
$ 87.7 |
|
|
|
$ 472.9 |
|
|
|
|
$ 65.7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Annual intangible amortization expense for the next five years will approximate $22.5 million in
2007, $21.0 million in 2008 and $19.3 million in 2009, 2010 and 2011, respectively.
80
Note 7
- DEBT
The companys debt is comprised of the following at December 31, 2006 and 2005:
|
|
|
|
|
|
|
|
|
|
|
2006 |
|
|
2005 |
|
Short-term debt: |
|
|
|
|
|
|
|
|
Yen
denominated, at weighted-average rates of 0.8% and 0.5% |
|
$ |
2.5 |
|
|
$ |
2.5 |
|
Other |
|
|
0.2 |
|
|
|
0.8 |
|
Current portion of long-term debt |
|
|
1.0 |
|
|
|
4.6 |
|
|
|
|
|
|
|
|
Total |
|
$ |
3.7 |
|
|
$ |
7.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Long-term debt: |
|
|
|
|
|
|
|
|
5.875% notes, due 2008, including
a fair value adjustment of $(1.1)
million and $(0.6) million
in 2006 and 2005,
respectively, for
unrealized losses on derivative hedge
instruments and remaining
unamortized gain on termination
of swaps of $5.2 million and $8.0
million in 2006 and 2005,
respectively |
|
$ |
204.1 |
|
|
$ |
207.4 |
|
|
|
|
|
|
|
|
|
|
4.625%
notes, due 2009, net of original issue discount of $0.2 million and $0.3
million in 2006 and 2005,
respectively, and fair
value
adjustments of $(4.1) million and
$(4.3) million for unrealized losses
on derivative hedge instruments
in 2006 and 2005, respectively |
|
|
377.5 |
|
|
|
395.4 |
|
|
|
|
|
|
|
|
|
|
5.5% notes, due 2014, net of
original issue discount of $2.4
million
and $2.7 million in 2006
and 2005, respectively |
|
|
447.6 |
|
|
|
447.3 |
|
|
|
|
|
|
|
|
|
|
7.25% debentures, due 2025 |
|
|
100.0 |
|
|
|
100.0 |
|
|
|
|
|
|
|
|
|
|
6.5% debentures, due 2034, net of
original issue discount of
$4.8 million and $4.9 million in
2006 and 2005,
respectively |
|
|
295.2 |
|
|
|
295.1 |
|
|
|
|
|
|
|
|
|
|
Debt supported by long-term
banking arrangements: |
|
|
|
|
|
|
|
|
Euro revolving credit borrowing, at EURIBOR plus
0.4% (4.1% and 2.9% at December 31,
2006 and 2005, respectively) |
|
|
112.2 |
|
|
|
215.6 |
|
Other |
|
|
2.4 |
|
|
|
6.7 |
|
|
|
|
|
|
|
|
|
|
|
1,539.0 |
|
|
|
1,667.5 |
|
Less current portion |
|
|
1.0 |
|
|
|
4.6 |
|
|
|
|
|
|
|
|
Total |
|
$ |
1,538.0 |
|
|
$ |
1,662.9 |
|
|
|
|
|
|
|
|
The scheduled principal payments for all outstanding debt are $3.7 million in 2007, $200.5 million
in 2008, $382.1 million in 2009, $112.5 million in 2010, $0.2 million in 2011 and $850.1 million
thereafter.
During the third quarter of 2006, the company repurchased $18.2 million of its 4.625% notes due in
2009. The weighted-average purchase price was 97.298% per note, resulting in a gain on retirement
of $0.5 million. The company also accelerated amortization of $0.6 million in debt issuance costs,
original issue discounts and losses on Treasury rate lock agreements associated with the
repurchased notes. The remaining outstanding balance on the 4.625% notes due in 2009 was $381.8
million as of December 31, 2006.
In September 2005, certain wholly owned international subsidiaries of the company entered into a
five-year unsecured committed 250.0 million revolving credit agreement. This credit agreement
permits these designated international subsidiaries to borrow at variable rates based on EURIBOR
plus a specified credit spread. In September 2006, two of the companys wholly owned foreign
subsidiaries amended their five-year unsecured committed 250.0 million credit
81
agreement such
that neither the company nor its subsidiaries are any longer subject to any investment or
acquisition restrictions. No other terms or conditions of the agreement were modified. As of
December 31, 2006 and 2005, borrowings of 85.0 million and 182.0 million were outstanding
under this agreement, respectively.
In November 2004, the company entered into interest rate swap agreements that effectively converted
the interest on $200.0 million of outstanding 4.625% notes due 2009 to a variable rate of six-month
LIBOR plus 40 basis points. In June 2004, the company entered into interest rate swap agreements
that effectively converted the interest on $200.0 million of outstanding 5.875% notes due 2008 to a
variable rate of six-month LIBOR plus 111 basis points. In addition, the company had an interest
rate swap agreement, which expired in October 2006, that exchanged variable-rate interest
obligations on a notional principal amount of Japanese yen 500.0 million for a fixed rate of 2.0%.
In September 2004, the company issued senior unsecured notes and debentures having an aggregate
principal amount of $1,150.0 million including: $400.0 million 4.625% notes due October 1, 2009;
$450.0 million 5.5% notes due October 1, 2014; and $300.0 million 6.5% debentures due October 1,
2034. The price to the public was 99.911% per 2009 note, 99.339% per 2014 note and 98.341% per
2034 debenture. The resulting original issue discount from the issuance of these notes and
debentures of $8.3 million was recorded as a reduction of the underlying debt issuances and is
being amortized over the life of the debt using the effective interest method. Interest is payable
semi-annually on April 1 and October 1 of each year, beginning April 1, 2005. The notes and
debentures have no sinking fund requirement, but are redeemable, in whole or in part, at the option
of the company. The proceeds from these notes and debentures were used to repay a portion of the
364-day credit facility that was utilized to bridge finance the Noveon International acquisition.
Including debt issuance costs, original issue discounts and losses on Treasury rate lock
agreements, the 2009 notes, 2014 notes and 2034 debentures have effective annualized interest rates
of approximately 5.3%, 6.3% and 6.7%, respectively, with a weighted-average interest rate for the
aggregate issuances of approximately 6.1%.
In August 2004, the company entered into a five-year $1,075.0 million unsecured bank credit
agreement consisting of: $575.0 million in term loans and a $500.0 million committed revolving
credit facility. This credit agreement permits the company to borrow at variable rates based upon
the U.S. prime rate or LIBOR plus a specified spread. The spread is dependent on the companys
long-term unsecured senior debt rating from Standard and Poors and Moodys Investor Services. In
September 2004, the company borrowed $575.0 million in term loans, the proceeds of which were used
to repay a portion of the 364-day credit facility used to bridge finance the Noveon International
acquisition. Principal on the term loans was due quarterly in equal installments of $14.4 million
beginning March 31, 2005, with any remaining unpaid balance due in September 2009. In the fourth
quarter of 2004, the company prepaid $75.0 million and, in 2005, the company prepaid the remaining
$500.0 million to pay off the bank term loan. The loans were prepayable at any time without
penalty. There were no outstanding revolving credit facility borrowings as of December 31, 2006
and 2005. In September 2006, the company amended its five-year unsecured committed U.S. bank
credit agreement to reduce the amount of revolving credit available under the agreement from $500.0
million to $350.0 million and extended the maturity date to September 2011. In addition, the
companys direct and indirect domestic subsidiaries were released as guarantors under the credit
agreement, and the company no longer is subject to any investment or acquisition restrictions. Due
to provisions in each of the three indentures underlying the companys outstanding public debt,
upon effectiveness of the amendment to the credit agreement described above, the companys direct
and indirect domestic subsidiaries were released as guarantors of the outstanding public debt
effective in September 2006.
In July 2002, the company terminated its interest rate swap agreements expiring December 2008,
which converted fixed-rate interest on $100.0 million of its 5.875% debentures to a variable rate.
In terminating the swaps, the company received cash of $18.1 million, which is being amortized as a
reduction of interest expense through December 1, 2008, the due date of the underlying debt. Gains
and losses on terminations of interest rate swap agreements designated as fair value hedges are
deferred as an adjustment to the carrying amount of the outstanding obligation and amortized as an
adjustment to interest expense related to the obligation over the remaining term of the original
contract life of the terminated swap agreement. In the event of early extinguishment of the
outstanding obligation, any unamortized gain or loss from the swaps would be recognized in the
consolidated statement of income at the time of such extinguishment. In 2002, the company recorded
a $17.3 million unrealized gain, net of accrued interest, on the termination of the interest rate
swaps as an increase in the underlying long-term debt. The remaining unrealized gain was $5.2
million and $8.0 million at December 31, 2006 and 2005, respectively.
In November 1998, the company issued notes having an aggregate principal amount of $200.0 million.
The notes are unsecured, senior obligations of the company that mature on December 1, 2008, and
bear interest at 5.875% per annum, payable semi-annually on June 1 and December 1 of each year.
The notes have no sinking fund requirement but are redeemable, in whole or in part, at the option
of the company. The company incurred debt issuance costs aggregating $10.5 million,
82
including a
loss of $6.5 million related to closed Treasury rate lock agreements originally entered into as a
hedge against changes in interest rates relative to the anticipated issuance of these notes.
The company has debentures outstanding, issued in June 1995, in an aggregate principal amount of
$100.0 million. These debentures are unsecured, senior obligations of the company that mature on
June 15, 2025, and bear interest at an annualized rate of 7.25%, payable semi-annually on June 15
and December 15 of each year. The debentures are not redeemable prior to maturity and are not
subject to any sinking fund requirements.
Interest paid, net of amounts capitalized, was $98.2 million, $104.3 million and $80.0 million
during 2006, 2005 and 2004, respectively. The company capitalizes interest on qualifying capital
projects. The amount of interest capitalized during 2006, 2005 and 2004 amounted to $1.5 million,
$0.7 million and $0.6 million, respectively.
Note 8 - FINANCIAL INSTRUMENTS
The company has various financial instruments, including cash and short-term investments,
investments in nonconsolidated companies, foreign currency forward contracts, commodity forward
contracts, interest rate swaps and short-term and long-term debt. The company has determined the
estimated fair value of these financial instruments by using available market information and
generally accepted valuation methodologies. The use of different market assumptions or estimation
methodologies could have a material effect on the estimated fair value amounts. The estimated fair
value of the companys debt instruments at December 31, 2006 and 2005 approximated $1,533.5 million
and $1,687.0 million, compared with the carrying value of $1,541.7 million and $1,670.8 million,
respectively.
The company is exposed to market risk from changes in interest rates. The companys policy is to
manage interest expense using a mix of fixed-rate and variable-rate debt. To manage this mix in a
cost-efficient manner, the company may enter into interest rate swaps in which the company agrees
to exchange, at specified intervals, the difference between fixed and variable interest amounts
calculated by reference to an agreed-upon notional principal amount. Interest payments receivable
and payable under the terms of the interest rate swap agreements are accrued over the period to
which the payment relates and the net difference is treated as an adjustment of interest expense
related to the underlying liability.
In November 2004, the company entered into interest rate swap agreements that effectively convert
the interest on $200.0 million of outstanding 4.625% notes due 2009 to a variable rate of six-month
LIBOR plus 40 basis points. The fair value of the interest rate swaps included in long-term debt
was $(4.1) million and $(4.3) million at December 31, 2006 and 2005, respectively. In June 2004,
the company entered into interest rate swap agreements that effectively convert the interest on
$200.0 million of outstanding 5.875% notes due 2008 to a variable rate of six-month LIBOR plus 111
basis points. The fair value of the interest rate swaps included in long-term debt was $(1.1)
million and $(0.6) million at December 31, 2006 and 2005, respectively. These swaps are designated
as fair-value hedges of underlying fixed-rate debt obligations and are recorded as an adjustment to
long-term debt and noncurrent assets or liabilities. These interest rate swaps qualify for the
short-cut method for assessing hedge effectiveness per SFAS No. 133, Accounting for Derivative
Instruments and Hedging Activities. Changes in fair value of the swaps are offset by the change
in fair value of the underlying debt. As a result, there was no impact to earnings in 2006 or 2005
due to hedge ineffectiveness.
The company also had an interest rate swap agreement that matured in October 2006 that exchanged
variable-rate interest obligations for a fixed rate on a notional principal amount of Japanese yen
500.0 million. This interest rate swap was designated as a cash-flow hedge.
In April 2004, the company terminated interest rate swap agreements resulting in a pretax charge of
$2.9 million recognized in 2004. The interest rate swap, which had an original expiration date of
March 2005, exchanged variable-rate interest obligations on a notional principal amount of $50.0
million for a fixed rate of 7.6%. The company terminated the interest rate swap as a result of the
companys debt and commercial paper credit rating being downgraded upon the announcement of the
Noveon International acquisition effectively eliminating the companys access to the commercial
paper market.
In June 2004, the company entered into several Treasury rate lock agreements with an aggregate
notional principal amount of $900.0 million, all maturing September 30, 2004, whereby the company
had locked in Treasury rates relating to a portion of the then anticipated public debt securities
issuance. These rate locks were designated as cash-flow hedges of the forecasted semi-annual
interest payments associated with the expected debt issuance. In September 2004, the company
incurred a pretax loss on the termination of these agreements in an aggregate amount of $73.9
million. Gains and losses on terminations of Treasury rate lock agreements designated as cash-flow
hedges are deferred and amortized as an adjustment to interest expense over the life of the
corresponding debt issuance using the effective interest method. The unamortized
83
balance of the Treasury rate lock recorded in accumulated other comprehensive income, net of tax,
was $41.2 million and $44.5 million at December 31, 2006 and 2005, respectively.
The company is exposed to the effect of changes in foreign currency rates on its earnings and cash
flow as a result of doing business internationally. In addition to working capital management,
pricing and sourcing, the company selectively uses foreign currency forward contracts to lessen the
potential effect of currency changes. The maximum amount of foreign currency forward contracts
outstanding at any one time was $35.5 million in 2006, $34.4 million in 2005 and $140.8 million in
2004. At December 31, 2006, the company had short-term forward contracts to buy or sell currencies
at various dates during 2007 for $28.8 million. At December 31, 2005, the company had short-term
forward contracts to buy or sell currencies at various dates during 2006 for $27.3 million.
Changes in the fair value of these contracts are recorded in other income. The fair value of these
instruments at December 31, 2006 and 2005, and the related adjustments recorded in other income,
were an unrealized gain (loss) of $0.2 million and $(0.2) million, respectively.
The company is exposed to market risk from changes in commodity prices. The company uses financial
instruments to manage the cost of natural gas and electricity purchases. These contracts have been
designated as cash-flow hedges and, accordingly, any effective unrealized gains or losses on open
contracts are recorded in other comprehensive income or loss, net of related tax effects. At
December 31, 2006 and 2005, the notional amounts of open contracts totaled $15.0 million and $10.1
million, respectively. A hedge liability of $1.9 million ($1.2 million net of tax) and $0.9
million ($0.6 million net of tax) was recorded at December 31, 2006 and 2005, respectively, which
represents the net unrealized losses or gains based upon current futures prices at that date.
Ineffectiveness was determined to be immaterial in 2006 and 2005. Contract maturities are less
than 12 months. As such, the company expects that all of these losses will be reclassified into
earnings within the next 12 months.
Note 9 - OTHER BALANCE SHEET INFORMATION
|
|
|
|
|
|
|
|
|
|
|
2006 |
|
|
2005 |
|
Receivables: |
|
|
|
|
|
|
|
|
Customers |
|
$ |
509.3 |
|
|
$ |
533.9 |
|
Affiliates |
|
|
4.0 |
|
|
|
8.1 |
|
Other |
|
|
60.3 |
|
|
|
43.6 |
|
|
|
|
|
|
|
|
Total |
|
$ |
573.6 |
|
|
$ |
585.6 |
|
|
|
|
|
|
|
|
Receivables are net of allowance for doubtful accounts of $7.5 million and $10.1 million at
December 31, 2006 and 2005, respectively.
|
|
|
|
|
|
|
|
|
|
|
2006 |
|
|
2005 |
|
Property and equipment - at cost:
|
|
|
|
|
|
|
|
|
Land and improvements |
|
$ |
177.0 |
|
|
$ |
178.0 |
|
Buildings and improvements |
|
|
457.8 |
|
|
|
456.2 |
|
Machinery and equipment |
|
|
1,820.2 |
|
|
|
1,912.2 |
|
Construction in progress |
|
|
91.0 |
|
|
|
75.1 |
|
|
|
|
|
|
|
|
Total |
|
$ |
2,546.0 |
|
|
$ |
2,621.5 |
|
|
|
|
|
|
|
|
Depreciation expense of property and equipment from continuing operations was $133.3 million,
$139.4 million and $115.4 million in 2006, 2005 and 2004, respectively. Depreciation expense of
property and equipment from discontinued operations was $4.4 million, $15.2 million and $21.3
million in 2006, 2005 and 2004, respectively.
84
|
|
|
|
|
|
|
|
|
|
|
|
2006 |
|
|
|
2005 |
|
Accrued expenses and other current liabilities: |
|
|
|
|
|
|
|
|
Employee compensation |
|
|
$ 108.1 |
|
|
|
$ 99.4 |
|
Income taxes |
|
|
48.5 |
|
|
|
56.3 |
|
Sales allowances and rebates |
|
|
33.8 |
|
|
|
30.3 |
|
Taxes other than income |
|
|
31.2 |
|
|
|
31.2 |
|
Interest |
|
|
17.9 |
|
|
|
17.6 |
|
Other |
|
|
50.7 |
|
|
|
50.8 |
|
|
|
|
|
|
|
|
|
|
Total |
|
|
$ 290.2 |
|
|
|
$ 285.6 |
|
|
|
|
|
|
|
|
|
|
Dividends payable at December 31, 2006 and 2005 were $17.9 million and $17.7 million, respectively,
and are included in accounts payable in the consolidated balance sheet.
Note 10 - SHAREHOLDERS EQUITY
The company has 147.0 million authorized shares consisting of 2.0 million shares of serial
preferred stock, 25.0 million shares of serial preference shares and 120.0 million common shares,
each of which is without par value. Common shares outstanding exclude common shares held in
treasury of 17.2 million and 18.2 million at December 31, 2006 and 2005, respectively.
In September 2004, the company issued and sold 13.4 million common shares at a price of $33.25 per
share. Net proceeds from the sale of common shares were $427.2 million and were used primarily to
repay the temporary bridge loan that financed a portion of the Noveon International acquisition.
In October 2004, the company issued an additional 1.3 million common shares at a price of $33.25
per share due to the exercise of the over-allotment option relating to the September common share
offering. This issuance generated net proceeds to the company of $42.8 million, which were
utilized to prepay $40.0 million in term loan debt.
The company has a shareholder rights plan under which one right to buy one-half common share has
been distributed for each common share held. The rights may become exercisable under certain
circumstances involving actual or potential acquisitions of 20% or more of the common shares by a
person or affiliated persons who acquire stock without complying with the requirements of the
companys articles of incorporation. The rights would entitle shareholders, other than this person
or affiliated persons, to purchase common shares of the company or of certain acquiring persons at
50% of the then current market value. At the option of the directors, the rights may be exchanged
for common shares, and may be redeemed in cash, securities or other consideration. The rights will
expire in October 2007.
85
Accumulated other comprehensive (loss) income shown in the consolidated statements of shareholders
equity at December 31, 2006, 2005 and 2004 is comprised of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized |
|
Unrecognized |
|
|
|
|
Foreign |
|
|
|
|
|
Gains |
|
Pension Plan |
|
Accumulated |
|
|
Currency |
|
Treasury |
|
(Losses) |
|
and Other |
|
Other |
|
|
Translation |
|
Rate |
|
on Interest |
|
Postretirement |
|
Comprehensive |
|
|
Adjustment |
|
Locks |
|
Rate Swaps |
|
Benefit Costs |
|
(Loss) Income |
Balance,
January 1, 2004, as previously reported |
|
|
$ (4.1 |
) |
|
|
$ |
|
|
|
$ (1.8 |
) |
|
|
$ (30.1 |
) |
|
|
$ (36.0 |
) |
Restatement adjustments, see Note 20 |
|
|
(1.8 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1.8 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, January 1, 2004, as restated |
|
|
(5.9 |
) |
|
|
|
|
|
|
(1.8 |
) |
|
|
(30.1 |
) |
|
|
(37.8 |
) |
Other comprehensive
income (loss): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pretax |
|
|
96.5 |
|
|
|
(72.9 |
) |
|
|
3.2 |
|
|
|
1.9 |
|
|
|
28.7 |
|
Tax benefit (provision) |
|
|
(1.9 |
) |
|
|
25.5 |
|
|
|
(1.1 |
) |
|
|
(0.7 |
) |
|
|
21.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
94.6 |
|
|
|
(47.4 |
) |
|
|
2.1 |
|
|
|
1.2 |
|
|
|
50.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, December 31, 2004, as restated |
|
|
88.7 |
|
|
|
(47.4 |
) |
|
|
0.3 |
|
|
|
(28.9 |
) |
|
|
12.7 |
|
Other comprehensive
(loss) income: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pretax |
|
|
(117.3 |
) |
|
|
4.4 |
|
|
|
|
|
|
|
(19.1 |
) |
|
|
(132.0 |
) |
Tax benefit (provision) |
|
|
1.9 |
|
|
|
(1.5 |
) |
|
|
|
|
|
|
5.4 |
|
|
|
5.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
(115.4 |
) |
|
|
2.9 |
|
|
|
|
|
|
|
(13.7 |
) |
|
|
(126.2 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, December 31, 2005, as restated |
|
|
(26.7 |
) |
|
|
(44.5 |
) |
|
|
0.3 |
|
|
|
(42.6 |
) |
|
|
(113.5 |
) |
Other comprehensive
income (loss): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pretax |
|
|
79.2 |
|
|
|
5.0 |
|
|
|
|
|
|
|
46.8 |
|
|
|
131.0 |
|
Tax benefit (provision) |
|
|
0.1 |
|
|
|
(1.7 |
) |
|
|
|
|
|
|
(13.9 |
) |
|
|
(15.5 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
79.3 |
|
|
|
3.3 |
|
|
|
|
|
|
|
32.9 |
|
|
|
115.5 |
|
Adjustment to recognize
pension and other postretirement
benefit plans funded status: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pretax |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(92.8 |
) |
|
|
(92.8 |
) |
Tax benefit |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30.0 |
|
|
|
30.0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(62.8 |
) |
|
|
(62.8 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, December 31, 2006, as restated |
|
|
$ 52.6 |
|
|
|
$ (41.2 |
) |
|
|
$ 0.3 |
|
|
|
$ (72.5 |
) |
|
|
$ (60.8 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
86
Note 11 - OTHER INCOME - NET
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2006 |
|
|
|
2005 |
|
|
|
2004 |
|
Settlement of insurance and legal matters |
|
|
$ 10.4 |
|
|
|
$ |
|
|
|
$ |
|
Currency exchange / transaction (loss) gain |
|
|
(2.9 |
) |
|
|
(0.6 |
) |
|
|
6.6 |
|
Equity earnings of nonconsolidated
companies |
|
|
1.0 |
|
|
|
0.8 |
|
|
|
0.8 |
|
Other - net |
|
|
|
|
|
|
1.6 |
|
|
|
(1.8 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
$ 8.5 |
|
|
|
$ 1.8 |
|
|
|
$ 5.6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dividends received from nonconsolidated companies were $0.2 million in 2006, $0.9 million in 2005
and $0.4 million in 2004.
Note 12 - INCOME TAXES
Income from continuing operations before income taxes consists of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2006 |
|
|
|
2005 |
|
|
|
2004 |
|
United States |
|
|
$ 75.5 |
|
|
|
$ 40.2 |
|
|
|
$ 32.2 |
|
Foreign |
|
|
186.5 |
|
|
|
200.0 |
|
|
|
102.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
$ 262.0 |
|
|
|
$ 240.2 |
|
|
|
$ 134.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The provision for income taxes from continuing operations consists of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2006 |
|
|
|
2005 |
|
|
|
2004 |
|
Current: |
|
|
|
|
|
|
|
|
|
|
|
|
United States: |
|
|
|
|
|
|
|
|
|
|
|
|
Federal |
|
|
$ (3.9 |
) |
|
|
$ 4.0 |
|
|
|
$ 1.4 |
|
State |
|
|
(0.7 |
) |
|
|
(0.2 |
) |
|
|
1.4 |
|
Foreign |
|
|
48.2 |
|
|
|
67.5 |
|
|
|
40.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
43.6 |
|
|
|
71.3 |
|
|
|
43.7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred: |
|
|
|
|
|
|
|
|
|
|
|
|
United States: |
|
|
|
|
|
|
|
|
|
|
|
|
Federal |
|
|
28.6 |
|
|
|
9.5 |
|
|
|
17.5 |
|
State |
|
|
8.5 |
|
|
|
6.1 |
|
|
|
(1.0 |
) |
Foreign |
|
|
1.5 |
|
|
|
(6.1 |
) |
|
|
(11.2 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
38.6 |
|
|
|
9.5 |
|
|
|
5.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
$ 82.2 |
|
|
|
$ 80.8 |
|
|
|
$ 49.0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
87
The differences between the provision for income taxes at the U.S. statutory rate and the tax shown
in the consolidated statements of income are summarized as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2006 |
|
|
|
2005 |
|
|
|
2004 |
|
Tax at statutory rate of 35% |
|
|
$ 91.7 |
|
|
|
$ 84.1 |
|
|
|
$ 47.1 |
|
U.S. and foreign tax on foreign dividends |
|
|
7.7 |
|
|
|
8.1 |
|
|
|
13.8 |
|
U.S. tax benefit on exports |
|
|
(4.1 |
) |
|
|
(5.0 |
) |
|
|
(1.8 |
) |
State and local income taxes |
|
|
5.1 |
|
|
|
3.8 |
|
|
|
0.3 |
|
Untaxed translation gains |
|
|
(0.5 |
) |
|
|
(0.8 |
) |
|
|
(2.5 |
) |
Provision impacts of foreign operations |
|
|
(19.3 |
) |
|
|
(11.4 |
) |
|
|
(7.9 |
) |
Other - net |
|
|
1.6 |
|
|
|
2.0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Provision for income taxes |
|
|
$ 82.2 |
|
|
|
$ 80.8 |
|
|
|
$ 49.0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The tax effects of temporary differences that give rise to significant portions of deferred tax
assets and liabilities at December 31 are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2006 |
|
|
|
2005 |
|
Deferred tax assets: |
|
|
|
|
|
|
|
|
|
|
|
|
Accrued compensation and benefits |
|
|
|
|
|
|
$ 148.4 |
|
|
|
$ 116.6 |
|
Inventory |
|
|
|
|
|
|
22.4 |
|
|
|
16.7 |
|
Cash flow hedges |
|
|
|
|
|
|
22.9 |
|
|
|
24.3 |
|
Net operating losses and tax credits carried forward |
|
|
|
|
|
|
29.9 |
|
|
|
94.9 |
|
Other |
|
|
|
|
|
|
23.8 |
|
|
|
27.0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total gross deferred tax assets |
|
|
|
|
|
|
247.4 |
|
|
|
279.5 |
|
Less valuation allowance |
|
|
|
|
|
|
(17.8 |
) |
|
|
(18.1 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net deferred tax assets |
|
|
|
|
|
|
229.6 |
|
|
|
261.4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred tax liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and other basis differences |
|
|
|
|
|
|
203.8 |
|
|
|
233.5 |
|
Foreign subsidiary and affiliate undistributed earnings |
|
|
|
|
|
|
7.9 |
|
|
|
6.5 |
|
Other |
|
|
|
|
|
|
11.9 |
|
|
|
13.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total gross deferred tax liabilities |
|
|
|
|
|
|
223.6 |
|
|
|
253.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net deferred tax assets |
|
|
|
|
|
|
$ 6.0 |
|
|
|
$ 7.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At December 31, 2006, the company had U.S. tax credit carryforwards and state and foreign net
operating loss carryforwards (NOLs). The companys U.S. tax credits totaled $15.3 million, of
which $8.4 million expire in 2007 through 2026, and $6.9 million have no expiration. The company
had $9.3 million of state tax benefit from NOLs, which expire in 2007 through 2026. Foreign NOLs
totaled $18.6 million, of which $15.0 million expire in 2008 through 2021 and $3.6 million, which
can be carried forward indefinitely. Additionally, the company has incurred losses in a foreign
jurisdiction where realization of the future economic benefit is so remote that the benefit is not
reflected as a deferred tax asset.
Gross deferred tax assets as of December 31, 2006 and 2005 were reduced by valuation allowances of
$17.8 million and $18.1 million, respectively, to reflect the amounts expected to be realized. Of
the $17.8 million in valuation allowances at December 31, 2006, $10.2 million relates to certain
Noveon International deferred tax assets existing at the time of the 2004 acquisition. Any
reversal of this portion of the valuation allowance reduces goodwill. No valuation allowance has
been recognized against the U.S. tax credits because management believes that the company will
generate sufficient future taxable income during the carryforward period in order to utilize these
credits.
88
U.S. income taxes and foreign withholding taxes are not provided on undistributed earnings of
foreign subsidiaries, which are considered to be indefinitely reinvested in the operations of such
subsidiaries. The amount of these earnings was approximately $718.3 million at December 31, 2006.
Determination of the net amount of unrecognized taxes with respect to these earnings is not
practicable.
Income taxes paid during 2006, 2005 and 2004 were $72.9 million, $75.7 million and $34.6 million,
respectively.
Note 13 - PENSION, PROFIT SHARING AND OTHER POSTRETIREMENT BENEFIT PLANS
The company has noncontributory defined benefit pension plans covering most employees. Pension
benefits under these plans are based on years of service and the employees compensation. The
companys funding policy in the United States is to contribute amounts to satisfy the funding
standards of the Internal Revenue Code of 1986, as amended (IRC), and the Employee Retirement
Income Security Act of 1974, as amended, and elsewhere to fund amounts in accordance with local
regulations. Several of the companys smaller defined benefit plans are not funded.
The investment objective of the funded pension plans sponsored by the company and certain
subsidiaries is to assure the timely payment of promised benefits at a minimum cost consistent with
prudent standards of investment, given the strength of the company and the subsidiaries, their
earnings record, the adequacy of each plans funding and the age of each entitys work force. The
plans utilize diversified investment portfolios and seek to earn returns consistent with a
reasonable level of risk. The long-term expected return on plan assets used to determine the net
periodic pension cost is based upon each entitys investment allocation and anticipated returns for
specific investment classes. In 2006, the company lowered the expected long-term rate of return
assumption for the U.S. pension plans 25 basis points to 8.25% (7.48% on a weighted-average basis
for all plans) based on investment mix and projected market conditions.
As long-term asset allocation is recognized as the primary determinant of performance, the
sponsoring entities generally utilize the following asset allocation targets to achieve their plan
investment objectives: 70% equity securities and 30% debt securities. The non-U.S. plans have a
slightly higher allocation to debt securities than the U.S. plans. As appropriate, allocation
targets and ranges may be established for various subcategories. Allocations are reviewed
periodically and adjusted as necessary. In January 2005, the company transferred the Noveon
International U.S. pension assets into one master trust arrangement with the companys existing
U.S. pension plans. As a result, the combined assets are subject to the same overall investment
strategy and management.
Approved pension plan investments include, but are not limited to: equities, fixed-income
securities, venture capital, cash and cash equivalent instruments and such other instruments
(including mutual fund investments), as the company may approve. Investments in tax-exempt
securities, commodities and options, other than covered calls, and the use of leverage are
prohibited. Plan investment managers may use derivatives to hedge currency risk and to maintain
full investment. Any other use of derivative instruments must be approved by the sponsoring
entity.
The market values of pension plan assets are compared periodically to the value of plan benefit
obligations. The future value of assets, as calculated based on the expected long-term rate of
return, are also compared to expected future plan benefit distributions and contributions to
determine the sufficiency of expected plan funding levels. Investment asset allocations are
revised as appropriate.
Plan assets are invested in marketable equity securities and fixed-income instruments. The
allocation of pension plan assets by major asset class is shown below on a weighted-average basis:
|
|
|
|
|
|
|
|
|
|
|
|
Percentage of Plan |
|
|
|
Assets |
|
|
|
at December 31 |
|
|
|
|
2006 |
|
|
|
2005 |
|
Asset
category: |
|
|
|
|
|
|
|
|
Equity securities |
|
|
73 |
% |
|
|
72 |
% |
Debt securities |
|
|
27 |
% |
|
|
28 |
% |
|
|
|
|
|
|
|
|
|
Total |
|
|
100 |
% |
|
|
100 |
% |
|
|
|
|
|
|
|
|
|
No equity or debt securities of the company or any of its subsidiaries were included in the pension
plans assets in 2006 and 2005, respectively.
89
The company also provides certain non-pension postretirement benefits, primarily health care and
life insurance benefits, for retired employees. Most of the legacy Lubrizol full-time employees in
the United States may become eligible for health care benefits upon retirement. Full-time
employees who retired between January 1, 1992 and December 31, 2002 are also eligible for life
insurance benefits. Participants contribute a portion of the cost of these benefits. The
companys non-pension postretirement benefit plans are not funded. As part of the Noveon
International integration efforts to provide consistent benefits, the company communicated to
employees in May 2005 changes to the benefits structure of certain of its U.S. pension and
postretirement benefit plans. This communication triggered a remeasurement of the related benefit
obligations and net periodic benefit cost in 2005 for both the legacy Noveon International U.S.
pension plans as well as for the U.S. postretirement benefit plan. The net impact of the benefit
and actuarial assumption changes reduced the companys aggregate net periodic pension and
postretirement benefit cost by $3.5 million in 2005. The annualized savings resulting from this
benefits change is estimated to be approximately $5.3 million.
In September 2006, the FASB issued SFAS No. 158, Employers Accounting for Defined Benefit Pension
and Other Postretirement Plans - an amendment of FASB Statements No. 87, 88, 106, and 132(R).
SFAS No. 158 requires an employer to recognize a plans funded status in its statement of financial
position, measure a plans assets and obligations as of the end of the employers fiscal year and
recognize the changes in a plans funded status in comprehensive income in the year in which the
changes occur. SFAS No. 158s requirement to recognize a plans funded status and new disclosure
requirements are effective for the company as of December 31, 2006. The requirement to measure
plan assets and benefit obligations as of the date of the companys fiscal year-end statement of
financial position is effective for fiscal years ending after December 15, 2008. Currently, the
company measures plan assets as of the date of its fiscal year-end. The company adopted the
required provisions of SFAS No. 158 on December 31, 2006.
The incremental effects of adopting SFAS No. 158 on the companys consolidated balance sheet at
December 31, 2006 were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance Before |
|
|
|
|
|
Balance After |
|
|
Applying |
|
SFAS No. 158 |
|
Applying |
|
|
SFAS No. 158 |
|
Adjustments |
|
SFAS No. 158 |
Current assets: |
|
|
|
|
|
|
|
|
|
|
|
|
Other current assets |
|
$ |
104.9 |
|
|
$ |
(6.9 |
) |
|
$ |
98.0 |
|
Noncurrent assets: |
|
|
|
|
|
|
|
|
|
|
|
|
Other assets |
|
$ |
65.5 |
|
|
$ |
1.2 |
|
|
$ |
66.7 |
|
Intangible assets - net |
|
$ |
329.2 |
|
|
$ |
(6.4 |
) |
|
$ |
322.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets |
|
$ |
4,403.0 |
|
|
$ |
(12.1 |
) |
|
$ |
4,390.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
Accrued expenses and other current liabilities |
|
$ |
287.2 |
|
|
$ |
3.0 |
|
|
$ |
290.2 |
|
Noncurrent liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
Pension obligations |
|
$ |
149.1 |
|
|
$ |
88.8 |
|
|
$ |
237.9 |
|
Other postretirement health care obligations |
|
$ |
104.7 |
|
|
$ |
(11.2 |
) |
|
$ |
93.5 |
|
Deferred income taxes |
|
$ |
110.3 |
|
|
$ |
(29.9 |
) |
|
$ |
80.4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities |
|
$ |
2,605.8 |
|
|
$ |
50.7 |
|
|
$ |
2,656.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated other comprehensive income (loss) |
|
$ |
2.0 |
|
|
$ |
(62.8 |
) |
|
$ |
(60.8 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total shareholders equity |
|
$ |
1,745.9 |
|
|
$ |
(62.8 |
) |
|
$ |
1,683.1 |
|
90
The change in the projected benefit obligation and plan assets for 2006 and 2005 and the amounts
recognized in the consolidated balance sheets at December 31 of the companys defined benefit
pension and non-pension postretirement plans were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pension Plans |
|
|
Other Benefits |
|
|
|
2006 |
|
|
2005 |
|
|
2006 |
|
|
2005 |
|
Change in Projected Benefit Obligation: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Projected benefit obligation at
beginning of year |
|
$ |
659.8 |
|
|
$ |
576.2 |
|
|
$ |
103.2 |
|
|
$ |
131.5 |
|
Service cost |
|
|
31.7 |
|
|
|
29.3 |
|
|
|
1.8 |
|
|
|
2.2 |
|
Interest cost |
|
|
34.9 |
|
|
|
32.2 |
|
|
|
5.4 |
|
|
|
6.4 |
|
Plan participants contributions |
|
|
0.9 |
|
|
|
0.8 |
|
|
|
3.6 |
|
|
|
3.3 |
|
Actuarial (gain) loss |
|
|
(21.0 |
) |
|
|
76.1 |
|
|
|
(0.7 |
) |
|
|
(8.5 |
) |
Currency exchange rate change |
|
|
35.0 |
|
|
|
(29.3 |
) |
|
|
1.1 |
|
|
|
(1.0 |
) |
Plan amendments |
|
|
2.5 |
|
|
|
2.3 |
|
|
|
|
|
|
|
(22.1 |
) |
Settlements / curtailments |
|
|
(2.8 |
) |
|
|
(1.0 |
) |
|
|
(1.5 |
) |
|
|
|
|
Divestitures |
|
|
(3.6 |
) |
|
|
|
|
|
|
(6.2 |
) |
|
|
|
|
Benefits paid |
|
|
(26.4 |
) |
|
|
(26.8 |
) |
|
|
(8.4 |
) |
|
|
(8.6 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Benefit obligation at end of year |
|
|
711.0 |
|
|
|
659.8 |
|
|
|
98.3 |
|
|
|
103.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in Plan Assets: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value of plan assets at beginning of year |
|
|
401.1 |
|
|
|
358.7 |
|
|
|
|
|
|
|
|
|
Actual return on plan assets |
|
|
50.6 |
|
|
|
46.1 |
|
|
|
|
|
|
|
|
|
Employer contributions |
|
|
24.0 |
|
|
|
38.7 |
|
|
|
4.8 |
|
|
|
5.3 |
|
Settlements |
|
|
|
|
|
|
(0.9 |
) |
|
|
|
|
|
|
|
|
Plan participants contributions |
|
|
0.9 |
|
|
|
0.8 |
|
|
|
3.6 |
|
|
|
3.3 |
|
Currency exchange rate change |
|
|
19.9 |
|
|
|
(15.5 |
) |
|
|
|
|
|
|
|
|
Adjustments |
|
|
1.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Benefits paid |
|
|
(26.4 |
) |
|
|
(26.8 |
) |
|
|
(8.4 |
) |
|
|
(8.6 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value of plan assets at end of year |
|
|
471.3 |
|
|
|
401.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Funded Status |
|
$ |
(239.7 |
) |
|
|
(258.7 |
) |
|
$ |
(98.3 |
) |
|
|
(103.2 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Items not yet recognized as a component of net periodic
pension and other postretirement benefit cost (credit): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrecognized net loss |
|
$ |
92.3 |
|
|
|
150.0 |
|
|
|
27.2 |
|
|
|
35.5 |
|
Unrecognized net transition obligation |
|
|
0.4 |
|
|
|
1.0 |
|
|
|
2.9 |
|
|
|
3.3 |
|
Unrecognized prior service cost (credit) |
|
|
25.0 |
|
|
|
24.8 |
|
|
|
(41.4 |
) |
|
|
(49.7 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
117.7 |
|
|
|
175.8 |
|
|
$ |
(11.3 |
) |
|
|
(10.9 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net amounts recognized |
|
|
|
|
|
$ |
(82.9 |
) |
|
|
|
|
|
$ |
(114.1 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net amounts recognized in the
consolidated balance sheets: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Prepaid benefit cost |
|
$ |
1.0 |
|
|
$ |
0.3 |
|
|
$ |
|
|
|
$ |
|
|
Intangible asset |
|
|
|
|
|
|
7.5 |
|
|
|
|
|
|
|
|
|
Accrued benefit liability |
|
|
(240.7 |
) |
|
|
(151.5 |
) |
|
|
(98.3 |
) |
|
|
(114.1 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Funded Status |
|
$ |
(239.7 |
) |
|
|
|
|
|
$ |
(98.3 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated other comprehensive loss |
|
|
|
|
|
|
60.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net amounts recognized |
|
|
|
|
|
$ |
(82.9 |
) |
|
|
|
|
|
$ |
(114.1 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
91
The accumulated benefit obligation for all defined benefit pension plans was $554.6 million and
$528.7 million at December 31, 2006 and 2005, respectively. The projected benefit obligation and
fair value of plan assets for pension plans with projected benefit obligations in excess of plan
assets were $697.4 million and $456.6 million, respectively, at December 31, 2006, and $655.8
million and $396.5 million, respectively, at December 31, 2005. The accumulated benefit obligation
and fair value of plan assets for pension plans with accumulated benefit obligations in excess of
plan assets were $539.0 million and $450.6 million, respectively, at December 31, 2006 and $321.6
million and $190.0 million, respectively, at December 31, 2005.
The company amortizes gains and losses, as well as the effects of changes in actuarial assumptions
and plan provisions, over the average remaining service period of participating employees expected
to receive benefits under the plans.
Net periodic pension cost of the companys defined benefit pension plans consists of:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2006 |
|
|
2005 |
|
|
2004 |
|
Service cost - benefits earned during period |
|
$ |
31.7 |
|
|
$ |
29.3 |
|
|
$ |
23.3 |
|
Interest cost on projected benefit obligation |
|
|
34.9 |
|
|
|
32.2 |
|
|
|
28.7 |
|
Expected return on plan assets |
|
|
(28.3 |
) |
|
|
(26.9 |
) |
|
|
(27.5 |
) |
Amortization of prior service costs |
|
|
2.5 |
|
|
|
2.4 |
|
|
|
1.8 |
|
Amortization of initial net obligation (asset) |
|
|
0.7 |
|
|
|
0.7 |
|
|
|
(0.1 |
) |
Recognized net actuarial loss |
|
|
8.5 |
|
|
|
5.5 |
|
|
|
3.8 |
|
Settlement / curtailment loss |
|
|
2.9 |
|
|
|
0.3 |
|
|
|
7.7 |
|
|
|
|
|
|
|
|
|
|
|
Net periodic pension cost |
|
$ |
52.9 |
|
|
$ |
43.5 |
|
|
$ |
37.7 |
|
|
|
|
|
|
|
|
|
|
|
|
The company recorded a $7.7 million settlement charge in 2004 primarily associated with workforce
reductions announced in June 2004 in the United States. |
|
The amount of net loss and prior service cost that is expected to be recognized as a component of
net periodic benefit cost in 2007 is $4.9 million and $2.7 million, respectively. |
|
Net periodic non-pension postretirement benefit cost consists of: |
|
|
2006 |
|
|
2005 |
|
|
2004 |
|
Service cost - benefits earned during period |
|
$ |
1.8 |
|
|
$ |
2.2 |
|
|
$ |
2.9 |
|
Interest cost on projected benefit obligation |
|
|
5.4 |
|
|
|
6.4 |
|
|
|
7.3 |
|
Amortization of prior service credits |
|
|
(8.4 |
) |
|
|
(7.7 |
) |
|
|
(6.3 |
) |
Amortization of initial net obligation |
|
|
0.4 |
|
|
|
0.4 |
|
|
|
0.4 |
|
Recognized net actuarial loss |
|
|
1.8 |
|
|
|
2.1 |
|
|
|
2.5 |
|
Settlement / curtailment loss |
|
|
(1.1 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net periodic non-pension postretirement benefit (credit) cost |
|
$ |
(0.1 |
) |
|
$ |
3.4 |
|
|
$ |
6.8 |
|
|
|
|
|
|
|
|
|
|
|
The amount of net loss, prior service cost (credit) and transition obligation that is expected to
be recognized as a component of net periodic non-pension postretirement benefit cost (credit) in
2007 is $1.3 million, $(6.8) million and $0.4 million, respectively.
92
The companys actuarial assumptions used to determine benefit obligations and earnings effects for
its defined benefit pension and non-pension postretirement plans are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pension Plans |
|
|
Other Benefits |
|
|
2006 |
|
2005 |
|
2006 |
|
2005 |
The weighted-average assumptions used to determine
benefit obligations at December 31: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Measurement date |
|
|
12/31 |
|
|
|
12/31 |
|
|
|
12/31 |
|
|
|
12/31 |
|
Discount rate |
|
|
5.63 |
% |
|
|
5.25 |
% |
|
|
5.99 |
% |
|
|
5.50 |
% |
Rate of compensation increase |
|
|
3.99 |
% |
|
|
3.92 |
% |
|
|
* |
|
|
|
* |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The weighted-average assumptions used to determine
net periodic benefit cost for years ended December 31: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Discount rate |
|
|
5.25 |
% |
|
|
5.72 |
% |
|
|
5.50 |
% |
|
|
6.20 |
% |
Expected long-term return on plan assets |
|
|
7.48 |
% |
|
|
7.71 |
% |
|
|
* |
|
|
|
* |
|
Rate of compensation increase |
|
|
3.92 |
% |
|
|
4.03 |
% |
|
|
* |
|
|
|
* |
|
* Disclosure not applicable
The following table shows the amounts the company contributed to its postretirement plans in 2005
and 2006 and the expected contributions for 2007:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pension |
|
Other |
|
|
|
|
Plans |
|
Plans |
|
Total |
2005 |
|
|
$ 38.7 |
|
|
|
$ 6.4 |
|
|
|
$ 45.1 |
|
2006 |
|
|
24.0 |
|
|
|
4.8 |
|
|
|
28.8 |
|
2007 (expected) |
|
|
61.3 |
|
|
|
4.8 |
|
|
|
66.1 |
|
Expected employer contributions for pension benefits in 2007 include $1.8 million for unfunded
plans. The expected contributions to these plans represent an actuarial estimate of future assumed
payments based on historic retirement and payment patterns. Actual amounts paid could differ from
this estimate.
Contributions by participants to the other benefit plans were $3.6 million and $3.3 million for the
years ended December 31, 2006 and 2005, respectively.
The following table shows the benefits expected to be paid in each of the next five years and the
aggregate benefits expected to be paid for the subsequent five years:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pension |
|
Other |
|
Total |
|
|
Benefits |
|
Benefits |
|
Benefits |
2007 |
|
|
$ 28.8 |
|
|
|
$ 4.8 |
|
|
|
$ 33.6 |
|
2008 |
|
|
30.4 |
|
|
|
5.1 |
|
|
|
35.5 |
|
2009 |
|
|
32.6 |
|
|
|
5.5 |
|
|
|
38.1 |
|
2010 |
|
|
36.8 |
|
|
|
5.9 |
|
|
|
42.7 |
|
2011 |
|
|
38.7 |
|
|
|
6.4 |
|
|
|
45.1 |
|
2012-2016 |
|
|
225.7 |
|
|
|
37.1 |
|
|
|
262.8 |
|
The other benefits in the above table are presented net of expected Medicare Part D subsidy
payments of $0.7 million in 2007, $0.8 million in 2008, $0.9 million in 2009, $1.0 million in 2010,
$1.1 million in 2011 and $6.7 million in 2012 - 2016. The weighted average of the assumed health
care cost trend rates used in measuring the accumulated
93
postretirement benefit obligation for the companys postretirement benefit plans at December 31,
2006 was 9.11% (8.01% at December 31, 2005), with subsequent annual decrements to an ultimate trend
rate of 5.14% by 2012. The assumed health care cost trend rates have a significant effect on the
amounts reported for the health care plans. A one-percentage-point change in the assumed health
care cost trend rate would have the following effects as of and for the year ended December 31,
2006:
|
|
|
|
|
|
|
|
|
|
|
One-Percentage-Point |
|
|
|
Increase |
|
|
Decrease |
|
Effect on postretirement benefit obligation |
|
$ 11.9 |
|
|
$ (10.2) |
Effect on total service and interest cost components |
|
$ 0.9 |
|
|
$ (0.8) |
The company also has defined contribution plans, principally involving profit sharing plans and /
or 401(k) savings plans, covering most employees in the United States and at certain non-U.S.
subsidiaries. Expense for all defined contribution retirement plans was $16.3 million in 2006,
$15.3 million in 2005 and $12.8 million in 2004.
Note 14 - LEASES
The company has commitments under operating leases primarily for office space, terminal facilities,
land, railcars and various computer and office equipment. Rental expense from continuing
operations was $26.4 million in 2006, $28.2 million in 2005 and $25.3 million in 2004. Future
minimum rental commitments under operating leases having initial or remaining non-cancelable lease
terms exceeding one year are $17.1 million in 2007, $13.8 million in 2008, $9.2 million in 2009,
$8.0 million in 2010, $5.6 million in 2011 and $8.6 million thereafter.
Note 15 - SEGMENT AND GEOGRAPHIC INFORMATION
The company is organized into two operating and reporting segments. The company changed the names
of its two reporting segments in 2007. The new segment names are Lubrizol Additives, previously
known as Lubricant Additives, and Lubrizol Advanced Materials, previously known as Specialty
Chemicals. The change was in name only as the management structure of the segments and product
lines included in each segment remained unchanged. The Lubrizol Additives segment represented 64%
of the companys consolidated revenues for 2006 and is comprised of the companys businesses in
engine additives and driveline and industrial oil additives. The Lubrizol Advanced Materials
segment represented 36% of the companys consolidated revenues for 2006 and is comprised of the
businesses in Noveon consumer specialties, engineered polymers and performance coatings.
Lubrizol Additives consists of two product lines: engine additives and driveline and industrial oil
additives. Engine additives is comprised of additives for lubricating engine oils, such as for
gasoline, diesel, marine and stationary gas engines and additive components, additives for fuel
products and refinery and oil field chemicals, as well as outsourcing strategies for supply chain
and knowledge center management. In addition, this product line sells additive components and
viscosity improvers within its lubricant and fuel additives product areas. Driveline and
industrial oil additives is comprised of additives for driveline oils, such as automatic
transmission fluids, gear oils and tractor lubricants and industrial oil additives, such as
additives for hydraulic, grease and metalworking fluids, as well as compressor lubricants.
Lubrizol Additives product lines generally are produced in company-owned shared manufacturing
facilities and largely sold to a common customer base. During 2005, the company sold the equipment
companies, ECS and LPS, and recorded the results of operations of these businesses in the (loss)
income from discontinued operations - net of tax line item in the consolidated statements of income
in 2005 and 2004 (see Note 4).
The Lubrizol Advanced Materials segment consists of Noveon consumer specialties, engineered
polymers and performance coatings product lines. The Noveon consumer specialties product line is
characterized by global production of acrylic thickeners, specialty monomers, film formers,
fixatives, emollients, silicones, surfactants, botanicals and process chemicals. The company
markets products in the Noveon consumer specialties product line to the personal care and
pharmaceutical primary end-use industries. The Noveon consumer specialties products are sold to
customers worldwide and these customers include major manufacturers of cosmetics, personal care
products, water soluble polymers and household products. The engineered polymers product line is
characterized by products such as TempRite® engineered polymers and Estane® thermoplastic
polyurethane. Engineered polymers products are sold to a diverse customer base comprised of major
manufacturers in the construction, automotive, telecommunications, electronics and recreation
industries. The performance coatings product line includes high-performance polymers and additives
for specialty paper, graphic arts, paint and textile coatings applications. During the second
quarter of 2006, the
94
company completed the sale of the FIIS and A&I businesses, while the sale of
the Telene business was completed during the first quarter of 2006. The company recorded the
results of operations of these divested businesses in the (loss)
income from discontinued operations - net of tax line item in the consolidated statements of income
for all periods presented (see Note 4).
The company primarily evaluates performance and allocates resources based on segment operating
income, defined as revenues less expenses identifiable to the product lines included within each
segment, as well as projected future returns. Segment operating income reconciles to consolidated
income from continuing operations before income taxes by deducting corporate expenses and corporate
other (expense) income that are not attributed to the operating segments, restructuring and
impairment charges, the write-off of acquired IPR&D and net interest expense.
95
The following table summarizes the results of the companys reportable segments for the years ended
December 31, 2006, 2005 and 2004:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2006 |
|
|
2005 |
|
|
2004 |
|
Lubrizol Additives: |
|
|
|
|
|
|
|
|
|
|
|
|
Revenues from external customers |
|
$ |
2,600.5 |
|
|
$ |
2,280.0 |
|
|
$ |
1,998.6 |
|
Equity earnings |
|
|
1.0 |
|
|
|
0.8 |
|
|
|
0.8 |
|
Amortization of intangibles |
|
|
3.1 |
|
|
|
3.0 |
|
|
|
3.0 |
|
Operating income |
|
|
303.0 |
|
|
|
263.3 |
|
|
|
238.2 |
|
Total assets |
|
|
1,397.6 |
|
|
|
1,324.0 |
|
|
|
1,341.9 |
|
Capital expenditures |
|
|
77.1 |
|
|
|
70.0 |
|
|
|
82.4 |
|
Depreciation |
|
|
71.7 |
|
|
|
79.7 |
|
|
|
86.2 |
|
Lubrizol Advanced Materials: |
|
|
|
|
|
|
|
|
|
|
|
|
Revenues from external customers |
|
$ |
1,440.3 |
|
|
$ |
1,342.2 |
|
|
$ |
865.8 |
|
Amortization of intangibles |
|
|
20.6 |
|
|
|
20.5 |
|
|
|
13.9 |
|
Operating income |
|
|
167.6 |
|
|
|
150.9 |
|
|
|
78.6 |
|
Total assets |
|
|
2,193.7 |
|
|
|
2,536.8 |
|
|
|
2,733.3 |
|
Capital expenditures |
|
|
40.2 |
|
|
|
51.3 |
|
|
|
40.1 |
|
Depreciation |
|
|
61.0 |
|
|
|
59.0 |
|
|
|
28.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Corporate: |
|
|
|
|
|
|
|
|
|
|
|
|
Total assets |
|
$ |
799.6 |
|
|
$ |
510.4 |
|
|
$ |
495.9 |
|
Capital expenditures |
|
|
8.4 |
|
|
|
0.6 |
|
|
|
0.1 |
|
Depreciation |
|
|
0.6 |
|
|
|
0.7 |
|
|
|
1.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Discontinued operations: |
|
|
|
|
|
|
|
|
|
|
|
|
Capital expenditures |
|
$ |
5.2 |
|
|
$ |
14.8 |
|
|
$ |
10.6 |
|
Depreciation |
|
|
4.4 |
|
|
|
15.2 |
|
|
|
21.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation to income from continuing
operations before income taxes: |
|
|
|
|
|
|
|
|
|
|
|
|
Segment operating income |
|
$ |
470.6 |
|
|
$ |
414.2 |
|
|
$ |
316.8 |
|
Corporate expenses |
|
|
(73.6 |
) |
|
|
(61.1 |
) |
|
|
(44.1 |
) |
Corporate other (expense) income - net |
|
|
(3.8 |
) |
|
|
|
|
|
|
6.2 |
|
Write-off of acquired IPR&D |
|
|
|
|
|
|
|
|
|
|
(34.0 |
) |
Restructuring and impairment charges |
|
|
(51.9 |
) |
|
|
(15.9 |
) |
|
|
(38.1 |
) |
Interest expense - net |
|
|
(79.3 |
) |
|
|
(97.0 |
) |
|
|
(72.3 |
) |
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before
income taxes |
|
$ |
262.0 |
|
|
$ |
240.2 |
|
|
$ |
134.5 |
|
|
|
|
|
|
|
|
|
|
|
96
Revenues from external customers by product line are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2006 |
|
|
2005 |
|
|
2004 |
|
Engine additives |
|
$ |
1,665.4 |
|
|
$ |
1,404.7 |
|
|
$ |
1,222.7 |
|
Driveline and industrial oil additives |
|
|
935.1 |
|
|
|
875.3 |
|
|
|
775.9 |
|
|
|
|
|
|
|
|
|
|
|
Total Lubrizol Additives |
|
|
2,600.5 |
|
|
|
2,280.0 |
|
|
|
1,998.6 |
|
|
|
|
|
|
|
|
|
|
|
Performance coatings |
|
|
543.7 |
|
|
|
537.6 |
|
|
|
366.2 |
|
Engineered polymers |
|
|
523.1 |
|
|
|
462.3 |
|
|
|
260.2 |
|
Noveon consumer specialties |
|
|
373.5 |
|
|
|
342.3 |
|
|
|
239.4 |
|
|
|
|
|
|
|
|
|
|
|
Total Lubrizol Advanced Materials |
|
|
1,440.3 |
|
|
|
1,342.2 |
|
|
|
865.8 |
|
|
|
|
|
|
|
|
|
|
|
Total revenues from external customers |
|
$ |
4,040.8 |
|
|
$ |
3,622.2 |
|
|
$ |
2,864.4 |
|
|
|
|
|
|
|
|
|
|
|
Revenues are attributable to countries based on the location of the customer. The United States is
the only country where sales to external customers comprise in excess of 10% of the companys
consolidated revenues. Revenues from external customers by geographic zone are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2006 |
|
|
2005 |
|
|
2004 |
|
United States |
|
$ |
1,637.0 |
|
|
$ |
1,492.3 |
|
|
$ |
1,159.1 |
|
Other North America |
|
|
187.2 |
|
|
|
178.3 |
|
|
|
151.0 |
|
Europe |
|
|
1,144.7 |
|
|
|
1,045.0 |
|
|
|
835.7 |
|
Asia-Pacific / Middle East |
|
|
823.5 |
|
|
|
708.8 |
|
|
|
560.5 |
|
Latin America |
|
|
248.4 |
|
|
|
197.8 |
|
|
|
158.1 |
|
|
|
|
|
|
|
|
|
|
|
Total revenues from external customers |
|
$ |
4,040.8 |
|
|
$ |
3,622.2 |
|
|
$ |
2,864.4 |
|
|
|
|
|
|
|
|
|
|
|
The companys sales and receivables are concentrated in the oil and chemical industries. Lubrizol
Additives customers consist primarily of oil refiners and independent oil blenders located in more
than 100 countries. The 10 largest customers, most of which are international oil companies and a
number of which are groups of affiliated entities, comprised approximately 39%, 39% and 42% of
consolidated net sales in 2006, 2005 and 2004, respectively. In 2006, 2005 and 2004, there was no
single customer that accounted for more than 10% of consolidated net sales.
Segment assets include receivables, inventories and long-lived assets including goodwill and
intangible assets. Corporate assets include cash and short-term investments and other current and
noncurrent assets.
The companys principal long-lived assets are located in the following countries at December 31:
|
|
|
|
|
|
|
|
|
|
|
2006 |
|
|
2005 |
|
United States |
|
$ |
1,525.3 |
|
|
$ |
1,827.8 |
|
Belgium |
|
|
375.1 |
|
|
|
346.1 |
|
United Kingdom |
|
|
154.4 |
|
|
|
152.5 |
|
France |
|
|
103.9 |
|
|
|
79.3 |
|
Hong Kong |
|
|
77.5 |
|
|
|
78.7 |
|
China |
|
|
45.1 |
|
|
|
45.5 |
|
Germany |
|
|
34.5 |
|
|
|
31.6 |
|
Other |
|
|
164.4 |
|
|
|
166.3 |
|
|
|
|
|
|
|
|
Total long-lived assets |
|
$ |
2,480.2 |
|
|
$ |
2,727.8 |
|
|
|
|
|
|
|
|
97
Income from continuing operations of non-U.S. subsidiaries was $136.8 million in 2006, $138.6
million in 2005 and $72.6 million in 2004. Dividends received from these subsidiaries were $0.4
million, $151.8 million and $1.2 million in 2006, 2005 and 2004, respectively.
Note 16 - STOCK COMPENSATION PLANS
All references to the number of shares and share units in this Note are based on actual share and
unit numbers and are not shown in millions.
Effective January 1, 2006, the company adopted the fair value recognition provisions of SFAS No.
123R, Share-Based Payment, using the modified prospective transition method and therefore has not
restated results for prior periods. Under this transition method, stock-based compensation expense
for 2006 includes compensation expense for all stock-based compensation awards granted prior to,
but not yet vested as of January 1, 2006, based on the grant-date fair value estimated in
accordance with the original provisions of SFAS No. 123, Accounting for Stock-Based Compensation.
Stock-based compensation expense for all stock-based compensation awards granted after January 1,
2006 is based on the grant-date fair value estimated in accordance with the provisions of SFAS No.
123R. The company recognizes these compensation costs, net of a forfeiture rate, on a
straight-line basis over the requisite service period of the award. The company estimates the
forfeiture rate based on its historical experience during the preceding 10 years. The impact of
adopting SFAS No. 123R in 2006 resulted in an increase in compensation expense of $2.4 million
pretax ($1.6 million after-tax).
Prior to January 1, 2006, the company accounted for stock-based compensation using the intrinsic
value method under the recognition and measurement principles of APB Opinion 25, Accounting for
Stock Issued to Employees and related Interpretations and applied SFAS No. 123, Accounting for
Stock-Based Compensation, as amended by SFAS No. 148, Accounting for Stock-Based Compensation -
Transition and Disclosure for disclosure purposes only. SFAS No. 123 disclosures included pro
forma net income and earnings per share as if the fair value-based method of accounting had been
used. Under the provisions of APB No. 25, no stock-based employee compensation cost is reflected
in net income, as all options granted under those plans had an exercise price equal to the market
value of the underlying stock on the date of grant.
The company utilizes the 2005 Stock Incentive Plan (2005 Plan) and other deferred compensation
plans to provide equity awards to its key employees. The 2005 Plan, approved by the companys
shareholders on April 25, 2005, provides for the granting of restricted and unrestricted shares and
options to buy common shares up to an amount equal to 4,000,000 common shares, of which no more
than 2,000,000 can be settled as full-value awards. After the 2,000,000 limit has been reached,
full-value awards are counted in a 3-to-1 ratio against the 4,000,000 limit. Options are intended
either to qualify as incentive stock options under the IRC, or to be non-statutory stock
options not intended to so qualify. Under the 2005 Plan, options generally become exercisable 50%
one year after date of grant, 75% after two years, 100% after three years and expire up to 10 years
after grant. The 2005 Plan generally supersedes the 1991 Stock Incentive Plan (1991 Plan), which
was terminated by the board of directors with respect to future grants effective November 15, 2004.
Options outstanding at December 31, 2006 for all grants under the 1991 Plan are fully vested and
remain exercisable until their expiration dates. The exercise price of stock options granted under
the 2005 Plan is not less than the fair market value of the shares on the date of grant. The 2005
Plan permits the granting of stock appreciation rights in connection with the grant of options. In
addition, the 2005 Plan provides each nonemployee director of the company an automatic annual grant
of restricted stock units worth $0.1 million, based on the fair market value of the companys
common shares on the date of the Annual Meeting of Shareholders. The restricted stock units
generally vest one year after the grant date. For all grants made prior to November 14, 2006, fair
market value was defined as the average of the high and low common share prices of the company on
the date of grant. For grants made on or after November 14, 2006, fair market value is defined as
the closing price of the companys common shares on the date of grant.
Under the 1991 Plan, the company had granted performance share stock awards to certain executive
officers. Common shares equal to the number of performance share stock awards granted were to be
issued if the market price of the companys common stock reached $45.00 per common share for 10
consecutive trading days or on March 24, 2003, whichever occurred first. Under certain conditions
such as retirement, a grantee of performance share stock awards could have been issued a pro-rata
number of common shares. The company recognized compensation expense related to performance share
stock awards ratably over the estimated period of vesting. On March 24, 2003, 3,500 shares were
issued and 57,250 shares were deferred into share units under the deferred compensation plan for
officers. The
98
company allocated 933 and 1,404 share units under this plan in 2006 and 2005,
respectively, which represent quarterly dividends paid on the companys shares. As of December 31,
2006, 37,299 share units were outstanding.
Under the Supplemental Retirement Plan for Donald W. Bogus, an account is credited with 500 share
units each year and is credited with additional share units for quarterly dividends paid on the
companys shares. When Mr. Bogus retires, the company will issue shares equal to the number of
share units in his account or the cash equivalent. The company has allocated 54, 55 and 67 share
units under this plan for 2006, 2005 and 2004, respectively, which represent quarterly dividends
paid on the companys shares. As of December 31, 2006, 2,336 share units were outstanding. For
share units attributable to grants credited after January 1, 2004, the payment will be in cash.
Under the Deferred Stock Compensation Plan for Outside Directors, each nonemployee director
received 500 share units each year on October 1 and is credited with additional share units for
quarterly dividends paid on the companys shares. When a participant ceases to be a director, the
company issues shares equal to the number of share units in the directors account. The company
has allocated to nonemployee directors 877, 1,022 and 1,351 share units under this plan for 2006,
2005 and 2004, respectively, which represent quarterly dividends paid on the companys shares. As
of December 31, 2006, 35,563 share units were outstanding. No new grants have been made under this
plan since January 1, 2004.
In addition, under the Deferred Compensation Plan for Directors, the company has allocated 669, 466
and 569 share units to nonemployee directors under this plan for 2006, 2005 and 2004, respectively.
These share units continue to accrue quarterly dividends paid on the companys shares. When a
participant ceases to be a director, the company issues shares equal to the number of share units
in the directors account. As of December 31, 2006, 31,682 share units for nonemployee directors
were outstanding.
Under the Executive Council Deferred Compensation Plan, participants may elect to defer any amount
of their variable pay. Deferred amounts are converted into share units based on the current market
price of the companys shares. There is a 25% company match. Additional share units are credited
for quarterly dividends paid on the companys shares. At the end of the deferral period, which is
at least three years, the company issues shares equal to the number of share units in the
participants account. The company has allocated to executive officers 31,662, 19,840 and 16,743
share units under this plan in 2006, 2005 and 2004, respectively. As of December 31, 2006, 92,523
share units for executive officers were outstanding. For share units attributable to the company
match credited after January 1, 2004, distributions will be made in cash.
Under the 1991 Plan, effective January 1, 2003, the company granted 15,000 restricted shares to
each of three executive officers. The shares will be issued only if the executive remains an
employee until January 1, 2008. Also, effective January 1, 2003, the company granted 5,000
restricted shares to one executive officer, which would be issued only if the executive remained
with the company until January 1, 2008. On July 26, 2004, this grant was amended to issue the
shares if the executive remained employed until July 29, 2004. The shares were issued on July 29,
2005. There are no voting or dividend rights on the restricted shares described in this paragraph
unless and until they are issued. The restricted shares stock awards had a fair value of $25.83
per share at the date of grant. The company recognizes compensation expense related to restricted
shares ratably over the estimated period of vesting.
Option activity under the 2005 Plan and 1991 Plan as of December 31, 2006 and changes during the
year ended December 31, 2006 were as follows:
99
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted- |
|
|
|
|
|
|
Average |
|
|
|
|
|
|
Exercise |
|
|
|
Shares |
|
|
Price |
Outstanding, January 1, 2006 |
|
|
4,283,917 |
|
|
$ |
32.35 |
|
Granted |
|
|
|
|
|
|
|
|
Exercised |
|
|
(938,950 |
) |
|
$ |
31.03 |
|
Forfeited |
|
|
(5,638 |
) |
|
$ |
29.72 |
|
|
|
|
|
|
|
|
|
|
Outstanding, December 31, 2006 |
|
|
3,339,329 |
|
|
$ |
32.72 |
|
|
|
|
|
|
|
|
|
|
Options exercisable, December 31, 2006 |
|
|
2,992,327 |
|
|
$ |
31.93 |
|
|
|
|
|
|
|
|
|
|
The aggregate intrinsic value of options outstanding at December 31, 2006 based on the companys
closing stock price on the last trading day of 2006, which would have been received by the option
holders had all options been exercised on that date was $58.1 million. The aggregate intrinsic
value of options exercisable at December 31, 2006 based on the companys closing stock price on the
last trading day of 2006, which would have been received by the option holders had all options
exercisable been exercised on that date, was $53.2 million. The total intrinsic value of stock
options exercised was $13.5 million, $13.0 million and $3.6 million in 2006, 2005 and 2004,
respectively. Intrinsic value is the amount by which the companys closing share price exceeds the
exercise price of the options multiplied by the number of in-the-money options. The
weighted-average remaining contractual term of options outstanding and exercisable at December 31,
2006 was 5.4 years and 5.0 years.
The fair value of share-based payment awards are estimated using the Black-Scholes option pricing
model. There were no stock options granted during 2006. The weighted-average fair value of stock
options granted during 2005 and 2004 was $9.87 and $6.50, respectively.
Disclosures under the fair-value method are estimated using the Black-Scholes option-pricing model
with the following weighted-average assumptions for stock option grants in the following years:
|
|
|
|
|
|
|
|
|
|
|
2005 |
|
2004 |
Risk-free interest rate |
|
|
4.3 |
% |
|
|
3.7 |
% |
Dividend yield |
|
|
2.5 |
% |
|
|
3.5 |
% |
Volatility |
|
|
21.2 |
% |
|
|
24.0 |
% |
Expected life (years) |
|
|
8.0 |
|
|
|
10.0 |
|
If the fair-value method to measure compensation cost for the above plans and awards had been used,
the compensation cost, which is required to be charged against income, would have been $6.5 million
in 2005 and $6.0 million in 2004. See Note 2 for the pro forma presentation.
Cash received from option exercises and purchases under the 2005 Plan and 1991 Plan during 2006 was
$31.3 million. The company realized a reduction in its income tax payable of $4.7 million in 2006
relating to the exercise of nonqualified stock options. For accounting purposes, these tax
benefits were realized as increases in paid-in capital included in the common shares caption in the
consolidated statement of shareholders equity.
As of December 31, 2006, there was $10.3 million of total before-tax unrecognized compensation cost
related to nonvested stock-based awards. That cost is expected to be recognized over a
weighted-average period of 1.6 years. The company is using previously purchased treasury shares
for all net shares issued for option exercises, long-term incentive plans and restricted stock
awards.
Nonvested restricted stock awards as of December 31, 2006 and changes during 2006 were as follows:
100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted- |
|
|
|
|
|
|
Average |
|
|
Share |
|
Grant Date |
|
|
|
Units |
|
|
|
Fair Value |
|
Nonvested at January 1, 2006 |
|
|
58,689 |
|
|
|
$ 29.01 |
|
Granted |
|
|
12,777 |
|
|
|
$ 42.27 |
|
Vested |
|
|
13,689 |
|
|
|
$ 39.45 |
|
Forfeited |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nonvested at December 31, 2006 |
|
|
57,777 |
|
|
|
$ 29.46 |
|
|
|
|
|
|
|
|
|
|
Under the companys long-term incentive program, dollar-based target awards were determined by the
organization and compensation committee of the board of directors in December 2002, December 2003,
February 2005 and December 2005 for the three-year performance periods of 2003-2005, 2004-2006,
2005-2007 and 2006-2008, respectively. The company recognized compensation expense of $4.9
million, $8.0 million and $5.1 million in 2006, 2005 and 2004, respectively, related to the cash
portion of these awards that are not share-based. In addition, a portion of each of the awards was
converted into a number of share units based on the price of the company common stock on the date
of the award. There are no voting or dividend rights associated with the share units until the end
of the performance period and a distribution of shares from the 2005 Plan, if any, is made. The
target awards correspond to pre-determined three-year earnings before interest, taxes, depreciation
and amortization (EBITDA) and/or earnings per share growth rate targets. In accordance with SFAS
No. 123R, compensation expense for these performance awards, except for the 2004-2006 award, was
calculated based on the grant-date fair value. The terms of the 2004-2006 award states that
payment will be in cash and as such liability accounting was used for this award and compensation
expense was calculated based on the year-end share closing price on December 31, 2006. In 2006,
the award for the 2003-2005 performance period was paid. The company allocated 338 share units
during 2006 for those participants who elected to defer their shares. As of December 31, 2006,
19,318 share units were outstanding.
Prior to the adoption of SFAS No. 123R, compensation expense for these awards was based on variable
accounting and was calculated using the closing stock price at period end. The other portion of
the 2002, 2003, February 2005 and December 2005 award grants is a cash award, which also is
determined for the same three-year performance periods.
The following table identifies the number of shares expected to be issued based on current
performance measures and the stock price on the date of grant for the performance shares granted:
|
|
|
|
|
|
|
|
|
|
|
Expected |
|
Average |
|
|
Number of Units |
|
Stock Price on |
Award |
|
to be Issued |
|
Date of Grant |
2004-2006 (a) |
|
|
178,541 |
|
|
|
$ 30.65 |
|
2005-2007 |
|
|
216,388 |
|
|
|
$ 39.44 |
|
2006-2008 |
|
|
154,060 |
|
|
|
$ 43.07 |
|
(a) |
|
On February 19, 2007, the organization and compensation committee of the board of directors
approved the issuance of 178,541 share units in lieu of a cash distribution. |
Performance-based stock awards as of December 31, 2006 and changes during 2006 were as follows:
101
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted- |
|
|
|
|
|
|
Average |
|
|
Share |
|
|
Grant Date |
|
|
Units |
|
|
Fair Value |
Nonvested at January 1, 2006 |
|
|
330,460 |
|
|
|
$ |
41.13 |
|
Granted |
|
|
|
|
|
|
|
|
|
Performance increase |
|
|
39,988 |
|
|
|
$ |
39.44 |
|
Vested |
|
|
|
|
|
|
|
|
|
Forfeited |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nonvested at December 31, 2006 |
|
|
370,448 |
|
|
|
$ |
40.95 |
|
|
|
|
|
|
|
|
|
The following table reflects the total stock-based compensation expense and the related tax benefit
recognized in the consolidated statements of income for 2006, 2005 and 2004:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2006 |
|
2005 |
|
2004 |
Restricted share units: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Long-term incentive program |
|
|
$ |
9.5 |
|
|
|
$ |
7.8 |
|
|
|
$ |
2.6 |
|
Other plans |
|
|
|
3.3 |
|
|
|
|
2.3 |
|
|
|
|
1.1 |
|
Stock options |
|
|
|
3.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
$ |
16.3 |
|
|
|
$ |
10.1 |
|
|
|
$ |
3.7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tax benefit |
|
|
$ |
6.1 |
|
|
|
$ |
3.8 |
|
|
|
$ |
1.4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The following table summarizes information about stock options outstanding, excluding the
performance share stock awards, restricted share stock awards and long-term incentive plan awards
at December 31, 2006:
102
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options Outstanding |
|
Options Exercisable |
|
|
|
|
|
|
|
Weighted-Average |
|
|
Weighted- |
|
|
|
|
|
Weighted- |
Range of |
|
Number |
|
|
Remaining |
|
|
Average |
|
Number |
|
Average |
Exercise |
|
Outstanding |
|
|
Contractual |
|
|
Exercise |
|
Exercisable |
|
Exercise |
Prices |
|
at 12/31/06 |
|
|
Life |
|
|
Price |
|
at 12/31/06 |
|
Price |
$ 19 - $ 25 |
|
|
86,612 |
|
|
2.1 years |
|
$ |
21.36 |
|
|
|
86,612 |
|
|
$ |
21.36 |
|
$ 25 - $ 31 |
|
|
1,929,878 |
|
|
4.9 years |
|
$ |
29.89 |
|
|
|
1,820,876 |
|
|
$ |
29.87 |
|
$ 31 - $ 38 |
|
|
708,839 |
|
|
4.5 years |
|
$ |
34.51 |
|
|
|
707,839 |
|
|
$ |
34.51 |
|
$ 38 - $ 45 |
|
|
614,000 |
|
|
8.6 years |
|
$ |
41.18 |
|
|
|
307,000 |
|
|
$ |
41.18 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,339,329 |
|
|
5.4 years |
|
$ |
32.72 |
|
|
|
2,922,327 |
|
|
$ |
31.93 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
103
Note 17 - RESTRUCTURING AND IMPAIRMENT CHARGES
In 2006, the company recorded aggregate restructuring and impairment charges of $51.9 million.
These charges primarily related to the write-down of a trade name in the Lubrizol Advanced
Materials segment and the phase-out of a manufacturing facility in the Lubrizol Additives segment.
The following table shows the reconciliation of the restructuring liability beginning January 1,
2004 by major restructuring activity:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liability |
|
Restructuring |
|
|
|
|
|
|
|
|
|
|
|
Liability |
|
|
January 1, |
|
and Impairment |
|
|
|
|
|
|
Non-cash |
|
December 31, |
|
|
2006 |
|
Charges |
|
Cash Paid |
|
Adjustments |
|
2006 |
Noveon trade name impairment |
|
|
$ |
|
|
|
|
|
$ 41.2 |
|
|
|
$ |
|
|
|
|
|
$ (41.2 |
) |
|
|
$ |
|
|
Bromborough, U.K. plant closure |
|
|
|
2.3 |
|
|
|
|
6.7 |
|
|
|
|
(8.2 |
) |
|
|
|
0.2 |
|
|
|
|
1.0 |
|
Lubrizol Advanced Materials
facility and line
closures and workforce
reductions |
|
|
|
2.5 |
|
|
|
|
4.1 |
|
|
|
|
(2.5 |
) |
|
|
|
(3.4 |
) |
|
|
|
0.7 |
|
Corporate / other workforce
reductions |
|
|
|
0.3 |
|
|
|
|
(0.1 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
0.2 |
|
Noveon International
restructuring
liabilities assumed |
|
|
|
1.3 |
|
|
|
|
|
|
|
|
|
(0.4 |
) |
|
|
|
|
|
|
|
|
0.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
6.4 |
|
|
|
|
$ 51.9 |
|
|
|
$ |
(11.1 |
) |
|
|
|
$ (44.4 |
) |
|
|
$ |
2.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liability |
|
Restructuring |
|
|
|
|
|
|
|
|
|
|
|
Liability |
|
|
January 1, |
|
and Impairment |
|
|
|
|
|
|
Non-cash |
|
December 31, |
|
|
2005 |
|
Charges |
|
Cash Paid |
|
Adjustments |
|
2005 |
Bromborough, U.K. plant closure |
|
|
$ |
|
|
|
|
|
$ 6.1 |
|
|
|
$ |
(3.1 |
) |
|
|
|
$ (0.7 |
) |
|
|
$ |
2.3 |
|
Lubrizol Advanced Materials facility
closures and workforce reductions |
|
|
|
|
|
|
|
|
9.0 |
|
|
|
|
(2.3 |
) |
|
|
|
(4.2 |
) |
|
|
|
2.5 |
|
Corporate / other workforce reductions |
|
|
|
2.7 |
|
|
|
|
0.7 |
|
|
|
|
(3.1 |
) |
|
|
|
|
|
|
|
|
0.3 |
|
Noveon International restructuring
liabilities assumed |
|
|
|
6.1 |
|
|
|
|
0.1 |
|
|
|
|
(5.0 |
) |
|
|
|
0.1 |
|
|
|
|
1.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
8.8 |
|
|
|
|
$ 15.9 |
|
|
|
$ |
(13.5 |
) |
|
|
|
$ (4.8 |
) |
|
|
$ |
6.4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liability |
|
Restructuring |
|
|
|
|
|
|
|
|
|
|
|
Liability |
|
|
January 1, |
|
and Impairment |
|
|
|
|
|
|
Non-cash |
|
December 31, |
|
|
2004 |
|
Charges |
|
Cash Paid |
|
Adjustments |
|
2004 |
Bromborough, U.K. plant closure |
|
|
$ |
|
|
|
|
|
$ 17.0 |
|
|
|
$ |
|
|
|
|
|
$ (17.0 |
) |
|
|
$ |
|
|
Bromborough, U.K. workforce reductions |
|
|
|
0.2 |
|
|
|
|
|
|
|
|
|
(0.2 |
) |
|
|
|
|
|
|
|
|
|
|
Corporate / other workforce reductions |
|
|
|
12.2 |
|
|
|
|
11.1 |
|
|
|
|
(20.6 |
) |
|
|
|
|
|
|
|
|
2.7 |
|
Pension settlement |
|
|
|
|
|
|
|
|
7.7 |
|
|
|
|
|
|
|
|
|
(7.7 |
) |
|
|
|
|
|
Noveon International restructuring
liabilities assumed |
|
|
|
|
|
|
|
|
0.2 |
|
|
|
|
(1.1 |
) |
|
|
|
7.0 |
|
|
|
|
6.1 |
|
PuriNOx asset impairment |
|
|
|
|
|
|
|
|
2.1 |
|
|
|
|
|
|
|
|
|
(2.1 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
12.4 |
|
|
|
|
$ 38.1 |
|
|
|
$ |
(21.9 |
) |
|
|
|
$ (19.8 |
) |
|
|
$ |
8.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As part of its corporate goal to enhance its one company identity and to reflect more accurately
its positioning in the marketplace, the company completed a corporate identity review in the fourth
quarter of 2006. Senior management of the company made a final determination in January 2007 that
the trade name Noveon no longer would be used to describe the Lubrizol Advanced Materials segment
of the company and that its use would be discontinued except in connection with the Noveon consumer
specialties product line. The company acquired the rights to the Noveon trade name in June 2004
when it acquired Noveon International. At the time of acquisition, an appraised value was attached
to the Noveon trade name. The company calculated a pretax charge of $41.2 million ($25.4 million
after-tax) to reduce the related asset to its estimated fair value. This charge was reflected in
the fourth quarter of 2006 as the company believed at that time it would more likely than not
discontinue the use of the Noveon trade name, except in the limited context of its Noveon consumer
specialties product line.
In September 2006, the company entered into an agreement to sell the manufacturing facility located
in Bromborough, United Kingdom. The sale closed in January 2007. In connection with the sale, the
company received net cash proceeds of $5.9 million and recorded a pretax gain of $2.9 million
during the first quarter of 2007. The gain will be classified as a restructuring credit associated
with closure of the facility. At December 31, 2006, the Bromborough site was classified as an
asset held for sale but was not disclosed separately on the balance sheet because the amount was
not material to the
104
companys consolidated financial position. In December 2004, management
decided to close this facility, which triggered an impairment charge of $17.0 million that was
recorded in December 2004 to reflect long-lived assets at their estimated fair values. The
estimated fair value of the long-lived assets was determined using a discounted cash flow model.
The company announced its decision to close the facility in January 2005. Production phase-out of
this site began in the third quarter of 2005 and was completed in 2006. During this phase-out,
production was transferred to higher-capacity facilities in France and the United States. There
were 70 employees impacted by this closure.
In 2005, management made the decision and the announcement to close two Lubrizol Advanced Materials
performance coatings production facilities located in the United States. The aggregate
restructuring charges recorded for these closures were $8.0 million, of which $1.4 million was
recorded in 2006. Total charges were comprised of $4.8 million in asset impairments, $1.1 million
in exit costs and $2.1 million in severance costs. The impairment charges for both facilities were
recorded to reduce the related assets to their estimated fair values, which were determined
primarily from third-party appraisals. Production from these sites was transferred to other
facilities in the United States. One facility, located in Mountaintop, Pennsylvania, was closed in
October 2005 and sold in January 2006. The other facility, located in Linden, New Jersey, was
closed in the third quarter of 2006. These closures resulted in a workforce reduction of 62
employees. Additional asset impairment charges of $2.7 million were recorded in 2006, which
primarily related to the planned closure of a performance coatings production line in the first
quarter of 2007. In May 2005, the company announced the reorganization of the Lubrizol Advanced
Materials performance coatings product line. This product line includes businesses acquired from
Noveon International as well as businesses included in the companys legacy operations. In
connection with the reorganization, management eliminated 26 positions in North America and Europe.
These reductions were completed during 2005 and resulted in a severance-related charge of $1.9
million for the year ended December 31, 2005.
In 2004, the company eliminated more than 100 positions, primarily affecting technical and
commercial employees located at the Wickliffe, Ohio headquarters. Most of these workforce
reductions were related to the restructuring following the acquisition of Noveon International.
These reductions were completed by December 31, 2004. In the second quarter of 2005, the company
began a process of identifying further opportunities to increase efficiency and productivity,
reduce costs and support the companys integration strategy of the Noveon International
acquisition. As a result, the company reduced headcount in the general and administrative area of
its Ohio headquarters. Through these restructuring efforts, the company eliminated seven positions
resulting in a severance-related charge of $0.7 million for the year ended December 31, 2005. All
of the affected employees had left their positions by June 30, 2005 and the remaining
personnel-related costs were paid in 2006.
In 2004, asset impairments and non-cash adjustments include $7.2 million in restructuring
liabilities assumed related to the legacy operations of Noveon International, $7.7 million of
pension settlement charges included in the accrued pension liability account and the PuriNOx asset
impairment charge of $2.1 million.
The charges for these cost reduction initiatives and impairments are reported as a separate line
item in the consolidated statements of income entitled Restructuring and impairment charges and
are included in the Total cost and expenses subtotal on the consolidated statements of income.
Note 18 - CONTINGENCIES
The company has numerous purchase commitments for materials, supplies and energy in the ordinary
course of business. The company also has numerous sales commitments for product supply contracts
in the ordinary course of business.
General
There are pending or threatened claims, lawsuits and administrative proceedings against the company
or its subsidiaries, all arising from the ordinary course of business with respect to commercial,
product liability and environmental matters, which seek remedies or damages. The company believes
that any liability that finally may be determined with respect to commercial and product liability
claims should not have a material adverse effect on the companys consolidated financial position,
results of operations or cash flows. From time to time, the company is also involved in legal
proceedings as a plaintiff involving contract, patent protection, environmental and other matters.
Gain contingencies, if any, are recognized when they are realized.
105
Environmental
The companys environmental engineers and consultants review and monitor environmental issues at
operating facilities and, where appropriate, the company initiates corrective and/or preventive
environmental projects to ensure environmental compliance and safe and lawful activities at its
current operations. The company also conducts compliance and management systems audits.
The company and its subsidiaries are generators of both hazardous and non-hazardous wastes, the
treatment, storage, transportation and disposal of which are regulated by various laws and
governmental regulations. These laws and regulations generally impose liability for costs to
investigate and remediate contamination without regard to fault and, under certain circumstances,
liability may be joint and several resulting in one party being held responsible for the entire
obligation. Liability also may include damages to natural resources. Although the company
believes past operations were in substantial compliance with the then-applicable regulations,
either the company or the predecessor of Noveon International, the Performance Materials Segment of
Goodrich Corporation (Goodrich), has been designated under a countrys laws and/or regulations as a
potentially responsible party (PRP) in connection with several sites including both third party
sites and or current operating facilities.
The company participates in the remediation process for onsite and third party waste management
sites at which the company has been identified as a PRP. This process includes investigation,
remedial action selection and implementation, as well as discussions and negotiations with other
parties, which primarily include PRPs, past owners and operators and governmental agencies. The
estimates of environmental liabilities are based on the results of this process. Inherent
uncertainties exist in these estimates primarily due to unknown conditions, changing governmental
regulations and legal standards regarding liability, remediation standards and evolving
technologies for managing investigations and remediations. The company revises its estimates
accordingly as events in this process occur and additional information is obtained.
The companys environmental reserves, measured on an undiscounted basis, totaled $14.2 million at
December 31, 2006 and $23.2 million at December 31, 2005. Of these amounts, $4.5 million and $3.4
million were included in accrued expenses and other current liabilities at December 31, 2006 and
2005, respectively. Goodrich provided Noveon International with an indemnity for various
environmental liabilities. The company estimates Goodrichs share of such currently identified
liabilities under the indemnity, which extends through February 2011, to be approximately
$3.5 million of which $0.5 million of the recovery is included in receivables and $3.0 million is
included in other assets. There are specific environmental contingencies for company-owned sites
for which third parties such as past owners and/or operators are the named PRPs and also for which
the company is indemnified by Goodrich. Goodrich currently is indemnifying Noveon International
for several environmental remediation projects. Goodrichs share of all of these liabilities may
increase to the extent such third parties fail to honor their obligations through February 2011.
The company believes that its environmental accruals are adequate based on currently available
information. The company believes that it is reasonably possible that $19.8 million in additional
costs may be incurred at certain locations beyond the amounts accrued as a result of new
information, newly discovered conditions, changes in remediation standards or technologies or a
change in the law. Additionally, as the indemnification from Goodrich extends through February
2011, changes in assumptions regarding when costs will be incurred may result in additional
expenses to the company. Additional costs in excess of $19.8 million cannot currently be
estimated.
GUARANTEES
On May 1, 2006, the company sold the FIIS business to SPM Group Holdings, LLC, now known as Emerald
Performance Materials, LLC (Emerald). As a result of the sale, Emerald became responsible for
contracts relating to FIIS, including a Toluene Sale and Purchase Agreement between SK Corporation
(SK) and the company dated December 6, 2005 (the Toluene Agreement). Although Emerald has assumed
the obligations under the Toluene Agreement, the company has guaranteed to SK the timely
performance of Emeralds payment obligations under the Toluene Agreement for purchases thereunder.
The term of the Toluene Agreement extends to January 31, 2008.
If Emerald does not satisfy its obligations under the Toluene Agreement, SK shall notify the
company and use commercially reasonable efforts to collect what is due from Emerald. If SK is
unable to collect from Emerald, then SK may make a demand on the company for payment of the
outstanding obligations. The guarantee is revocable by the company upon 60 days prior written
notice.
106
Because of the guarantees existing revocation clause, the company estimates that the maximum
liability under the guarantee would be approximately $15.2 million, representing the estimated
liability for two shipments to Emerald. However, the company believes that it is highly unlikely
that an event would occur requiring the company to pay any monies pursuant to the guarantee.
Accordingly, no liability has been reflected in the accompanying consolidated balance sheet at
December 31, 2006.
INDEMNIFICATIONS
In connection with the sale of the FIIS business, the company has provided indemnifications to
Emerald with respect to the business sold. These indemnifications have been associated with the
price and quantity of raw material purchases, permit costs, costs incurred due to the inability to
obtain permits and environmental matters. In each of these circumstances, payment by the company
is dependent on Emerald filing a claim. In addition, the companys obligations under these
agreements may be limited in terms of time and/or amount. It is not possible to predict the
maximum potential amount of future payments under certain of these agreements due to the
conditional nature of the companys obligations and the unique facts and circumstances involved in
each particular agreement. The company believes that if it were to incur a loss in any of these
matters, such loss would not have a material effect on the companys business, financial condition
or results of operations. For those indemnification agreements where a payment by the company is
probable and estimable, a liability has been recorded as of December 31, 2006.
107
Note 19 - QUARTERLY FINANCIAL DATA (UNAUDITED)
The following table sets forth the quarterly results of operations for the years ended December 31,
2006 and 2005. Such amounts give effect to the restatement discussed in Note 20.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2006 |
|
|
First (1) |
|
Second (1) |
|
Third (1) |
|
Fourth (1) |
|
Full Year |
|
|
As Previously |
|
As |
|
As Previously |
|
As |
|
As Previously |
|
As |
|
As Previously |
|
As |
|
As Previously |
|
As |
|
|
Reported |
|
Restated |
|
Reported |
|
Restated |
|
Reported |
|
Restated |
|
Reported |
|
Restated |
|
Reported |
|
Restated |
Net sales |
|
$ |
984.1 |
|
|
$ |
984.1 |
|
|
$ |
1,041.1 |
|
|
$ |
1,041.1 |
|
|
$ |
1,031.0 |
|
|
$ |
1,031.0 |
|
|
$ |
984.6 |
|
|
$ |
984.6 |
|
|
$ |
4,040.8 |
|
|
$ |
4,040.8 |
|
Gross profit |
|
$ |
245.0 |
|
|
$ |
244.1 |
|
|
$ |
265.4 |
|
|
$ |
264.5 |
|
|
$ |
248.1 |
|
|
$ |
247.2 |
|
|
$ |
236.0 |
|
|
$ |
235.4 |
|
|
$ |
994.5 |
|
|
$ |
991.2 |
|
Income from continuing operations |
|
$ |
45.8 |
|
|
$ |
45.3 |
|
|
$ |
63.5 |
|
|
$ |
63.0 |
|
|
$ |
50.8 |
|
|
$ |
50.1 |
|
|
$ |
21.7 |
|
|
$ |
21.4 |
|
|
$ |
181.8 |
|
|
$ |
179.8 |
|
Discontinued operations |
|
|
(60.7 |
) |
|
|
(60.7 |
) |
|
|
(12.4 |
) |
|
|
(12.4 |
) |
|
|
(0.5 |
) |
|
|
(0.5 |
) |
|
|
(2.6 |
) |
|
|
(2.6 |
) |
|
|
(76.2 |
) |
|
|
(76.2 |
) |
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
$ |
(14.9 |
) |
|
$ |
(15.4 |
) |
|
$ |
51.1 |
|
|
$ |
50.6 |
|
|
$ |
50.3 |
|
|
$ |
49.6 |
|
|
$ |
19.1 |
|
|
$ |
18.8 |
|
|
$ |
105.6 |
|
|
$ |
103.6 |
|
|
|
|
|
|
|
|
|
|
|
|
Per common share basic: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations |
|
$ |
0.67 |
|
|
$ |
0.66 |
|
|
$ |
0.92 |
|
|
$ |
0.92 |
|
|
$ |
0.74 |
|
|
$ |
0.73 |
|
|
$ |
0.32 |
|
|
$ |
0.31 |
|
|
$ |
2.65 |
|
|
$ |
2.62 |
|
Discontinued operations |
|
|
(0.89 |
) |
|
|
(0.89 |
) |
|
|
(0.18 |
) |
|
|
(0.18 |
) |
|
|
(0.01 |
) |
|
|
(0.01 |
) |
|
|
(0.04 |
) |
|
|
(0.04 |
) |
|
|
(1.11 |
) |
|
|
(1.11 |
) |
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
$ |
(0.22 |
) |
|
$ |
(0.23 |
) |
|
$ |
0.74 |
|
|
$ |
0.74 |
|
|
$ |
0.73 |
|
|
$ |
0.72 |
|
|
$ |
0.28 |
|
|
$ |
0.27 |
|
|
$ |
1.54 |
|
|
$ |
1.51 |
|
|
|
|
|
|
|
|
|
|
|
|
Per common share diluted: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations |
|
$ |
0.66 |
|
|
$ |
0.65 |
|
|
$ |
0.92 |
|
|
$ |
0.91 |
|
|
$ |
0.73 |
|
|
$ |
0.72 |
|
|
$ |
0.31 |
|
|
$ |
0.31 |
|
|
$ |
2.62 |
|
|
$ |
2.59 |
|
Discontinued operations |
|
|
(0.88 |
) |
|
|
(0.88 |
) |
|
|
(0.18 |
) |
|
|
(0.18 |
) |
|
|
|
|
|
|
|
|
|
|
(0.04 |
) |
|
|
(0.04 |
) |
|
|
(1.10 |
) |
|
|
(1.10 |
) |
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
$ |
(0.22 |
) |
|
$ |
(0.23 |
) |
|
$ |
0.74 |
|
|
$ |
0.73 |
|
|
$ |
0.73 |
|
|
$ |
0.72 |
|
|
$ |
0.27 |
|
|
$ |
0.27 |
|
|
$ |
1.52 |
|
|
$ |
1.49 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2005 |
|
|
First (2) |
|
Second (2) |
|
Third (2) |
|
Fourth (2) |
|
Full Year |
|
|
As Previously |
|
As |
|
As Previously |
|
As |
|
As Previously |
|
As |
|
As Previously |
|
As |
|
As Previously |
|
As |
|
|
Reported |
|
Restated |
|
Reported |
|
Restated |
|
Reported |
|
Restated |
|
Reported |
|
Restated |
|
Reported |
|
Restated |
Net sales |
|
$ |
848.8 |
|
|
$ |
848.8 |
|
|
$ |
942.3 |
|
|
$ |
942.3 |
|
|
$ |
899.5 |
|
|
$ |
899.5 |
|
|
$ |
931.6 |
|
|
$ |
931.6 |
|
|
$ |
3,622.2 |
|
|
$ |
3,622.2 |
|
Gross profit |
|
$ |
229.8 |
|
|
$ |
229.0 |
|
|
$ |
246.7 |
|
|
$ |
245.8 |
|
|
$ |
229.7 |
|
|
$ |
228.8 |
|
|
$ |
216.0 |
|
|
$ |
215.1 |
|
|
$ |
922.2 |
|
|
$ |
918.7 |
|
Income from continuing operations |
|
$ |
40.1 |
|
|
$ |
39.5 |
|
|
$ |
50.2 |
|
|
$ |
49.7 |
|
|
$ |
42.7 |
|
|
$ |
42.2 |
|
|
$ |
28.5 |
|
|
$ |
28.0 |
|
|
$ |
161.5 |
|
|
$ |
159.4 |
|
Discontinued operations |
|
|
8.4 |
|
|
|
8.4 |
|
|
|
9.9 |
|
|
|
9.9 |
|
|
|
5.9 |
|
|
|
5.9 |
|
|
|
3.6 |
|
|
|
3.6 |
|
|
|
27.8 |
|
|
|
27.8 |
|
|
|
|
|
|
|
|
|
|
|
Net income $(0.22) $(0.23) $0.74 $ 0.73 $ 0.73 $ 0.72 $ 0.27 $ 0.27 $ 1.52 $ 1.49 |
Net income |
|
$ |
48.5 |
|
|
$ |
47.9 |
|
|
$ |
60.1 |
|
|
$ |
59.6 |
|
|
$ |
48.6 |
|
|
$ |
48.1 |
|
|
$ |
32.1 |
|
|
$ |
31.6 |
|
|
$ |
189.3 |
|
|
$ |
187.2 |
|
|
|
|
|
|
|
|
|
|
|
|
Per common share basic: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations |
|
$ |
0.59 |
|
|
$ |
0.59 |
|
|
$ |
0.74 |
|
|
$ |
0.73 |
|
|
$ |
0.63 |
|
|
$ |
0.62 |
|
|
$ |
0.42 |
|
|
$ |
0.41 |
|
|
$ |
2.38 |
|
|
$ |
2.35 |
|
Discontinued operations |
|
|
0.13 |
|
|
|
0.13 |
|
|
|
0.14 |
|
|
|
0.14 |
|
|
|
0.08 |
|
|
|
0.08 |
|
|
|
0.05 |
|
|
|
0.05 |
|
|
|
0.41 |
|
|
|
0.41 |
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
$ |
0.72 |
|
|
$ |
0.72 |
|
|
$ |
0.88 |
|
|
$ |
0.87 |
|
|
$ |
0.71 |
|
|
$ |
0.70 |
|
|
$ |
0.47 |
|
|
$ |
0.46 |
|
|
$ |
2.79 |
|
|
$ |
2.76 |
|
|
|
|
|
|
|
|
|
|
|
|
Per common share diluted: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations |
|
$ |
0.59 |
|
|
$ |
0.58 |
|
|
$ |
0.73 |
|
|
$ |
0.72 |
|
|
$ |
0.62 |
|
|
$ |
0.61 |
|
|
$ |
0.41 |
|
|
$ |
0.40 |
|
|
$ |
2.35 |
|
|
$ |
2.32 |
|
Discontinued operations |
|
|
0.12 |
|
|
|
0.12 |
|
|
|
0.14 |
|
|
|
0.14 |
|
|
|
0.08 |
|
|
|
0.08 |
|
|
|
0.05 |
|
|
|
0.05 |
|
|
|
0.40 |
|
|
|
0.40 |
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
$ |
0.71 |
|
|
$ |
0.70 |
|
|
$ |
0.87 |
|
|
$ |
0.86 |
|
|
$ |
0.70 |
|
|
$ |
0.69 |
|
|
$ |
0.46 |
|
|
$ |
0.45 |
|
|
$ |
2.75 |
|
|
$ |
2.72 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
The company recorded restructuring and impairment charges of $1.8 million, $1.8 million, $2.7
million and $45.6 million in the first, second, third and fourth quarters of 2006, respectively. |
|
(2) |
|
The company recorded restructuring and impairment charges of $6.1 million, $5.4 million, $1.1
million and $3.3 million in the first, second, third and fourth quarters of 2005, respectively. |
108
The sum of the quarterly earnings per-share amounts does not equal the annual amount reported since
per-share amounts are computed independently for each quarter and for the full year based upon
respective weighted-average common shares outstanding and other dilutive shares.
Note
20 - RESTATEMENT OF CONSOLIDATED FINANCIAL STATEMENTS
On October 22, 2007, the company concluded to restate its previously issued financial statements
because of reporting errors relating to five postemployment employee benefit plans in three foreign
countries. Accordingly, the company has restated the consolidated balance sheets as of December 31,
2006 and 2005
and the consolidated statements of income, consolidated statements of cash flows and consolidated
statements of shareholders equity for fiscal years 2006, 2005 and 2004.
The impact of the restatement decreased income from continuing operations and net income for 2006
by $2.0 million or 1.1% and 1.9%, respectively, for 2005 by $2.1 million or 1.3% and 1.1%,
respectively, and for 2004 by $1.7 million or 1.9% and 1.8%, respectively, from amounts previously
reported. The restatement had no effect on the companys previously reported revenues or net cash
flows. The cumulative effect of the errors decreased shareholders equity as of December 31, 2006,
2005, 2004 and January 1, 2004 by $24.3 million, $15.3 million, $15.0 million and $12.3 million,
respectively.
The errors primarily arose in three different postemployment employee benefit plans at a wholly
owned subsidiary and in postemployment employee benefit plans for employees at two of the companys
consolidated joint ventures. Four of these postemployment employee benefit plans had been accounted
for inappropriately on a cash basis rather than an accrual basis as required by U.S. GAAP, while
the accrual recorded in the financial statements for the fifth plan was not calculated in
accordance with U.S. GAAP. The cumulative effect of the errors resulted in an understatement of
postemployment employee benefit plan liabilities of $38.9 million and $27.1 million at December 31,
2006 and 2005, respectively.
109
The following tables show the impact of the restatement:
Consolidated Statement of Income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31, 2006 |
|
|
(as previously |
|
|
|
|
(In Millions of Dollars Except Per Share Data) |
|
reported) |
|
(adjustments) |
|
(as restated) |
Net sales |
|
|
$ 4,036.4 |
|
|
|
$ |
|
|
|
$ 4,036.4 |
|
Royalties and other revenues |
|
|
4.4 |
|
|
|
|
|
|
|
4.4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues |
|
|
4,040.8 |
|
|
|
|
|
|
|
4,040.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales |
|
|
3,041.9 |
|
|
|
3.3 |
|
|
|
3,045.2 |
|
Selling and administrative expenses |
|
|
381.7 |
|
|
|
|
|
|
|
381.7 |
|
Research, testing and development expenses |
|
|
205.5 |
|
|
|
|
|
|
|
205.5 |
|
Amortization of intangible assets |
|
|
23.7 |
|
|
|
|
|
|
|
23.7 |
|
Restructuring and impairment charges |
|
|
51.9 |
|
|
|
|
|
|
|
51.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total costs and expenses |
|
|
3,704.7 |
|
|
|
3.3 |
|
|
|
3,708.0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income - net |
|
|
8.3 |
|
|
|
0.2 |
|
|
|
8.5 |
|
Interest income |
|
|
20.4 |
|
|
|
|
|
|
|
20.4 |
|
Interest expense |
|
|
(99.7 |
) |
|
|
|
|
|
|
(99.7 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before income taxes |
|
|
265.1 |
|
|
|
(3.1 |
) |
|
|
262.0 |
|
Provision for income taxes |
|
|
83.3 |
|
|
|
(1.1 |
) |
|
|
82.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations |
|
|
181.8 |
|
|
|
(2.0 |
) |
|
|
179.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from discontinued operations - net of tax |
|
|
(76.2 |
) |
|
|
|
|
|
|
(76.2 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
|
$ 105.6 |
|
|
|
$ (2.0 |
) |
|
|
$ 103.6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic earnings (loss) per share: |
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations |
|
|
$ 2.65 |
|
|
|
$ (0.03 |
) |
|
|
$ 2.62 |
|
Discontinued operations |
|
|
(1.11 |
) |
|
|
|
|
|
|
(1.11 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share, basic |
|
|
$ 1.54 |
|
|
|
$ (0.03 |
) |
|
|
$ 1.51 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings (loss) per share: |
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations |
|
|
$ 2.62 |
|
|
|
$ (0.03 |
) |
|
|
$ 2.59 |
|
Discontinued operations |
|
|
(1.10 |
) |
|
|
|
|
|
|
(1.10 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share, diluted |
|
|
$ 1.52 |
|
|
|
$ (0.03 |
) |
|
|
$ 1.49 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
110
Consolidated Statement of Income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31, 2005 |
|
|
(as previously |
|
|
|
|
(In Millions of Dollars Except Per Share Data) |
|
reported) |
|
(adjustments) |
|
(as restated) |
Net sales |
|
|
$ 3,618.8 |
|
|
|
$ |
|
|
|
$ 3,618.8 |
|
Royalties and other revenues |
|
|
3.4 |
|
|
|
|
|
|
|
3.4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues |
|
|
3,622.2 |
|
|
|
|
|
|
|
3,622.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales |
|
|
2,696.6 |
|
|
|
3.5 |
|
|
|
2,700.1 |
|
Selling and administrative expenses |
|
|
348.4 |
|
|
|
|
|
|
|
348.4 |
|
Research, testing and development expenses |
|
|
198.9 |
|
|
|
|
|
|
|
198.9 |
|
Amortization of intangible assets |
|
|
23.5 |
|
|
|
|
|
|
|
23.5 |
|
Restructuring and impairment charges |
|
|
15.9 |
|
|
|
|
|
|
|
15.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total costs and expenses |
|
|
3,283.3 |
|
|
|
3.5 |
|
|
|
3,286.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income - net |
|
|
1.6 |
|
|
|
0.2 |
|
|
|
1.8 |
|
Interest income |
|
|
8.1 |
|
|
|
|
|
|
|
8.1 |
|
Interest expense |
|
|
(105.1 |
) |
|
|
|
|
|
|
(105.1 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before income taxes |
|
|
243.5 |
|
|
|
(3.3 |
) |
|
|
240.2 |
|
Provision for income taxes |
|
|
82.0 |
|
|
|
(1.2 |
) |
|
|
80.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations |
|
|
161.5 |
|
|
|
(2.1 |
) |
|
|
159.4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from discontinued operations - net of tax |
|
|
27.8 |
|
|
|
|
|
|
|
27.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
|
$ 189.3 |
|
|
|
$ (2.1 |
) |
|
|
$ 187.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic earnings per share: |
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations |
|
|
$ 2.38 |
|
|
|
$ (0.03 |
) |
|
|
$ 2.35 |
|
Discontinued operations |
|
|
0.41 |
|
|
|
|
|
|
|
0.41 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share, basic |
|
|
$ 2.79 |
|
|
|
$ (0.03 |
) |
|
|
$ 2.76 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings per share: |
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations |
|
|
$ 2.35 |
|
|
|
$ (0.03 |
) |
|
|
$ 2.32 |
|
Discontinued operations |
|
|
0.40 |
|
|
|
|
|
|
|
0.40 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share, diluted |
|
|
$ 2.75 |
|
|
|
$ (0.03 |
) |
|
|
$ 2.72 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
111
Consolidated Statement of Income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31, 2004 |
|
|
(as previously |
|
|
|
|
(In Millions of Dollars Except Per Share Data) |
|
reported) |
|
(adjustments) |
|
(as restated) |
Net sales |
|
|
$ 2,860.5 |
|
|
|
$ |
|
|
|
$ 2,860.5 |
|
Royalties and other revenues |
|
|
3.9 |
|
|
|
|
|
|
|
3.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues |
|
|
2,864.4 |
|
|
|
|
|
|
|
2,864.4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales |
|
|
2,101.7 |
|
|
|
2.9 |
|
|
|
2,104.6 |
|
Selling and administrative expenses |
|
|
284.8 |
|
|
|
|
|
|
|
284.8 |
|
Research, testing and development expenses |
|
|
184.8 |
|
|
|
|
|
|
|
184.8 |
|
Amortization of intangible assets |
|
|
16.9 |
|
|
|
|
|
|
|
16.9 |
|
Write-off of acquired in-process research and developmen |
|
|
34.0 |
|
|
|
|
|
|
|
34.0 |
|
Restructuring and impairment charges |
|
|
38.1 |
|
|
|
|
|
|
|
38.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total costs and expenses |
|
|
2,660.3 |
|
|
|
2.9 |
|
|
|
2,663.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income - net |
|
|
5.4 |
|
|
|
0.2 |
|
|
|
5.6 |
|
Interest income |
|
|
4.8 |
|
|
|
|
|
|
|
4.8 |
|
Interest expense |
|
|
(77.1 |
) |
|
|
|
|
|
|
(77.1 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before income taxes |
|
|
137.2 |
|
|
|
(2.7 |
) |
|
|
134.5 |
|
Provision for income taxes |
|
|
50.0 |
|
|
|
(1.0 |
) |
|
|
49.0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations |
|
|
87.2 |
|
|
|
(1.7 |
) |
|
|
85.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from discontinued operations - net of tax |
|
|
6.3 |
|
|
|
|
|
|
|
6.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
|
$ 93.5 |
|
|
|
$ (1.7 |
) |
|
|
$ 91.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic earnings per share: |
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations |
|
|
$ 1.57 |
|
|
|
$ (0.03 |
) |
|
|
$ 1.54 |
|
Discontinued operations |
|
|
0.11 |
|
|
|
|
|
|
|
0.11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share, basic |
|
|
$ 1.68 |
|
|
|
$ (0.03 |
) |
|
|
$ 1.65 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings per share: |
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations |
|
|
$ 1.56 |
|
|
|
$ (0.03 |
) |
|
|
$ 1.53 |
|
Discontinued operations |
|
|
0.11 |
|
|
|
|
|
|
|
0.11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share, diluted |
|
|
$ 1.67 |
|
|
|
$ (0.03 |
) |
|
|
$ 1.64 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
112
Consolidated Balance Sheet
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2006 |
|
|
(as previously |
|
|
|
|
(In Millions of Dollars) |
|
reported) |
|
(adjustments) |
|
(as restated) |
ASSETS |
|
|
|
|
|
|
|
|
|
|
|
|
Cash and short-term investments |
|
|
$ 575.7 |
|
|
$ |
|
|
|
|
$ 575.7 |
|
Receivables |
|
|
573.6 |
|
|
|
|
|
|
|
573.6 |
|
Inventories |
|
|
589.0 |
|
|
|
|
|
|
|
589.0 |
|
Other current assets |
|
|
98.0 |
|
|
|
|
|
|
|
98.0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total current assets |
|
|
1,836.3 |
|
|
|
|
|
|
|
1,836.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Property and equipment - at cost |
|
|
2,546.0 |
|
|
|
|
|
|
|
2,546.0 |
|
Less accumulated depreciation |
|
|
1,464.7 |
|
|
|
|
|
|
|
1,464.7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Property and equipment - net |
|
|
1,081.3 |
|
|
|
|
|
|
|
1,081.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Goodwill |
|
|
1,076.1 |
|
|
|
|
|
|
|
1,076.1 |
|
Intangible assets - net |
|
|
322.8 |
|
|
|
|
|
|
|
322.8 |
|
Investments in non-consolidated companies |
|
|
7.7 |
|
|
|
|
|
|
|
7.7 |
|
Other assets |
|
|
62.0 |
|
|
|
4.7 |
|
|
|
66.7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL |
|
|
$ 4,386.2 |
|
|
$ |
4.7 |
|
|
|
$ 4,390.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS
EQUITY |
|
|
|
|
|
|
|
|
|
|
|
|
Short-term debt and current portion of long-term
debt |
|
|
$ 3.7 |
|
|
$ |
|
|
|
|
$ 3.7 |
|
Accounts payable |
|
|
340.5 |
|
|
|
|
|
|
|
340.5 |
|
Accrued expenses and other current liabilities |
|
|
287.8 |
|
|
|
2.4 |
|
|
|
290.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities |
|
|
632.0 |
|
|
|
2.4 |
|
|
|
634.4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Long-term debt |
|
|
1,538.0 |
|
|
|
|
|
|
|
1,538.0 |
|
Pension obligations |
|
|
218.5 |
|
|
|
19.4 |
|
|
|
237.9 |
|
Other postretirement benefit obligations |
|
|
82.0 |
|
|
|
11.5 |
|
|
|
93.5 |
|
Noncurrent liabilities |
|
|
66.7 |
|
|
|
5.6 |
|
|
|
72.3 |
|
Deferred income taxes |
|
|
88.9 |
|
|
|
(8.5 |
) |
|
|
80.4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities |
|
|
2,626.1 |
|
|
|
30.4 |
|
|
|
2,656.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Minority interest in consolidated companies |
|
|
52.7 |
|
|
|
(1.4 |
) |
|
|
51.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Contingencies and commitments |
|
|
|
|
|
|
|
|
|
|
|
|
Preferred stock without par value - unissued |
|
|
|
|
|
|
|
|
|
|
|
|
Common shares without par value |
|
|
710.1 |
|
|
|
|
|
|
|
710.1 |
|
Retained earnings |
|
|
1,050.2 |
|
|
|
(16.4 |
) |
|
|
1,033.8 |
|
Accumulated other comprehensive loss |
|
|
(52.9 |
) |
|
|
(7.9 |
) |
|
|
(60.8 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
Total shareholders equity |
|
|
1,707.4 |
|
|
|
(24.3 |
) |
|
|
1,683.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL |
|
|
$ 4,386.2 |
|
|
$ |
4.7 |
|
|
|
$ 4,390.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
113
Consolidated Balance Sheet
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December
31, 2005 |
|
|
(as previously |
|
|
|
|
(In Millions of Dollars) |
|
reported) |
|
(adjustments) |
|
(as restated) |
ASSETS |
|
|
|
|
|
|
|
|
|
|
|
|
Cash and short-term investments |
|
|
$ 262.4 |
|
|
$ |
|
|
|
|
$ 262.4 |
|
Receivables |
|
|
585.6 |
|
|
|
|
|
|
|
585.6 |
|
Inventories |
|
|
586.0 |
|
|
|
|
|
|
|
586.0 |
|
Other current assets |
|
|
138.3 |
|
|
|
|
|
|
|
138.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total current assets |
|
|
1,572.3 |
|
|
|
|
|
|
|
1,572.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Property and equipment - at cost |
|
|
2,621.5 |
|
|
|
|
|
|
|
2,621.5 |
|
Less accumulated depreciation |
|
|
1,437.1 |
|
|
|
|
|
|
|
1,437.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Property and equipment - net |
|
|
1,184.4 |
|
|
|
|
|
|
|
1,184.4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Goodwill |
|
|
1,138.8 |
|
|
|
|
|
|
|
1,138.8 |
|
Intangible assets - net |
|
|
404.6 |
|
|
|
2.6 |
|
|
|
407.2 |
|
Investments in non-consolidated companies |
|
|
7.6 |
|
|
|
|
|
|
|
7.6 |
|
Other assets |
|
|
58.6 |
|
|
|
2.3 |
|
|
|
60.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL |
|
|
$ 4,366.3 |
|
|
$ |
4.9 |
|
|
|
$ 4,371.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS EQUITY |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-term debt and current portion of long-term debt |
|
|
$ 7.9 |
|
|
$ |
|
|
|
|
$ 7.9 |
|
Accounts payable |
|
|
372.2 |
|
|
|
|
|
|
|
372.2 |
|
Accrued expenses and other current liabilities |
|
|
284.8 |
|
|
|
0.8 |
|
|
|
285.6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities |
|
|
664.9 |
|
|
|
0.8 |
|
|
|
665.7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Long-term debt |
|
|
1,662.9 |
|
|
|
|
|
|
|
1,662.9 |
|
Pension obligations |
|
|
125.7 |
|
|
|
14.9 |
|
|
|
140.6 |
|
Other postretirement benefit obligations |
|
|
102.6 |
|
|
|
6.9 |
|
|
|
109.5 |
|
Noncurrent liabilities |
|
|
78.3 |
|
|
|
4.5 |
|
|
|
82.8 |
|
Deferred income taxes |
|
|
113.7 |
|
|
|
(6.0 |
) |
|
|
107.7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities |
|
|
2,748.1 |
|
|
|
21.1 |
|
|
|
2,769.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Minority interest in consolidated companies |
|
|
51.0 |
|
|
|
(0.9 |
) |
|
|
50.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Contingencies and commitments |
|
|
|
|
|
|
|
|
|
|
|
|
Preferred stock without par value - unissued |
|
|
|
|
|
|
|
|
|
|
|
|
Common shares without par value |
|
|
663.7 |
|
|
|
|
|
|
|
663.7 |
|
Retained earnings |
|
|
1,016.0 |
|
|
|
(14.3 |
) |
|
|
1,001.7 |
|
Accumulated other comprehensive loss |
|
|
(112.5 |
) |
|
|
(1.0 |
) |
|
|
(113.5 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
Total shareholders equity |
|
|
1,567.2 |
|
|
|
(15.3 |
) |
|
|
1,551.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL |
|
|
$ 4,366.3 |
|
|
$ |
4.9 |
|
|
|
$ 4,371.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
114
Consolidated Statement of Cash Flows
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31, 2006 |
|
|
(as previously |
|
|
|
|
(In Millions of Dollars) |
|
reported) |
|
(adjustments) |
|
(as restated) |
|
CASH PROVIDED BY (USED FOR): |
|
|
|
|
|
|
|
|
|
|
|
|
OPERATING ACTIVITIES |
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
|
$ 105.6 |
|
|
|
$ (2.0 |
) |
|
|
$ 103.6 |
|
Adjustments to reconcile net income to cash
provided by operating activities: |
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
161.8 |
|
|
|
|
|
|
|
161.8 |
|
Deferred income taxes |
|
|
29.8 |
|
|
|
(1.2 |
) |
|
|
28.6 |
|
Deferred compensation |
|
|
19.5 |
|
|
|
|
|
|
|
19.5 |
|
Restructuring and impairment charges |
|
|
105.6 |
|
|
|
|
|
|
|
105.6 |
|
Loss from divestitures and sales of property and equipment |
|
|
9.6 |
|
|
|
|
|
|
|
9.6 |
|
Change in current assets and liabilities, net of acquisitions and divestitures: |
|
|
|
|
|
|
|
|
|
|
|
|
Receivables |
|
|
(3.4 |
) |
|
|
|
|
|
|
(3.4 |
) |
Inventories |
|
|
(56.2 |
) |
|
|
|
|
|
|
(56.2 |
) |
Accounts payable, accrued expenses and other current liabilities |
|
|
(58.5 |
) |
|
|
1.4 |
|
|
|
(57.1 |
) |
Other current assets |
|
|
3.4 |
|
|
|
|
|
|
|
3.4 |
|
|
|
|
|
|
|
(114.7 |
) |
|
|
1.4 |
|
|
|
(113.3 |
) |
Change in noncurrent liabilities |
|
|
6.6 |
|
|
|
1.9 |
|
|
|
8.5 |
|
Other items - net |
|
|
11.0 |
|
|
|
(0.1 |
) |
|
|
10.9 |
|
|
|
|
Total operating activities |
|
|
334.8 |
|
|
|
|
|
|
|
334.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
INVESTING ACTIVITIES |
|
|
|
|
|
|
|
|
|
|
|
|
Capital expenditures |
|
|
(130.9 |
) |
|
|
|
|
|
|
(130.9 |
) |
Net proceeds from divestitures and sales of property and equipment |
|
|
281.9 |
|
|
|
|
|
|
|
281.9 |
|
Other items - net |
|
|
0.4 |
|
|
|
|
|
|
|
0.4 |
|
|
|
|
Total investing activities |
|
|
151.4 |
|
|
|
|
|
|
|
151.4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
FINANCING ACTIVITIES |
|
|
|
|
|
|
|
|
|
|
|
|
Changes in short-term debt - net |
|
|
(0.6 |
) |
|
|
|
|
|
|
(0.6 |
) |
Repayments of long-term debt |
|
|
(143.4 |
) |
|
|
|
|
|
|
(143.4 |
) |
Dividends paid |
|
|
(71.2 |
) |
|
|
|
|
|
|
(71.2 |
) |
Proceeds from the exercise of stock options |
|
|
31.3 |
|
|
|
|
|
|
|
31.3 |
|
|
|
|
Total financing activities |
|
|
(183.9 |
) |
|
|
|
|
|
|
(183.9 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash |
|
|
11.0 |
|
|
|
|
|
|
|
11.0 |
|
|
|
|
Net increase in cash and short-term investments |
|
|
313.3 |
|
|
|
|
|
|
|
313.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and short-term investments at the beginning of year |
|
|
262.4 |
|
|
|
|
|
|
|
262.4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and short-term investments at the end of year |
|
|
$ 575.7 |
|
|
|
$ |
|
|
|
$ 575.7 |
|
|
|
|
115
Consolidated Statement of Cash Flows
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31, 2005 |
|
|
(as previously |
|
|
|
|
(In Millions of Dollars) |
|
reported) |
|
(adjustments) |
|
(as restated) |
|
CASH PROVIDED BY (USED FOR): |
|
|
|
|
|
|
|
|
|
|
|
|
OPERATING ACTIVITIES |
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
|
$ 189.3 |
|
|
$ |
(2.1 |
) |
|
|
$ 187.2 |
|
Adjustments to reconcile net income to cash
provided by operating activities: |
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
179.8 |
|
|
|
|
|
|
|
179.8 |
|
Deferred income taxes |
|
|
10.3 |
|
|
|
(1.2 |
) |
|
|
9.1 |
|
Deferred compensation |
|
|
16.3 |
|
|
|
|
|
|
|
16.3 |
|
Restructuring and impairment charges |
|
|
11.1 |
|
|
|
|
|
|
|
11.1 |
|
Gain from divestitures and sales of property and equipment |
|
|
(3.9 |
) |
|
|
|
|
|
|
(3.9 |
) |
Change in current assets and liabilities, net of acquisitions and divestitures: |
|
|
|
|
|
|
|
|
|
|
|
|
Receivables |
|
|
(52.9 |
) |
|
|
|
|
|
|
(52.9 |
) |
Inventories |
|
|
(47.5 |
) |
|
|
|
|
|
|
(47.5 |
) |
Accounts payable, accrued expenses and other current liabilities |
|
|
56.0 |
|
|
|
0.1 |
|
|
|
56.1 |
|
Other current assets |
|
|
6.9 |
|
|
|
|
|
|
|
6.9 |
|
|
|
|
|
|
|
(37.5 |
) |
|
|
0.1 |
|
|
|
(37.4 |
) |
Change in noncurrent liabilities |
|
|
5.4 |
|
|
|
3.2 |
|
|
|
8.6 |
|
Other items - net |
|
|
(8.6 |
) |
|
|
|
|
|
|
(8.6 |
) |
|
|
|
Total operating activities |
|
|
362.2 |
|
|
|
|
|
|
|
362.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
INVESTING ACTIVITIES |
|
|
|
|
|
|
|
|
|
|
|
|
Capital expenditures |
|
|
(136.7 |
) |
|
|
|
|
|
|
(136.7 |
) |
Net proceeds from divestitures and sales of property and equipment |
|
|
30.1 |
|
|
|
|
|
|
|
30.1 |
|
Other items - net |
|
|
(0.2 |
) |
|
|
|
|
|
|
(0.2 |
) |
|
|
|
Total investing activities |
|
|
(106.8 |
) |
|
|
|
|
|
|
(106.8 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
FINANCING ACTIVITIES |
|
|
|
|
|
|
|
|
|
|
|
|
Changes in short-term debt - net |
|
|
(4.0 |
) |
|
|
|
|
|
|
(4.0 |
) |
Repayments of long-term debt |
|
|
(512.2 |
) |
|
|
|
|
|
|
(512.2 |
) |
Proceeds from the issuance of long-term debt |
|
|
235.8 |
|
|
|
|
|
|
|
235.8 |
|
Dividends paid |
|
|
(70.4 |
) |
|
|
|
|
|
|
(70.4 |
) |
Payment of debt issuance costs |
|
|
(0.8 |
) |
|
|
|
|
|
|
(0.8 |
) |
Proceeds from the exercise of stock options |
|
|
38.8 |
|
|
|
|
|
|
|
38.8 |
|
|
|
|
Total financing activities |
|
|
(312.8 |
) |
|
|
|
|
|
|
(312.8 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash |
|
|
(16.1 |
) |
|
|
|
|
|
|
(16.1 |
) |
|
|
|
Net decrease in cash and short-term investments |
|
|
(73.5 |
) |
|
|
|
|
|
|
(73.5 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and short-term investments at the beginning of year |
|
|
335.9 |
|
|
|
|
|
|
|
335.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and short-term investments at the end of year |
|
|
$ 262.4 |
|
|
$ |
|
|
|
|
$ 262.4 |
|
|
|
|
116
Consolidated Statement of Cash Flows
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year
Ended December 31, 2004 |
|
|
(as previously |
|
|
|
|
(In Millions of Dollars) |
|
reported) |
|
(adjustments) |
|
(as restated) |
CASH PROVIDED BY (USED FOR): |
|
|
|
|
|
|
|
|
|
|
|
|
OPERATING ACTIVITIES |
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
$ |
93.5 |
|
|
$ |
(1.7 |
) |
|
$ |
91.8 |
|
Adjustments to reconcile net income to cash
provided by operating activities: |
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
154.7 |
|
|
|
|
|
|
|
154.7 |
|
Write-off of acquired in-process
research and development |
|
|
34.0 |
|
|
|
|
|
|
|
34.0 |
|
Deferred income taxes |
|
|
5.9 |
|
|
|
(1.0 |
) |
|
|
4.9 |
|
Deferred compensation |
|
|
3.4 |
|
|
|
|
|
|
|
3.4 |
|
Restructuring and impairment charges |
|
|
27.5 |
|
|
|
|
|
|
|
27.5 |
|
Loss from divestitures and sales of
property and equipment |
|
|
3.1 |
|
|
|
|
|
|
|
3.1 |
|
Change in current assets and
liabilities, net of acquisitions and
divestitures: |
|
|
|
|
|
|
|
|
|
|
|
|
Receivables |
|
|
(38.4 |
) |
|
|
|
|
|
|
(38.4 |
) |
Inventories |
|
|
(50.0 |
) |
|
|
|
|
|
|
(50.0 |
) |
Accounts payable, accrued
expenses and other current
liabilities |
|
|
80.5 |
|
|
|
0.2 |
|
|
|
80.7 |
|
Other current assets |
|
|
2.5 |
|
|
|
|
|
|
|
2.5 |
|
|
|
|
|
|
|
(5.4 |
) |
|
|
0.2 |
|
|
|
(5.2 |
) |
Change in noncurrent liabilities |
|
|
9.0 |
|
|
|
2.6 |
|
|
|
11.6 |
|
Other items - net |
|
|
5.9 |
|
|
|
(0.1 |
) |
|
|
5.8 |
|
|
|
|
Total operating activities |
|
|
331.6 |
|
|
|
|
|
|
|
331.6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
INVESTING ACTIVITIES |
|
|
|
|
|
|
|
|
|
|
|
|
Capital expenditures |
|
|
(133.2 |
) |
|
|
|
|
|
|
(133.2 |
) |
Acquisitions - net of cash received and
liabilities assumed |
|
|
(958.4 |
) |
|
|
|
|
|
|
(958.4 |
) |
Net proceeds from divestitures and sales of
property and equipment |
|
|
3.0 |
|
|
|
|
|
|
|
3.0 |
|
Other items - net |
|
|
(0.2 |
) |
|
|
|
|
|
|
(0.2 |
) |
|
|
|
Total investing activities |
|
|
(1,088.8 |
) |
|
|
|
|
|
|
(1,088.8 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
FINANCING ACTIVITIES |
|
|
|
|
|
|
|
|
|
|
|
|
Changes in short-term debt - net |
|
|
(72.6 |
) |
|
|
|
|
|
|
(72.6 |
) |
Repayments of long-term debt |
|
|
(1,193.0 |
) |
|
|
|
|
|
|
(1,193.0 |
) |
Proceeds from the issuance of long-term debt |
|
|
1,743.3 |
|
|
|
|
|
|
|
1,743.3 |
|
Dividends paid |
|
|
(57.6 |
) |
|
|
|
|
|
|
(57.6 |
) |
Proceeds from sale of common shares, net of
underwriting
commissions and offering expenses of
$20.2 million |
|
|
470.0 |
|
|
|
|
|
|
|
470.0 |
|
Payment of debt issuance costs |
|
|
(16.8 |
) |
|
|
|
|
|
|
(16.8 |
) |
Payment of treasury rate lock upon
settlement |
|
|
(73.9 |
) |
|
|
|
|
|
|
(73.9 |
) |
Payment on termination of interest rate
swaps |
|
|
(2.9 |
) |
|
|
|
|
|
|
(2.9 |
) |
Proceeds from the exercise of stock options |
|
|
12.0 |
|
|
|
|
|
|
|
12.0 |
|
|
|
|
Total financing activities |
|
|
808.5 |
|
|
|
|
|
|
|
808.5 |
|
Effect of exchange rate changes on cash |
|
|
25.9 |
|
|
|
|
|
|
|
25.9 |
|
|
|
|
Net increase in cash and short-term
investments |
|
|
77.2 |
|
|
|
|
|
|
|
77.2 |
|
|
Cash and short-term investments at the
beginning of year |
|
|
258.7 |
|
|
|
|
|
|
|
258.7 |
|
|
|
|
|
Cash and short-term investments at the end
of year |
|
$ |
335.9 |
|
|
$ |
|
|
|
$ |
335.9 |
|
|
|
|
117